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1. Introduction 
1.1. ,-Unsaturated carbonyl compounds 
The enone unit is one of the most important moiety that exist in natural and unnatural 
compounds. This moiety plays an important role in medicinal chemistry and industry 
as a starting material (e.g. ethyl acrylate, a monomer for the production of acrylic 
polymer).1 These compounds could be listed as: ,-unsaturated ketones, 
aldehydes, esters and amides (Figure 1).2-4  
 
Figure 1: Examples of ,-unsaturated carbonyl compounds. 
1.1.1. The role of ,-unsaturated carbonyl compounds in inflammation 
Inflammation is a normal response of living tissues against injury, in order to repair 
the infected cells or defense against pathogens. Transcription factors play an 
important role in the inflammation process, in the normal cells the transcription factor 
Nrf2 (nuclear factor-erythroid-2-related factor 2) is deactivated by a protein called 
Keap1 (Kelch-like ECH-associated protein1). During the inflammation process the 
thiol residues in Keap1 can be oxidized to form disulfide bonds or react as a Michael 
donor with the ,-unsaturated carbonyl compounds. In both cases the result is a 
free Nrf2 which can pass through the nucleus and binds to the antioxidant response 
elements, which cause anti-inflammatory protein production such as heme 
oxygenase 1 (HO-1) (Figure 2).5-6 
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Figure 2: Mechanism of Nrf2 activation.  
One other important factor for control of inflammation is the transcriptional factor NF-
κB (nuclear factor-kappa B). In the unstimulated cells the NF-κB exists in the 
cytoplasm as a dimer of NF-κB1 (p50) and Rel A (p65), which binds with the inhibitor 
IκB. The process to activate the NF-κB starts from the signals come to the 
cytoplasm in which the IκB is phosphorylated by the IKK complex (IκB kinase) 
followed by ubiquitination of the IκB, as a result, the NF-κB becomes free and active 
to penetrate inside the nucleus and bind with the DNA to produce proinflammatory 
genes like iNOS (inducible NO synthase) and COX-2 (cyclooxygenase-2). Different 
stimuli can activate the NF-κB such as T and B cell mitogens, bacterial 
lipopolysaccharide, viruses, UV-light and tumor necrosis factor (TNF). Thus the NF-
κB pathway is very important in the cancer therapeutic chemopreventive approach 
since inhibition of this way using synthetic drugs (such as ,-unsaturated carbonyl 
compounds) can either prevent cancer development or inhibit cancer cell growth 
(Figure 3).5-6         
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Figure 3: Regulation of NF-κB pathway by ,-unsaturated carbonyl compounds, (NF-κB: nuclear 
factor-kappa B; a heterodimer of p50 and p65 proteins; IKK: IκB kinase; IκB: inhibitor of kappa B,  
Ub-Ub-Ub: ubiquitination; ,: ,-unsaturated carbonyl compound; iNOS: inducible NO synthase; 
COX-2: cyclooxygenase-2). 
1.1.2. Reactivity of ,-unsaturated carbonyl compounds 
The reactivity of many ,-unsaturated carbonyl compounds depends on their 
behavior as Michael acceptors. Nevertheless, enone moieties are able to have 
radical scavenging properties, reductive potential and double bond isomerization 
(Figure 4).2   
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Figure 4: Possible reactivities of ,-unsaturated compounds.2 
The activity of the Michael system correlates strongly to the substituents on both - 
and β- positions which lead to variable biological activities. Honda et al.7 showed that 
introducing a cyano group on the -position of the oleanolic acid derivatives (Figure 
5) can enhance the inhibition of production of NO induced in mouse macrophages. 
 
Figure 5: Effect of -substituted on the inhibition of NO production in mouse macrophages.7 
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In order to measure the reactivity of ,-unsaturated carbonyl compounds as Michael 
accepters, Amslinger and Al-Rifai developed kinetic thiol assay, to assess the 
reactivity of chalcones towards thiols. Second order-rate constants (k2) were used to 
compare the reactivity of different chalcones. The optimized conditions were using 
solvent mixture (100 mM TRIS-HCl, pH=7.4, 2 mM EDTA/ethylene glycol (20:80)), 
the thiol was cysteamine, the wavelength determined after UV-Vis scans and LC-MS 
measurements and the thiol-adduct product was characterized by LC-MS 
measurements. Under these conditions different -X-chalcones were screened with 
k2 values in the range of 0.004 M-1s-1 for -COOH-chalcones to 5750 M-1s-1 for -CN-
chalcones (Scheme 1).8 These results showed again the effect of the -substitutions 
on the behavior of the ,-unsaturated carbonyl compounds to be Michael acceptors.  
 
Scheme 1: Reaction of -X-chalcones with cysteamine. 
1.1.3. Biological activities of ,-unsaturated carbonyl compounds 
,β-Unsaturated carbonyl compounds display a wide spectrum of biological activities 
such as antibacterial, anti-inflammatory and anticancer. Kaempferol (6) (Figure 6) is 
a flavonol that presents at high level in tea, broccoli, grapes and strawberries. It can 
prevent the formation of reactive oxygen species (ROS) in RAW264.7 cells, a mouse 
macrophage cell line.9 New study on curcumin (7) showed that curcumin can inhibit 
the proliferation and invasion of MHCC97-H cells. The result provides supporting to 
curcumin clinical use.10 Caffeic acid phenethyl ester (CAPE) (8) was tested against 
six different cancer cell lines and showed high selectivity as antiproliferative of liver-
metastatic murine colon 26-L5 carcinoma cell line up to (EC50 = 0.02 µM).11 A natural 
product dicerandrol C (9) which is a metabolite of Phomopsis longicolla the fungi 
isolated from the red seaweed Bosterychia radicans had significant antibacterial 
activity against Staphylococcus aureus (ATCC 6538) and Staphylococcus 
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saprophyticus (ATCC 15305) with minimum inhibitory concentrations of 1.33 µM and 
2.66 µM, respectively.12  
 
Figure 6: Some biological active ,-unsaturated carbonyl compounds. 
1.1.4. Synthesis of ,-unsaturated carbonyl compounds 
The most common method to form the enone unit is the condensation reaction 
between an aldehydes and a ketones in acidic, basic medium and sometimes 
catalysts. The reaction conditions depend on the aldehydes and the ketones. The 
Claisen-Schmidt condensation is one of the best strategies to form the enone in 
basic medium. Scheme 2 shows the mechanism of this reaction to produce the 
chalcone in which the base deprotonates the ketone to form the enolate that attacks 
the aldehyde to produce a -hydroxyketone, followed by dehydration to afford the 
desired chalcone.13 
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Scheme 2: Mechanism of the Claisen-Schmidt condensation. 
Other methods to form such an enone are usage of salts,14 or using Lewis acids like 
AlCl3 and TiCl4 to couple ,-unsaturated acyl chlorides with a vinyl moiety.15 
The Wittig reaction was also used to produce the ,-unsaturated carbonyl 
compound, as an example Kodama et al.16 coupled an aldehyde with phosphonium 
yild in the total synthesis of zerumbone (1). 
Additionally, the Heck reaction using palladium catalyst is very useful in some cases 
to form ,-unsaturated carbonyl derivatives by coupling aryl halides (specially aryl 
iodide) with vinyl ketones or aldehydes (Scheme 3).17 
 
Scheme 3: Derivatization of an ,-unsaturated carbonyl compound via Heck reaction. 
The proposed mechanism of Heck reaction starts with generation of Pd(0) catalyst 
followed by oxidative addition into C-X bond, then syn addition of Ar-Pd(II)XL2 to vinyl 
moiety, in some cases C-C bond rotation occurs to form less steric hindrance 
skeleton. The final product generates by syn -hydride elimination to regenerate 
Pd(0)L2 (Scheme 4).18     
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Scheme 4: General mechanism of the Heck reaction. 
Due to a wide use of Heck reaction especially in natural product synthesis, different 
Pd-catalysts have been used such as Pd(OAc)2, Pd2(dba)3 and PdCl2(PPh3)2.19  
1.2. Antimicrobial activity and multidrug resistance  
Infections microorganisms by bacteria, fungi and viruses cause a continuous and 
serious threat to human health and life since decades, which lead to continuous drug 
development. The antimicrobial agents could be natural products such as penicillin 
(13) or synthesized such as ciprofloxacin (14) (Figure 7). 
 
Figure 7: Structures of penicillin (13) and ciprofloxacin (14). 
Antimicrobial agents act selectively on the microbial functions with minimal effects or 
without affecting steward functions. In general, antimicrobial agents can be described 
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as either bacteriostatic or bactericidal. Bacteriostatic antimicrobial agents only inhibit 
the growth or the multiplication of the bacteria giving the immune system of the host 
time to clear them from the body, in this case the bacteria elimination process 
depends on the competence of the immune system. Examples for the bacteriostatic 
compounds are chloramphenicol which inhibits the protein synthesis in the bacteria, 
while sulfonamides inhibit folate synthesis. The second type of antimicrobial agents is 
bactericidal agents which kill the bacteria and therefore with or without a competent 
immune system of the steward the bacteria will be killed, examples are penicillins 
(13) and cephalosporins which inhibit the cell wall synthesis, while quinolones inhibit 
DNA synthesis.20-21 
In order to survive, the microorganism developed different methods to resist the 
effect of antimicrobial agents which is called multidrug resistance (MDR). The 
microorganism can resist the drugs in different ways (Figure 8), such as drug efflux, 
in which the microorganism pumps the drug out of the cell. A second method is 
altering the cell wall permeability which leads to decrease of the drug concentration 
in the cell, a third is mutation in the cell that causes changes in the drug target in 
which the drug can’t bind to the target any more, a forth is the up regulation of the 
target protein in the cell. In this case the drug deactivates few targets but there still 
alternative targets which still make the desired functions for the cell. Finally MDR can 
occur by applying the cell specific enzymes to deactivate the drug or destroy it.22  
Introduction 
10 
 
 
Figure 8: Mechanisms of multidrug resistance (with permission).22  
Due to MDR, the drug will be inefficacious and not available useful to treat the 
infection, which means a big challenge for scientists to search for new antimicrobial 
agents.  
1.3. The cyclopentenone unit in natural products 
The cyclopentenone skeleton (which contains ,-unsaturated carbonyl) is a 
common moiety exists in natural products. The hygrophorone (15) (Figure 9), a 
cyclopentenone natural product derived from the fruiting bodies of the mushroom 
Hygrophorus shows promising antifungal activity.23 Haneishi et al. succeeded to 
isolate novel antibacterial cyclopentenone derivatives from the culture filtrate of a 
streptomycete called methylenomycins A (16) and methylenomycins B (17), which 
showed inhibition against different gram-positive and gram-negative bacteria.24  
Liao et al.25 in 2005 were able to isolate and characterize lathyranoic acid A (18), a 
natural product from the seeds of Euphorbia lathyris and a common Traditional 
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Chinese Medicine used for ascites, coprostasis, anuresis, amenorrhea, venous 
stasis, terminal schistosomiasis, scabies, and snakebite.  
The methanol extracted fraction from the fruiting bodies of Tylopilus eximius shows 
antibacterial properties, this extract has a compound with a cyclopentenone moiety 
with two phenolic groups and with a hydroxyl group in the -position called tylopilusin 
A (19), which inhibits the yellow pigment (staphyloxanthin) produced by methicillin-
resistant Staphylococcus aureus (MRSA). The yellow pigment in the Staphylococcus 
aureus works as an antioxidant to protect it from reactive oxygen species (ROS) 
produced by the host immune system (Figure 9).26  
 
 
Figure 9: Some biologically active cyclopentenone natural products. 
1.3.1. Spirocyclopentenones in natural products 
In addition to the cyclopentenone unit in some natural products, there are many 
natural products which contain a spirocyclopentenone unit. Members of the 
acutumine family (20, 21 and 22) (Figure 10) are natural products from 
Menispermum dauricum, a plant widely used in the Traditional Medicine of China 
with analgesic and antipyretic properties, from which Yu et al.27 in 2002 isolated 
acutumine derivatives, the spirocyclopentenone isolated compounds show selective 
inhibition of T-cell growth. Another example is hypserpanine A (23) which was 
isolated from Hypserpa nitida and show an interesting activity as antihepatitis B.28 
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Figure 10: Acutumine natural products. 
Park et al.29 recently described new secondary metabolites from the 24 h broth 
culture of Lysinibacillus fusiformis KMC003 derived from acidic coal-mine drainage 
which have a spirocyclopentenone moiety with a hydroxyl group in the -position 
called spirobacillene A (24) and spirobacillene B (25). The newly isolated compounds 
show weak antibacterial properties (Figure 11). 
 
Figure 11: Structures of spirobacillene A (24) and spirobacillene B (25). 
Another example for the spirocyclopentenone in natural products was isolated by 
Jang et al.4 in 2005 from Limnophila geoffrayi, a plant used in the Traditional 
Medicine of Thailand due to its antipyretic, expectorant and galactagogue 
prosperities. The new isolated compound which has two enone units, a 
spirocyclopentenone system and a phenolic moiety is called limnophilaspiroketone 
(2) (Figure 12). Moreover, Suksaamrarm et al.30 isolated some flavones from the 
same plant as antimycobacterial and antioxidant agents. The essential oil received 
from Limnophila geoffrayi by Thongdon-A and Inprakhon in 2009 show highly 
antimicrobial and strong insecticidal activities.31 
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Figure 12: Structure of limnophilaspiroketone (2) and image of Limnophial geoffryi. 
1.3.2. Derivatives of limnophilaspiroketone (Limno-CPs) 
Since limnophilaspiroketone has a unique skeleton, Sabine Amslinger and Simon 
Lindner were able to synthesize derivatives which have a similar skeleton to the 
natural product limnophilaspiroketone called Limno-CPs.32 The sequence started with 
protection of 4-hydroxybenzaldehyde (26) with iPr group to form compound 27 in 
99% yield after 2 h (Scheme 5). After that aldol condensation was applied between 
compound 27 with 1-ethynylcyclopentanol, the produced benzyl alcohol (28) was 
oxidized by MnO2 to the corresponding carbonyl group (29). Then the key step 
comes by cyclization using Et2NH in EtOH-H2O mixture afford iPr-Limno-CP (30) in 
76% yield. Finally isopropyl deprotection by BCl3 produced the desired product (31) 
in overall yield 54%.        
Scheme 5: Synthesis of Limno-CP (31).32 
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For more investigations different substituents were introduced in the -position of the 
enone unit to the prepared Limno-CP in order to study the behavior of the derivatives 
as Michael acceptors. Table 1 shows the conditions and the yields of the synthesized 
compounds. 
Table 1: Synthesis of -X-Limno-CPs.32   
 
Y 
Starting material  
Conditions X 
Product 
Yield (%) 
H NFSI, THF, reflux, 16 h F 5 
H NCS, MeOH, reflux, 16 h Cl 91 
H NBS, MeCN, 0 °C, 30 min Br 88 
H Br2, Et3N, CHCl3, 0 °C, 3 h Br 92 
H NIS, MeCN, reflux, 16 h I 88 
H I2, PDC, CH2Cl2, r.t, 3 h I 72 
Br NaCN, NiBr2, NMP, µw, 200 
°C, 10 min 
CN 89 
CN aq 12 M NaOH-1,4-dioxane 
(1:1), r.t, 1.5 h 
CONH2 73 
Br PhB(OH)2, Pd2(dba)3, PPh3, 
Et2NH, PhMe-EtOH-H2O, 
reflux, 20 h 
Ph* 79 
*Similar structure to the COX-2 inhibitor Rofecoxib.  
The synthesized compounds were deprotected using BCl3 to form a set of phenolic 
derivatives in 82-99% yield after 3-40 h. All the compounds were tested as Michael 
acceptors by the kinetic thiol assay and none of them showed Michael acceptor 
activity as no reaction was observed, which reflect the low electrophilicity of the 
system.32 
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1.4. Zerumbone  
Zerumbone (1) (Figure 13), a cyclic 11-membered ring natural product with ,-
unsaturated carbonyl group. It is the main component of the essential oil of Zingiber 
zerumbet Smith. The first isolation of this compound was in 1960, and since that the 
attention was increased.33 
 
Figure 13: Structure of zerumbone (1) and the X-ray structure.34 
1.4.1. Biological activity of zerumbone and its derivatives 
Xian et al. showed in 2006 that zerumbone (1) is able to significantly suppress the 
proliferation of leukemia NB4 cells by inducing G2/M cell cycle arrest, followed by 
apoptosis with an IC50 value 10 µM.35 Furthermore, Kim et al. studied the effect of 
zerumbone (1) in vivo in colon and lung cancer in mice. The study shows the ability 
of zerumbone (1) as chemopreventive of colon and lung cancer in mice. These 
properties came from the antiproliferative, apoptosis inducing, anti-inflammatory and 
suppression of NF-κB and HO-1.36 Similarly, Abdelwahab et al.37 found in 2011 that 
zerumbone (1) is able to inhibit proliferative of T-acute lymphoblastic leukemia cells. 
In addition, zerumbone shows promising activity as anticholinesterase.38 
Recently, a study showed the attractive activity of zerumbone (1) in vitro (MCF-7 and 
MDA-MB-231 cells) and (MDA-MB-213 cells) to inhibit growth of human breast 
cancer cells in association with apoptosis induction.39 Moreover, zerumbone (1) 
inhibited the NF-κB-dependent proangiogenic, which is related to block the 
pancreatic cancer-associated angiogenesis.40  
Shin et al.41 reported the ability of zerumbone (1) to activate Nrf2 which induces HO-
1 in mouse skin and cultured murine epidermal cells. Importantly, the derivatives 
produced by reducing the carbonyl group to the alcohol or remove it completely did 
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not show any activity. This proves the important role of the ,-unsaturated carbonyl 
group in the biological properties of the zerumbone. Zerumbone (1) also inhibits 
RANKL, a receptor that activates NF-κB and is responsible for many diseases such 
as cancer, chronic inflammatory and bone resorption by inhibition of IκB kinase, 
IκB phosphorylation and IκB degradation.42   
Natural zerumbone derivatives have been isolated from Buddleja species (Figure 
14). The plant is used in Chinese Traditional Medicine. The flowers of Buddleja 
officinalis, are Traditional Chinese Medicine used for the treatment of conjunctival 
congestion and clustered nebulae, whereas the roots of Buddleja asiatica Lour are 
used as an anti-inflammatory agent. Similar usage of Buddleja globosa is reported 
from Chile, where the leaves and flowers are used for washing injury and treating 
ulcers.43 
 
Figure 14: Some naturally occuring zerumbone analogues. 
Further investigations of zerumbone led Kitayama et al.44 to synthesize new 
antibacterial derivatives. The new derivatives 38, 39, 40 and 41 (Figure 15) showed 
selective inhibition of gram-positive bacteria (Bacillus subtilis 168), especially the 
open chain analogues 40 and 41. While all the derivatives did not show any activity 
against gram-negative bacteria (Escherichia coli MC4100). 
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Figure 15: Some antibacterial (38-41) and antimalarial (42-44) synthetic zerumbone derivatives. 
Amine and cyano zerumbone derivatives 42, 43 and 44 (Figure 15) displyed 
antimalarial activity with IC50 values 5.6, 7.0 and 7.5 µM, respectively. The IC50 
values against normal cell line were 26-47 µM which make them not suitable as 
antimalarial drugs.45 Furthermore, some zerumbone analogues were able to 
suppress NO generation and the study showed the importance of the conjugated 
system for this behavior.46    
1.4.2. Total synthesis of zerumbone   
Kodoma et al.16 published in 1987 the first total synthesis of zerumbone (Scheme 6). 
The sequence started with a substitution reaction between geranyl bromide 45 and 
methyl isobutyrate to produce ester 46, followed by a selective epoxidation using 
NBS and K2CO3. The epoxide was converted to the vicinal diol 47 by perchloric acid. 
The next step was to reduce the ester 48 to the corresponding alcohol 49 by LiAlH4, 
then sodium periodate was used to cleave the bond in the vicinal diol to give the 
corresponding aldehyde 50. An ester group was introduced to the aldehyde by Wittig 
reaction giving compound 51, followed by oxidation of the alcohol to aldehyde 52 
which is protected by ethylene glycol (53). Then, the ketophosphonate 54 is prepared 
by coupling the ester group in 53 with dimethyl methyl phosphonate using n-BuLi as 
a base. Deprotection of the aldehyde and treating it with sodium hydride gives the 
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desired zerumbone (1) in 3% overall yield. At the same time 55% from the dimer was 
obtained, many conditions were screened to suppress the dimer including increased 
the dilution factor but still high yield was observed. 
 
Scheme 6: Total synthesis of zerumbone.16 
1.5. 1,3,4-Oxadiazole derivatives 
The 1,3,4-oxadiazole is a five membered heterocyclic ring compound containing one 
oxygen atom in position 1 and two nitrogen atoms in positions 3 and 4. This skeleton 
gives the compound special properties which make it one of the most regular studied 
oxadiazole isomer 58 (Figure 16). 
 
Figure 16: Oxadiazole isomers. 
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1.5.1. Biological activity of 1,3,4-oxadiazole derivatives 
As a special feature, compounds containing the 1,3,4-oxadiazole moiety have broad 
biological activities including antibacterial, antifungal, anti-inflammatory, antiviral, 
anticancer and antihypertensive. Figure 17 shows two examples of compounds 
containing the 1,3,4-oxadiazole unit in late stage clinical development.47  
 
Figure 17: Structures of raltegravir and zibotentan, drugs that are in late stage clinical development. 
In order to enhance the biological activity of the 1,3,4-oxadiazole derivatives, some 
examples in the literature combined this unit with another biologically active moiety 
like an enone unit. Figure 18 shows the 1,3,4-oxadiazole ring in combination with an 
,-unsaturated carbonyl moiety to give antibacterial compounds.48-49 
 
Figure 18: Antibacterial compounds with 1,3,4-oxadiazole unit combined with the enone moiety. 
Some substitutions on the 1,3,4-oxadiazole ring like the pyridinyl moiety showed 
interesting biological activities, such as 2,3-dihydro-1,3,4-oxadiazole 58 is analgesic 
active agent while compound 59 is an anticancer agent (Figure 19).50-51 On the other 
hand, a thiol group in position 2 of the ring demonstrated a wide spectrum of 
biological activities such as antibacterial activity (e.g. compound 60),52 antidiabetic53, 
anti-inflammatory and analgesic activity like compound 61.54  
Recently, Zhang et al.55 prepared a new 1,3,4-oxadiazole-2-thiol derivative 62 with 
pyridinyl moiety in position 5. The compound showed high activity against four 
Introduction 
20 
 
different cancer cell lines HEPG2, MCF7, SW1116 and BGC823 with IC50 values 
0.76-1.54 µM (Figure 19).  
 
Figure 19: Biologically active 1,3,4-oxadiazole derivatives with a pyridinyl unit and some with a sulfur 
bridge. 
1.5.2. Concepts to synthesize 1,3,4-oxadiazole derivatives 
Several synthetic methods have been reported for the preparation of dialkyl and 
diaryl 1,3,4-oxadiazoles, Figure 20 summarize some of these methods.47 
 
Figure 20: Concepts to synthesize disubstituted 1,3,4-oxadiazole derivatives.47 
Ya et al.56 developed an oxidation cyclization of hydrazones to 1,3,4-oxadiazoles 
using stoichiometric amount of iodine in presence of potassium carbonate. The 
proposed reaction mechanism is shown in Scheme 7. 
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Scheme 7: Proposed mechanism of 1,3,4-oxadiazole ring formation using iodine.56 
In some cases the cyclization process can be done using an oxidizing agent like 
CAN,57 or using a catalyst such as Cu(OTf)2.58 
1,3,4-oxadiazole derivatives can also be prepared starting from an acid chloride and 
hydrazide to produce a 2,5-disubstituted-1,3,4-oxadiazole ring in a good yield 
(Scheme 8).59 This sequence uses mild conditions and a nontoxic agent like TsCl 
and Et3N, CDI, EDC and SOCl2 to form the ring, while other methods use some 
aggressive conditions such as POCl3 under reflux.60  
 
Scheme 8: Synthesis of the 2,5-disubstituted-1,3,4-oxadiazole compounds. 
Although the Huisgen reaction (Scheme 9) is less common than the other methods to 
synthesize 1,3,4-oxadiazole compounds, it is useful in some cases. In this reaction a 
tetrazole compound is combined with an acid chloride or an acid anhydride.61 Firstly, 
the tetrazole attacks the carbonyl in the acid chloride or anhydride to form the amide, 
the formed tetrazole amide is unstable so, extrusion of N2 gas occurs to generate 
1,5-dipole which is subsequently cyclized to the desired product.62  
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Scheme 9: Mechanism of the Huisgen reaction.62 
It is possible also to generate 1,3,4-oxadiazole ring from the reaction between 
carboxylic acids and hydrazide using POCl3. This method is unfavorable due to the 
aggressive reagent (POCl3) nevertheless, it is used in some cases.63  
The common method to synthesize 2,3-dihydro-1,3,4-oxadiazole ring is by 
generating the hydrazide 63 (Scheme 10) followed by Schiff base formation with an 
aldehyde or a ketone to form the hydrazone 64. The last step in this method is 
refluxing the hydrazone in acetic anhydride to form the desired product 65.64 
 
Scheme 10: Synthesis of 2,3-dihydro-1,3,4-oxadiazole derivatives using the Schiff base strategy.64 
The mechanism of the cyclization (Scheme 11) starts with deportonation of the amide 
(N-H). The produced oxygen anion attacks the carbon atom of the C=N bond, the 
results is forming the 2,3-dihydro-1,3,4-oxadiazole with nitrogen anion in position 3. 
Finally, the anion attacks the acetic anhydride to add the acetyl group to position 3 of 
the ring and regenerate the acetate again.49 
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Scheme 11: Mechanism of 2,3-dihydro-1,3,4-oxadiazole ring formation. 
1.5.3. Synthesis of 2,3-dihydro-1,3,4-oxadiazoles with an additional enone unit 
In order to combine two biological active moieties, namely the 1,3,4-oxadiazole ring 
and an ,-unsaturated system, Desai and Dodiya49 prepared 2,3-dihydro-1,3,4-
oxadiazole with an acetyl group at position 3, then the Claisen-Schmidt condensation 
is applied using KOH in ethanol using microwave to insert the enone unit at position 
3 of the ring in a 63-78% yield (Scheme 12).49 Kaur et al.65 used the same method 
except that they used NaOH in refluxing ethanol. 
Scheme 12: Synthesis of 1,3,4-oxadiazole ring with an ,--unsaturated carbonyl system by the 
Claisen-Schmidt condensation.  
1.5.4. Synthesis of 1,3,4-oxadiazole-2-thiol derivatives 
The most common method to introduce the thiol group to the oxadiazole ring is the 
reaction between the hydrazides with carbon disulfide in ethanol and KOH followed 
by acidification to produce 1,3,4-oxadiazole-2-thiol, which exists as thiol-thione 
tautomerism. In this mechanism the hydrazone nitrogen atom attacks the carbon in 
the carbon disulfide in alcoholic KOH to form potassium salt followed by cyclization to 
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produce 1,3,4-oxadiazole-2-thiopotassium salt which is finally protonated by HCl 
forming the desired product (Scheme 13).66   
 
Scheme 13: Mechanism of 1,3,4-oxadiazole-2-thiol formation.66 
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2. Aim of the work 
The present thesis focuses on the synthesis of a library of compounds containing an 
,-unsaturated carbonyl group. First of all, new derivatives from the natural product 
limnophilaspiroketone are intended to be synthesized including N-Limno-CP, S-
Limno-CP and methylene-Limno-CP. Consequently, new method has to apply in 
order to attempt synthesize the natural product limnophilaspiroketone, since there is 
no total synthesis available until now for the synthesis of limnophilaspiroketone. 
Starting from the biological activity of the natural product zerumbone, which has 
gained attention recently, a new strategy is applied in order to synthesize zerumbone 
and some analogues. The method described by Kodama et al.16 to synthesize 
zerumbone has 13 steps with an overall yield 0.6%. All research on zerumbone still 
uses the isolated zerumbone from the plant Zingiber zerumbet Smith, so a new 
method is necessary to produce the zerumbone with an efficient synthetic method.  
Also, a series of heterocyclic compounds are prepared which combine three 
important biological moieties including: 1,3,4-oxadiazole ring, ,-unsaturated 
carbonyl group and pyridinyl unit. Since all these building blocks have interesting 
biological activity and no examples in the literature in which all these parts are 
combined in one skeleton. In this work 20 derivatives are synthesized with different 
substituents and different positions in order to study the relationship between the 
substituents and the biological activities of the synthesized compounds. The new 
derivatives are evaluated as antiproliferative, antibacterial and antifungal agents. 
Finally, the compounds are evaluated for their Michael acceptor activity with thiols, 
and it is attempted to find a relationship between the Michael acceptor activity and 
the biological properties of the compounds. 
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3. Results and discussion 
3.1. Methods to synthesize Limno-CPs derivatives 
3.1.1. Synthesis of methylene-Limno-CP and -X-methylene-Limno-CP 
The attractive biological activity of the Limnophila geoffrayi a plant used in the 
Traditional Medicine of Thailand, encouraged us to synthesize derivatives of the 
natural product limnophilaspiroketone. The derivative methylene-Limno-CP 
synthesized first followed by introducing substituents in the -position.  
The first step in the sequence (Scheme 14) was the protection of the phenolic group 
of 4-hydroxy iodobenzene (68) with isopropyl group to afford 69 in quantitative yield. 
Then lithium-iodide exchange was applied followed by adding 2-cyclopenten-1-one in 
order to generate compound 70. The exchange was failed, and no product was 
observed with both n-BuLi and t-BuLi.  
 
Scheme 14: Attempts to synthesize iPr-methylene-Limno-CP (72). 
The reason could be related to the strong electron donating isopropoxy group in the 
para position, which lead to increase the electron density in the C-I bond and 
decrease the affinity of the exchange. 
Since the first pathway failed, a new strategy was applied to synthesize compound 
71 directly from compound 69. This time a Heck reaction (Scheme 15) was used to 
couple 4-isopropoxyiodobenzene (69) with 2-cyclopenten-1-one using palladium 
acetate as a catalyst and potassium fluoride as base.17 The reaction took place at 
130 °C to afford the aryl cyclopentenone 71 in 54% yield after 20 h. Since the bromo 
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derivative is cheaper than the iodo the same condition was used to prepare 
compound 71 from the 4-isopropoxybromobenzene but only traces from the desired 
product was produced with very weak conversion. This happens because the 
cleavage of the C-I bond is easier than the C-Br in the oxidative addition step during 
the Heck reaction (Scheme 15).  
 
Scheme 15: Synthesis 3-(4-isopropoxyphenyl)cyclopent-2-enone (71) by the Heck reaction. 
With compound 71 in hand, the next step was forming a spirosystem with 
cyclopentenone ring to produce iPr-methylene-Limno-CP (72). Table 2 shows the 
conditions under which the desired product was prepared. Generally, the reactions 
gave multiple products since the SN2 reaction for 1,4-dibromobutane is competing 
with an elimination reaction to form alkenes mixture. Also the allylic position on the 
cyclopentene-1-one is able to undergo a substitution reaction and 5% of the 
dispirosystem 73 was isolated. The best result was acquired by refluxing in benzene 
with t-BuOK67 giving the compound 72 in 37% yield. 
Table 2: Synthesis of -Limno-CPs   
 
Entry Conditions Yield (%) of 72 Yield (%) of 73 
1 n-BuLi, diisopropylamine, 
THF, -78 °C, 2 h 
Complex mixture - 
2 NaNH2, Et2O, reflux, 24 h Traces - 
3 t-BuOK, benzene, r.t., 3 h 22 - 
4 t-BuOK, benzene, reflux, 3 h 37 5 
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By preparing compound 72 we were able to introduce substituents in the -position. 
Firstly, -bromo-methylene-Limno-CP 75 was produced using Br2 followed by 
eliminating HBr with Et3N in 81% yield after 3 h (Scheme 16). The second way to 
synthesize the -bromo-methylene-Limno-CP was using NBS in MeCN at 0 °C for 40 
min which gave the product 75 in 88% yield. -Chloro-methylene Limno-CP 74 and 
-iodo-methylene-Limno-CP 76 were synthesized using NCS and NIS, respectively, 
by refluxing for 20 h to afford 72% and 84% yield, respectively. 
 
Scheme 16: Synthesis of -X-methylene-Limno-CPs (X: Cl, Br and I). 
The -CN-methylene-Limno-CP 77 (Scheme 17) was obtained from the iodo 
derivative 76 using microwave irradiation, NaCN as a nitrile source and NiBr2 as a 
catalyst at 200 °C. The yield was 85% after just 10 min using high boiling point 
solvent N-methyl-2-pyrrolidone (NMP).32 
 
Scheme 17: Synthesis of -CN-methylene Limno-CP 77. 
The -I and -Br-methylene-Limno-CP were the key intermediates in the synthesis of 
other derivatives.  
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Suzuki coupling32 (Scheme 18) was applied to produce -aryl-methylene-Limno-CP. 
Herein, -C6H5-methylene-Limno-CP 78 was prepared from -I-methylene-Limno-CP 
76 with 71% yield after 20 h and -4-NO2-C6H4-methylene-Limno-CP 79 was 
prepared from the -Br-methylene-Limno-CP 75 with 76% yield after 20 h 
 
Scheme 18: Synthesis of -aryl-methylene-Limno-CPs by the Suzuki coupling. 
Trials to form -F-methyleneLimno-CP failed despite the fact that different conditions 
such as selectfluor/MeCN,68 NFSI/THF32 and Bu4NBr/KF/DMSO69 were screened 
and no conversion of the starting material was observed.  
To generate the free hydroxyl group in the methylene-Limno-CPs six equivalents 
BCl3 were used at -78 °C to obtain a complete deprotection with excellent yields. In 
general, all reactions gave excellent yields (91-96%) (Table 3), as well as showing 
fast reactions in most cases except 72 and 79 which needed 16 h for a complete 
conversion. 
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Table 3: Deprotection of methylene-Limno-CP derivatives. 
 
Starting 
material 
X Time (h) Product Yield (%)  
72 H 16 80 93 
74 Cl 1 81 90 
75 Br 1 82 91 
76 I 1 83 96 
77 CN 3 84 96 
78 Ph 1 85 95 
79 p-NO2-C6H4 16 86 91 
With all compounds in hand, we tried to compare the Michael acceptor activities of 
the synthesized derivatives, therefore a 96-well plate based thiol assay was used to 
determine the second order-rate constants this work was done by my colleague 
Hermina Petkes in Amslinger group. The reactions (Scheme 19) were carried out in a 
buffer containing 100 mM TRIS-HCl at pH 7.4, 2 mM EDTA–ethylene glycol 20:80 
under pseudo-first-order conditions at a concentration of 40 μM for methylene-Limno-
CPs and 500 fold of cysteamine as a thio Michael donor. None of the synthesized 
compounds was active towards a Micheal addition of cysteamine. This proved, that 
these molecules have an electron rich ,-unsaturated carbonyl system and also 
steric hindrance with two substitutes in the -position which lead to poor Michael 
acceptors. 
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Scheme 19: Reaction of methylene-Limno-CPs as thiol-Michael addition with cysteamine. 
3.1.2. Attempts for the synthesis of N-Limno-CP and S-Limno-CP  
The next derivatives related to the natural product limnophilaspiroketone are S-
Limno-CP (87) and N-Limno-CP (88) where the oxygen atom in the furan ring in the 
Limno-CP (31) is replaced by sulfur and nitrogen, respectively (Figure 21). 
 
Figure 21: Structures of Limno-CP analogues. 
To prepare S-Limno-CP (87) and N-Limno-CP (88), intermediate 91 (Scheme 20) 
was needed in which the ring closing could take place by NaSH for the S-Limno-CP 
and RNH2 for the N-Limno-CP. The desired intermediate 91 can be synthesized 
starting from p-isopropoxyiodobenzene (69) using a Sonogashira coupling with 
ethynyltrimethylsilane and a palladium catalyst. The reaction worked smoothly to give 
compound 89 with quantitative yield after 12 h. The next step was the removal of the 
TMS group in order to generate the terminal alkyne. In this case a solution of 
KOH/MeOH at room temperature was enough to produce compound 90 in 
quantitative yield after just 1 h. Then the desired intermediate 91 could be prepared 
by the Friedel-Crafts acylation of terminal alkyne 90 with chloroacetyl chloride using 
AlCl3.70-71 The reaction took place at -78 °C to room temperature for around 1 h 
affording 26% yield.  
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The intermediate 91 was ready then to generate the five membered heterocyclic 
rings, using NaSH for iPr-S-Limno-CP (94) and primary amines for iPr-N-Limno-CP 
(95) 
Scheme 20: Attempts to synthesize S-Limno-CP (87) and N-Limno-CP (88). 
To synthesize compound 92, NaSH·x H2O was used. Despite of screening different 
solvents and solvent free conditions (Table 4, Entry 1, 2, 3 and 4), complex mixtures 
were always observed even with cooling to -78 °C. The reaction was very fast and 
the starting material was completely converted within 10 min and complex mixture 
was opserved in the TLC. The same was observed when methyl amine (Table 4, 
Entry 5) was used in order to synthesize compound 93. This suggests that 
intermediate 91 is not stable under the screened conditions to produce the desired 
derivatives S-Limno-CP (87) and N-Limno-CP (88), which mean no further 
possibilities for this pathway. 
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Table 4: Approaches to synthesize compounds 92 and 93.   
 
Entry Y Reagent Solvent T (°C) t (min) Result 
1 S NaHS·x H2O acetone r.t. 10 decomposition 
2 S NaHS·x H2O CH2Cl2 -10 10 decomposition 
3 S NaHS·x H2O CH2Cl2 -78 10 decomposition 
4 S NaHS·x H2O - -10 10 decomposition 
5 MeN MeNH2, THF THF -10 30 decomposition 
An alternative method to synthesize N-Limno-CP utilizes the reaction of terminal 
alkyne 90 with 1,2-epoxycyclohexane (96) to form the secondary alcohol 97 (Scheme 
21). The reaction took place with boron trifluoride etherate72 at -78 °C for 3 h to give 
only 21% yield of the desired product 97 and multiple by products. The next step was 
an oxidation of the alcohol 97 using IBX in DMSO73 in order to synthesize compound 
98, no reaction at all was observed even at 90 °C. 
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Scheme 21: Attempts to synthesize N-Limno-CP (88). 
Referring to the cyclization step in the mechanism of Limno-CP synthesis, the OH 
group in compound 29 (Scheme 22) could be replaced with a thiol group to form 
compound 98, then by the same cyclization process as in the Limno-CP could be 
applied. For the thiol generation, the Lawesson's reagents was used under the same 
conditions in Nishio, T procedure74 Surprisingly, new compound was observed in 
66% yield after 4 h at room temperature. The mass spectrum showed mass peak at 
288.12, while the 1H-NMR and 13C-NMR show a cyclic product. In this case there are 
two possible isomers: the first possible skeleton is iPr-S-Limno-CP (94) while the 
second possible isomer is the iPr-thiocarbonyl-Limno-CP (99).  
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Scheme 22: Treatment of compound 29 with the Lawesson's reagent. 
In order to distinguish between the two isomers and determine the correct skeleton, 
two experiments were done. The first experiment was measuring the IR, in this case 
it was significant that the band at around 1675 cm-1 which corresponds to the 
conjugated ,-unsaturated carbonyl group was missing (Figure 22), while a strong 
bands can be observed at 1117 cm-1 related to the thiocarbonyl group.  
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Figure 22: IR spectrum showing thiocarbonyl-Limno-CP (99). 
The band at 1117 cm-1 matchs the range of conjugated thiocarbonyl group (Figure 
23),75-76 therefore, the IR data most likely shows the thiocarbonyl compound 99. 
 
Figure 23: Wave numbers 1/λ (cm-1) for conjugated thiocarbonyl group (C=S).75-76  
The second experiment aimed at proving the product was a treatment of the iPr-
Limno-CP (30) with the Lawesson's reagent in order to convert the carbonyl group to 
the thiocarbonyl group by refluxing in toluene for 48 h. This produced the 
thiocarbonyl-Limno-CP (99) in 45% yield. At this point by comparing the 1H-NMR 
spectrum of the product with the 1H-NMR spectrum of the unknown compound 
(Figure 24), it was clear that the two spectra are identical which proves that the 
unknown product is thiocarbonyl-Limno-CP (99). 
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Figure 24: 1H-NMR spectrum showing thiocarbonyl-Limno-CP (99), A: 1H NMR for 99 from the 
starting material 29, B: 1H NMR for 99 from the starting material 30.  
The proposed mechanism for formation of thiocarbonyl compound 99, start with 
decomposition of Lawesson's reagent to dithiophosphine ylide 100 (Scheme 23): The 
sulfur atom in the ylide attacks the -position of the unsaturated carbonyl moiety 
while the -position is protonated to form compound 101. The hydroxyl group in 101 
attacks the carbonyl group and simultaneously the oxygen atom in the carbonyl 
group attacks the phosphorus cation in the dithiophosphine ylide to form six 
membered ring fused with furan ring 102. Finally, six membered ring in compound 
102 opens to form the thiocarbonyl compound 99. The driving force is forming the 
P=O bond in the by-product.     
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Scheme 23: Proposed mechanism to synthesize compound 99. 
3.2. Limnophilaspiroketone 
The natural product limnophilaspiroketone (2) was isolated as a racemic mixture, with 
interesting skeleton combining two ,-unsaturated systems with a phenolic moiety 
and also with a spirosystem. These specifications are encouraging to try synthesize 
such a compound. 
3.2.1 Retrosynthesis of limnophilaspiroketone 
To synthesize limnphilaspiroketone (2), firstly the 3(2H)-furanone ring could be 
formed by the method used by Sabine Amslinger and Simon Lindner on the 
synthesis of Limno-CP from the corresponding alcohol (Scheme 24).32  
Scheme 24: Retrosynthesis leading to cyclization of compound 104 to form limnphilaspiroketone (2). 
The proposed mechanism (Scheme 25) shows that diethylamine attacks the -
position of the ,-unsaturated carbonyl system in compound 29, while the -position 
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is protonated by water to form 105. Subsequently, the tert-alcohol attacks the 
carbonyl group to form the furan ring in 106, after that the nitrogen atom forms 
iminium cation 107 under elimination of hydroxide ion. Finally, the iminium cation is 
converted to carbonyl group in the presence of water to give the desired product 
30.32     
 
Scheme 25: Proposed mechanism of the cyclization reaction to form 3(2H)-furanone ring (30).32 
Compound 104 (Scheme 26) can be derived from the corresponding benzyl alcohol 
108 by oxidation reaction using PCC or MnO2 in CH2Cl2. The other two tert-alcohols 
will not be oxidized. The alkyne 108 can be generated from two moieties: the terminal 
alkyne 109 and the cyclopentenone compound 110. This reaction could be done by 
treating the alkyne with n-BuLi followed by nucleophilic addition selectively to the 
non-conjugated carbonyl group in compound 110. Since compound 110 has three 
carbonyl groups where one is an ester, which is the poorest electrophile comparing 
to the other carbonyl groups. The second carbonyl group forms an enone system 
which causes decrease in the electrophilicity. In this case the priority is to the third 
non-conjugated carbonyl group which can react with the terminal alkyne 109. 
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Scheme 26: Retrosynthesis of compound 104. 
The analogue 109 (Scheme 26) could be synthesized by the Grignard reaction 
between the protected benzaldehyde 111 and ethynylmagnesium bromide. 
Compound 110 could be generated from the deprotection of the carbonyl group in 
the known compound 113. Gottfried et al.77 synthesized in 1985 compound 113 
(Scheme 27) from tetramethoxy-1,4-benzoquinone (114) with sodium metaperiodate 
in methanol. The mechanism of the reaction starts by attacking the oxygen atom in 
the sodium metaperiodate by the double bond from the tetramethoxy-1,4-
benzoquinone, followed by ester rearrangement to constrict the ring from a six to a 
five membered ring. 
 
Scheme 27: Gottfried et al.77 mechanism to form cyclopentenone 113 from tetramethoxy-1,4-
benzoquinone. 
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3.2.2. Approaches to synthesize limnophilaspiroketone 
Firstly, 4-hydroxybenzaldehyde (112) must be protected and since 
limnophilaspiroketone (2) has two methoxy groups, the phenolic OH could be 
deprotected selectively at the end. Hence, the isopropyl group was used since it can 
be selectively removed by BCl3. The reaction gave quantitative yield after 4 h with 
isopropyl bromide (Scheme 28). The 4-isopropoxybenzaldehyde (111) was treated 
with ethynylmagnesium bromide solution at -78 °C in THF affording the terminal 
alkyne 95 after 2 h in 98% yield. 
 
Scheme 28: Grignard reaction to form the benzylic alcohol 109 with a terminal alkyne moiety.  
The second step was the preparation of the cyclopentenone skeleton 110. Using the 
commercially available tetrachloro-1,4-benzoquinone (115) with four equivalents 
sodium methoxide (Scheme 29), orange crystals of tetramethoxy-1,4-benzoquinone 
(114) were obtained in 79% yield after 6 h. Then the six membered ring was contract 
to a five membered ring by ester rearrangement. Here, tetramethoxy-1,4-
benzoquinone (114) was treated with sodium metaperiodate in a solvent mixture 
(MeOH-H2O, 10:1) at 70 °C for 50 h. The reaction gave 21% yield, while doing the 
same reaction in the microwave at 60 °C in MeOH gave 19% yield after 3 h. It is 
worth noting that the second method is just useful on small scale, since larger scale 
(> 1 g) could not performed with the setting in use.      
 
Scheme 29: Synthesis of compound 113 by ester rearrangement.  
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By having compound 113 in hand, the next step was the deprotection of the 
dimethylacetal in order to generate the carbonyl group which is needed in the next 
step. To deprotect the dimethylacetal different conditions were screened (Table 5). 
Herein, weak acids did not show any reaction even under reflux. Moreover, even 
when a stronger acid like TFA at 50 °C was used no reaction took place. The 
reaction with sulfuric acid at room temperature showed no conversion while heating 
to 40 °C caused degradation of the material without any product as seen in the mass 
spectrum. Similar results were obtained with BCl3, I2,78 Ce(OTF)3,79 PCC,80 CuSO4,81 
and CAN82 which are known as a dimethylacetal deprotection reagents. 
Table 5: Attempted reactions to generate the carbonyl group in 113.  
 
 Reagent Solvent T (°C) t (h) Result 
PTSA acetone reflux 36 no reaction 
PTSA H2O reflux 24 no reaction 
AcOH H2O r.t. 48 no reaction 
AcOH H2O reflux 24 no reaction 
TFA - r.t. 24 no reaction 
TFA - 50 48 no reaction 
1 M HCl H2O r.t. 24 no reaction 
H2SO4 CH2Cl2 r.t. 24 complex mixture 
H2SO4 - r.t. 24 no reaction 
H2SO4 - 40 0.25 complex mixture 
CAN MeCN/H2O (1:1) 70 24 no reaction 
Ce(OTf)3 CH3NO2 reflux 24 no reaction 
CuSO4/NaI acetone reflux 48 no reaction 
I2 acetone reflux 48 no reaction 
BCl3 CH2Cl2 -78  5 complex mixture 
PCC -   60  24 no reaction 
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Since all the trials to deprotect the dimethylacetal failed, a new strategy was used in 
order to synthesize compound 110. If one treats trimethoxy-1,4-benzoquinone 116 
with sodium metaperiodate (Scheme 30), then the ester reareangment could take 
place to afford 118. Finally, the hemiacetal in compound 118 will convert immediately 
to carbonyl group and afford 110.   
 
Scheme 30: Proposed mechanism to form cyclopentenone 110 from the 1,4-benzoquinone 116. 
Compound 116 was prepared by treating compound 114 with one equivalent BCl3 
(Scheme 31), which led to selective deprotection of one methoxy group in 
quantitative yield after 2 h at -78 °C. 
   
Scheme 31: Selective deprotection of one methoxy group with BCl3. 
Some literature assumed that sodium metaperiodate forms an epoxide with a double 
bond followed by epoxide ring opening in the presence of water or alcohol. This 
behavior encouraging to screen different epoxide agents with compound 116 to 
produce the desired analogue 110. Starting with NaIO4 in MeOH no reaction was 
observed (Table 6, Entry 1) while a solvent mixture (MeOH-H2O, 10:1) with NaIO4 
gave the undesired product 119 in 23% yield. 1H-NMR (Figure 25) shows only 3 
(OCH3) groups and one CH, while mass spectrometry showed peak at 202.16 which 
belongs to the skeleton 119.  
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Figure 25: 1H-NMR spectrum of compound 119.  
The same observation was obtained using oxone in dioxane-H2O (3:1) which 
afforded 119 in 53% yield (Table 6, Entry 3), while using H2O2 in dioxane-H2O (3:1) 
showed a new undesired side product 120 with 51% yield. In two other experiments 
t-BuOOH and DBU gave a mixture within just 10 min. While no reaction was 
observed by mCPBA after 20 h (Table 6, Entry 6).  
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Table 6: Epoxidation reactions of p-quinone 116. 
 
Entry Reagent Solvent T (°C) t (h) Product (Yield %) 
1 NaIO4 MeOH 70 50 no reaction 
2 NaIO4 MeOH:H2O 
(10:1) 
70 50 119 (23) 
3 Oxone dioxane:H2O 
(3:1) 
60 48 119 (53) 
4 H2O2, K2CO3 dioxane:H2O 
(3:1) 
reflux 2 120 (51) 
5 t-BuOOH, 
DBU 
CH2Cl2 r.t. 10 min mixture 
6 mCPBA CH2Cl2 0-r.t. 20 no reaction 
Scheme 32 (A) shows how compound 119 was formed, in this mechanism the 1,2-
dicarbonyl cyclopentenone derivative 110 was produced from the hemiacetal 121, 
and then the oxidizing agent cleaved the bond between the two carbonyl groups to 
afford dicarboxylic acid intermediate 123. Intramolecular esterification took place to 
give γ-lactone 124, finally, decarboxylation of compound 124 produced the desired 
product 119. Paju et al.83 described similar pathway (Scheme 32, B) in which 1,2-
dicarbonyl cyclopentenone derivative 126 was treated with H2O2 in acetic acid. This 
causes ring cleavage and formation of dicarboxylic acid analogues 127, followed by 
intramolecular cyclization to produce the γ-lactone 128. The mechanism of the 
reaction clearly shows that the desired product 110 is formed during the reaction but 
it is not stable under the conditions with the screened oxidizing agents.    
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Scheme 32: A: Proposed mechanism to form the γ-lactone 119 by oxidation of 1,2-dicarbonyl 
compound 110. B: Paju et al.83 proposed mechanism to form the γ-lactone 128. 
Different methods were failed to deprotect the carbonyl group in compound 113, but 
there are still other methods available which could be tried in the future to prepare 
compound 110. 
3.3. Zerumbone  
3.3.1. Retrosynthetic approach towards the total synthesis of zerumbone  
Despite the fact that the natural product zerumbone (1) is known since 1960, there is 
still no efficient method to synthesize it on a large scale and the commercially 
available zerumbone (1) is still isolated from plant. Many factors make the synthesis 
of zerumbone (1) a big challenge such as low functionality, highly strained 11-
membered ring, rigid part with divinyl carbonyl group and the stereochemistry with 
three E-configured double bonds. 
The retrosynthesis of zerumbone (1) (Scheme 33) started with breake the the non-
conjugated double bond. Ring closing metathesis could be used to convert the 
precursor 129 to zerumbone (1) using ruthenium catalysts.   
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Scheme 33: Retrosynthesis of the last step in the zerumbone synthesis.  
Examples from the literature show different types of catalysts which can be used 
depending on the ring size, functional groups in the skeleton, stereochemistry and 
the flexibility of the compound. Figure 26 shows the most common catalysts used in 
alkene ring closing metathesis. Ruthenium catalysts, including 1st (130) and 2nd (131) 
generation Grubbs catalysts have become mainstay of the modern ring closing 
metathesis. The percentage of the catalyst in these types of reactions is mostly 1-
20%, with some exceptions (i.e. > 20%).84 The Hovedya-Grubbs catalyst (HGC) 
(132) was used in some applications where the Grubbs catalysts were inefficient. 
Less common catalysts like those having Mo (Schrock’s catalyst)84 (133) and 
aluminum tris(2,6-diphenylphenoxide) ATPH (Yamamoto catalyst)85 (134) are some 
times useful in special cases. Generally, in ring closing reactions, the concentration 
of the precursor plays an important role since high concentrations lead to dimer or 
polymer formation, while very low concentrations cause decrease in the reaction rate. 
Wide range of reaction conditions were used such as solvents (benzene, toluene and 
CH2Cl2) and temperature (room temperature to reflux in toluene). 
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Figure 26: The most common catalysts used in the alkene ring closing metathesis. 
The mechanism of the RCM (Scheme 34) using Grubbs I (108) starts with 
coordination between the Ru and the double bond followed by the elimination of 
P(Cy)3 to form a four membered ring intermediate, then ring opening step occurs to 
produce the Ru=C bond and ethylene gas. The same sequence takes place with the 
second double bond. Finally, the ruthenium complex regenerates again to give the 
desired cyclic compound.  
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Scheme 34: Mechanism of alkene ring closing metathesis using Grubbs I catalyst.86 
The precursor 129 (Scheme 35) can be synthesized using the Claisen-Schmidt 
condensation between the aldehyde 136 and the ,-unsaturated ketone 137.        
 
Scheme 35: Synthesis of precursor 129 by the Claisen-Schmidt condensation. 
Aldehyde 136 was synthesized in the literature by different methods. De Kimpe et 
al.87 used isobutyraldehyd (138) with t-BuNH2 to form the imine (Scheme 36). The 
imine 139 was treated with LDA for 1 h at 0 °C, followed by the addition of 
allylbromide to afford the imine product 140. Final hydrolyzation with oxalic acid led 
to the corresponding aldehyde 136 in total yield of 83%. Noack and Göttlich,88 used a 
similar method with morpholine instead of t-BuNH2. 
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Scheme 36: Aldehyde 136 synthesized by De Kimpe et al.87 
Cai et al.89 prepared aldehyde 136 (Scheme 37) during the synthesis of the natural 
product buddledone A. In this method, isobutyronitrile (141) was deprotonated by 
lithium diethylamide followed by substitution reaction with allylbromide to produce the 
nitrile compound 142 which was reduced to the corresponding aldehyde 136 by 
DIBAL-H in total yield of 91% of aldehyde 136. The same reduction procedure gave 
98% yield of aldehyde 136 by Yang, T.90 
 
Scheme 37: Aldehyde 136 synthesized by Cai et al.89 
The ,-unsaturated ketone 137 (Scheme 38) could be prepared using the Horner-
Wadsworth-Emmons reaction between the aldehyde 143 and diethyl (3-oxobutan-2-
yl)phosphonate 144. Herein, aldehyde 143 could be generated by reduction of the 
corresponding nitrile 145, which could be produced from the substitution reaction 
between acetonitrile and methyl allylchloride (146). The diethyl (3-oxobutan-2-
yl)phosphonate (144) could be synthesized from the corresponding 3-chlorobutan-2-
one (147) with triethylphosphite. 
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Scheme 38: Retrosynthesis planed of ketone 137. 
3.3.2. Synthetic approaches towards zerumbone   
To synthesize aldehyde 113 (Scheme 39), isobutyronitril (118) was deprotonated by 
lithium diethylamide followed by a substitution reaction with allylbromide to produce 
the desired nitrile 142 in 98% yield. Nitrile 142 was reduced by DIBAL-H to the 
corresponding aldehyde 136 in 98% yield after 8.5 h.  
 
Scheme 39: Synthesis of aldehyde 136. 
The next step was the preparation of the aldehyde 143. In this case acetonitrile was 
treated with lithium diethylamide (Scheme 40) followed by adding methyl 
allylchloride. The desired nitrile 145 was not observed and only amixture of di- and 
tri-alkylated acetonitrile 148 and 149 were observed.  
Scheme 40: Attempt to synthesize nitrile 145 from acetonitrile. 
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The reason is the acetonitrile has a high pKa value 25 which means a strong 
conjugated base, this led to deprotonate the monoalkylated product 145 and formed 
the di- and tri-substituted acetonitrile 148 and 149. Aldehyde 143 (Scheme 41) was 
synthesized by Clarke et al.91 fromed methyl allylalcohol (150) using Johnson-Claisen 
rearrangement to produce the ester 151. The produced ester was reduced to the 
alcohol followed by oxidation to the corresponding aldehyde 143. 91      
 
Scheme 41: Aldehyde 143 synthesized by Clarke et al.91 using Johnson-Claisen rearrangement 
followed by oxidation-reduction reactions. 
The starting material methyl allylalcohol is expensive, so instead of this method, a 
new method could be applied using very cheap starting material isoprenol (152). In 
this work isoprenol (152) (Scheme 42) was tosylated using Et3N as a base,92 to 
produce compound 153 in quantitative yield. Substitution reaction of the tosylate 
group in compound 153 with sodium cyanide in DMSO at 90 °C92 produced the nitrile 
compound 145 in quantitative yield after 2 h. The nitrile 145 was reduced by DIBAL-H 
to the corresponding aldehyde 143 in excellent yield. This method gave an excellent 
yield over three steps without any special reagent.   
 
Scheme 42: Synthesis of aldehyde 143 starting from isoprenol 152. 
Having aldehyde 143, the next step was to prepare diethyl (3-oxobutan-2-
yl)phosphonate (144) in order to apply the Horner-Wadsworth-Emmons reaction 
(Scheme 43). The method of Corbel et al.93 was used to synthesize the phosphonate 
compound 144 by protection of the carbonyl group in 3-chlorobutan-2-one (147) with 
methyl hydrazinecarboxylate to prevent by-products and improve the yield. Then, a 
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substitution reaction with triethylphosphite was performed by refluxing in toluene for 9 
h to give 64% yield of compound 144. The Horner-Wadsworth-Emmons reaction 
between compound 144 and aldehyde 143 took place using DBU or NaH as a base. 
The E-isomer was the only isolated product with 77% and 26% yield for NaH and 
DBU, respectively.   
 
Scheme 43: Synthesis of the Horner-Wadsworth-Emmons phosphonate reagent. 
The next step was forming the precursor 129. The Claisen-Schmidt condensation is 
one of the most common methods to form enone unit. The results (Table 7) show 
that the hydroxide bases were not suitable since one equivalent (Table 7, Entry 1 and 
3) from the base did not show any conversion in the starting material. The same 
observation when we tried three equivalents KOH at room temperature (Table 7, 
Entry 4), while using KOH in refluxed EtOH or MeOH (Table 7, Entry 5 and 7) led to 
complex mixture. Three equivalents of KOH at 50 °C caused decomposition of the 
aldehyde 136 (Table 7, Entry 6). Also DBU refluxing in MeOH,94 did not show any 
reaction (Table 7, Entry 8), while NaH at 0 °C to room temperature,95 after 1.5 h gave 
9% yield of the product 129 with only E-isomer (Table 7, Entry 9). Since the NaH 
gave low yield, more investigations were done by t-BuOK in benzene at room 
temperature.67 Here, the yield were around 11% as a mixtures of the Z and E-
isomers were observed (Table 7, Entry 10 and 11). Both trifluoroacetic acid (TFA) 
(Table 7, Entry 12) and piperidinium trifluoroacetate salt14 (Table 7, Entry 14) did not 
show any reaction, while LDA89 (Table 7, Entry 13) produced a complex mixture even 
at -78 °C.    
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Table 7: Synthesis of precursor 129 by the Claisen-Schmidt condensation. 
 
Entry Base (eq) Solvent T (°C) t (h) Result 
1 NaOH (1) EtOH 60 48 no reaction 
2 NaOH (2.5) EtOH 60 48 complex mixture 
3* KOH (1) EtOH 30 6 no reaction 
4 KOH (3) EtOH rt 6 no reaction 
5 KOH (3) EtOH reflux 2 complex mixture 
6 KOH (3) EtOH 50 3 decomposition of 136 
7 KOH (2) MeOH reflux 3 complex mixture 
8 DBU (1) MeOH reflux 48 no reaction 
9 NaH (1.2) THF 0 - r.t. 1.5 9% of 129 (E) 
10 t-BuOK (1.2) benzene r.t. 1 11% of 129 (E and Z) 
11 t-BuOK (0.6) benzene r.t. 3 12% of 129 (E and Z) 
12 TFA (0.05) EtOH reflux 48 no reaction 
13 LDA (1.1) THF -78 2.5 complex mixture 
14 piperidinium 
trifluoroacetate 
(0.2) 
EtOH reflux 48 no reaction 
* Ultrasound was used in the reaction.  
The final step was trying to convert precursor 129 to the zerumbone (1) by ring 
closing metathesis using Ru catalysts. It was easy to decide whether we got the 
desired product or not by using zerumbone as a reference in the thin layer 
chromatography (TLC). The screening was started using 0.12 mM of precursor 129 
with 20 mol% of Grubb’s II catalyst (131). The reaction did not show the desired 
product in the TLC and the mass spectrum showed peak at [M+]= 304.0. A new by-
products were observed using Hovedya-Grubbs catalyst (132) at 80 °C in toluene or 
in refluxed CH2Cl2 (Table 8, Entry 2 and 3) the mass spectra showed peaks at 
Results and discussion 
55 
 
[M+NH4]+= 306.2. While the amount of Hovedya-Grubbs catalyst (132) was increased 
to 50 mol% a complex mixture was observed without any peak for the zerumbone (1) 
in the mass spectrum (Table 8, Entry 4). By using 10 mol% of Grubb’s I catalyst 
(130) in refluxing CH2Cl2 isomerization reaction took place which means the same 
molecular weight as the starting material was observed in the mass spectrum 
([M+H]+ = 247.2) but different Rf value on TLC, the 1H-NMR was not strong enough 
to characterize all the peaks but at least the terminal vinyl protons disappeared. In 
order to avoid this isomerization reaction p-benzoquinone was used as an additive to 
trap the ruthenium hydride which causes the isomerization reaction. The way how p-
benzoquinone prevents the isomerization is not fully understood, but it could work 
either by prevention of the ruthenium hydride complex formation or by trapping the 
ruthenium hydride immediately during the reaction.96 By using p-benzoquinone as an 
additive with Hovedya-Grubbs catalyst (Table 8, Entry 6) new by-product was 
observed with peak in the mass spectrum at [M+H]+= 305.2. 
Table 8: Approaches to zerumbone formation by ring closing metathesis. 
 
Entry Catalyst (mol%) Solvent T (°C) t (h) Result 
1 Grubb’s(II) (20) toluene 60 20 [M+]= 304.0 
2 HGC (20) toluene 80 20 [M+NH4]+= 306.2 
3 HGC (20) CH2Cl2 reflux 20 [M+NH4]+= 306.2 
4 HGC (50) CH2Cl2 reflux 20 complex mixture 
5 Grubb’s I (10) CH2Cl2 reflux 20 isomerization 
[M+H]+= 247.2 
6§ HGC (20) toluene 80 6 [M+H]+= 305.2 
7§* HGC (20) toluene 80 20 dimer 
§ p-benzoquinone was used as an additive. *Using 0.5 mM precursor. 
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By increasing the concentration of the starting material to 0.5 mM (Table 8, Entry 7) 
the HRMS shows [M+H]+ = 465.3722 which means that a dimer was formed. Also the 
1H-NMR spectrum (Figure 27) shows a dimer formation in which the two molecules 
were connected from the less steric hindered double bonds.   
 
Figure 27: 1H-NMR spectrum of the dimer. 
The unsuccessful screening for the ring closing metathesis step could be related to 
the tow vinyl groups around the carbonyl group with E-configuration (Figure 28), give 
some rigidity to the precursor 129. This rigidity prevent joining the two terminal 
double bonds together.  
a 
b 
c 
d e 
f g h i j 
k 
CDCl3 H2O 
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Figure 28: Three dimensional structure estimation of precursors 129 and 154.  
Therefore a new precursor with less number of double bonds 154 (Figure 28) could 
be more fixable, but a problem in the stability of the aldehyde 143 was observed 
since it was decomposed within 10 days even at -20 °C. To solve this problem, 
aldehyde 136 could be used instead of aldehyde 143 to optimize the conditions and 
after that aldehyde 143 could be used again to prepare zerumbone (1).  
The new precursor 154 (Scheme 44) could be synthesized using two equivalents 
from aldehyde 136. The advantage of this method is no need for phosphonate 
reagent which makes the sequence shorter. 
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Scheme 44: Retrosynthesis for the more flexible precursor 154. 
Ketone 155 can be synthesized by the Claisen-Schmidt condensation between 
aldehyde 136 and ethylmethylketone (156). In these reactions LDA/MsCl89 gave a 
very good yield with 73% after 24 h (Table 9, Entry 1), while LDA/MOMCl97 (Table 9, 
Entry 2) produced the desired product 155 in 58% yield after 10 h. Using 
morpholinium trifluoroacetate with ethylmethylketone (156) as a solvent 9% yield was 
observed after 48 h (Table 9, Entry 3). With t-BuOK reflux in benzene 22% yield of 
155 was afforded after 20 h (Table 9, Entry 4). Further investigations using the 
Kelleher et al.98 conditions with LiI reflux in Et2O, here, 81% yield from the product 
155 was afforded after 30 h using excess from the aldehyde 136 (ratio 136/156 = 1.4) 
(Table 9, Entry 5). By decreasing the ratio 136/156 to 0.9 no big different was 
observed and the desired ketone 155 was produced in 79% yield after 30 h (Table 9, 
Entry 6). When the solvent was changed to CH2Cl2.with 2 equivalents LiI no reaction 
took place after 48 h refluxed, since LiI is slightly soluble in Et2O and it is not soluble 
in CH2Cl2.  
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Table 9: Synthesis of ketone 155  
 
Entry Conditions Ratio 136/156 Yield (%) 
1 a. LDA (1.1 eq), THF, -78 °C, 3.5 h 
b. MsCl (2.4 eq), Et3N, CH2Cl2, 0 °C-
r.t., 20 h 
1.1 73 
2 a. LDA (1.1 eq), THF, -78 °C, 3.5 h 
b. MOMCl (2 eq), DIPEA, CH
2
Cl
2
, 0 
°C-r.t., 6 h 
0.9 58 
3 Morpholinium trifluoroacetate (0.2 
eq), 80 °C, 48 h 
* 9 
4 t-BuOK (1.1 eq), benzene, reflux, 20 
h 
1.1 22 
5 LiI (2.5eq), Et2O, reflux, 30 h 1.4 81 
6 LiI (3 eq), Et2O, reflux, 30 h 0.9 79 
7 LiI (2 eq), CH2Cl2, reflux, 48 h 0.9 no reaction 
* Ethylmethylketone was used as a solvent with 1 eq of 136. 
The precursor 154 could be synthesized by aldol reaction between ketone 155 and 
aldehyde 136. Using LDA led to a complex mixture since mixing the ketone 155 first 
with LDA led to self-reaction (Table 10, Entry 1). While stabilizing the enolate with a 
TMS group by Mukaiyama aldol reaction followed by using TiCl4 as a Lewis acid 
gave 13% yield product after 2 h and multiple by-products (Table 10, Entry 2). In 
contrast, LiI in Et2O at 70 °C did not show any reaction in this case (Table 10, Entry 
3).   
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Table 10: Synthesis of precursor 154.    
 
Entry Conditions* Ratio 155/136 Result/ yield (%) 
1 a. LDA (1.2 eq), THF, -78 °C, 2 h, 
b. NH4Cl 
1.5 complex mixture 
2 a. LHMDS (2 eq), THF, -78 °C 
then Et3N (3 eq), TMSCl (3 eq), 1.5 
h.   
b. TiCl4 (1 eq), CH2Cl2, -78 °C, 40 
min 
 
1 13 
3 LiI (3 eq), Et2O, 70 °C, 48 h, 
Sealed tube 
1 no reaction 
The precursor 154 has less double bonds which means it is more flexible than the 
first precursor 129. Ring closing metathesis was applied using different ruthenium 
catalysts with 0.12 mM concentration of the starting material and 20 mol% of the 
catalyst. In these cases Grubbs I (130) (Table 11, Entry 1) and Grubbs II (131) (Table 
11, Entry 2) did not show any reaction. When Hovedya-Grubbs catalyst (132) was 
used, a new product was observed on the TLC while the mass spectrometry shows 
the same molecular weight as starting material which means that an isomerization 
reaction was occurred (Table 11, Entry 3). Adding p-benzoquinone to the reaction as 
an additive caused side product formation (Table 11, Entry 4), while using catalyst 
135 refluxed in toluene didn’t show any reaction (Table 11, Entry 5). 
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Table 11: Attempted to ring closing metathesis of precursor 154 
 
Entry Catalyst (mol%) Solvent T (°C) t (h) Result 
1 Grubb’s(II) 
(20) 
toluene 80 20 no reaction 
2 Grubb’s (I) 
(10) 
toluene reflux 48 no reaction 
3 HGC (20) toluene 80 6 isomerization reaction 
4§ HGC (20) toluene 80 6 unidentified product 
5 135 toluene reflux 4 d no reaction 
§ p-Benzoquinone 0.2 equivalent was used as an additive. 
All the attempts to produce the cyclic product were failed. By looking to similar 
skeletons in the literature many examples show problems when nine, ten and eleven 
membered rings need to be formed, since they all are highly strained. Cai et al.89 
prepared the 11-membered ring natural product buddledone A (32), all their trials to 
convert the precursor 156 to buddledone A (32) failed under different catalysts and 
conditions (Scheme 45). Then they decided to protect the carbonyl group, in this 
case the new carbon center became sp3 hybridized which makes the precursor more 
flexible towards ring closing metathesis. TMSCN was used as a protection group for 
the carbonyl group to produce compound 159, but approaches to form the ring by 
HGC in toluene for two days led to isomeric product 160. To solve this problem, p-
benzoquinone was used as an additive. Finally, the ring closing succeeded with HGC 
followed by regenerating the carbonyl group to produce buddledone A (32) in 59% 
yield over two steps.89                
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Scheme 45: Synthesis of buddldone A (32) by Cai et al.89 
Herein, more investigations are need in the future to make the precursor more 
flexible, which could be achieved by using TMSCN to protect the carbonyl group 
(Scheme 46, A). An alternative method (Scheme 46, B) could be by reducing the 
carbonyl group to the corresponding alcohol to form sp3 center and then the ring 
closing metathesis take place followed by regeneration the carbonyl group. 
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Scheme 46: Proposed synthesis for zerumbone (1) by convert the carbonyl group to sp3 hybridized. 
A: Using TMSCN, B: by reduction to alcohol. 
3.4. 1,3,4-Oxadiazole derivatives with an additional enone unit 
All the previous sections were attempted to synthesize natural products with an 
enone system or tried to prepare derivatives from the natural products with some 
groups in the -position of the conjugated system. The next idea was combined the 
enone unit with the synthetic biological active moiety oxadiazole.  
3.4.1. Synthesis of 1,3,4-oxadiazoles with an additional enone unit in position 
two 
To combine 1,3,4-oxadiazole moiety with an enone unit in position 2 and a pyridinyl 
moiety in position 5 of the ring, isonicotinic ester 165 (Scheme 47) was treated with 
hydrazine monohydrate under refluxing in ethanol63 this gave 89% yield of the 
hydrazide 166 after 3 h. Then the isonicotinic hydrazide 166 was treated with triethyl 
orthoformate at 120 °C to afford the oxadiazole ring with a pyridinyl moiety 167 to 
yield 95% after 20 h. The next step was attempted to introduce a TMS group in 
position two of the ring to get 168 using Zarudnitskii’s99 method. The TMS group 
could be substituted with an acetyl group to produce compound 169. Finally, the 
Claisen-Schmidt condensation could be applied to get the desired derivatives 141. 
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Scheme 47: Attempts to synthesize 1,3,4-oxadiazole ring with an additional ,-unsaturated carbonyl 
unit in position 2 
Different conditions were tried in order to have the compound 168 with a TMS group. 
Firstly, TMSCl and TMSBr were used with Et3N (Table 12, Entry 1 and 2), no 
conversion was observed after 30 h and 48 h, respectively, even with increasing the 
temperature. The same result was observed with strong bases such as DIPEA and n-
BuLi even with bromide as a leaving group (Table 12, Entry 3 and 4). Consequently, 
cinnamoyl chloride was used in order to directly insert an enone to the oxadiazole 
ring, different bases ranging from Et3N as a weak base (Table 12, Entry 5) to strong 
bases like n-BuLi (Table 12, Entry 6) and NaH (Table 12, Entry 7) were used but no 
conversion at all was observed for the oxadiazole compound 167. Then acryloyl 
chloride was used in a Friedel Crafts acylation using AlCl3 as a Lewis acid, but still no 
conversion was observed (Table 12, Entry 8). The same observation was made 
when cinnamoyl chloride was treated with TiCl4 at -78 °C (Table 12, Entry 9).    
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Table 12: Approaches to introduce TMS group or enone unit to 1,3,4-oxadiazole 167.  
 
Entry R X Base/ 
Acid (eq) 
Solvent T (°C) t (h) Comment 
1 - Cl Et3N Et2O r.t.-reflux 30 n.c. 
2 - Br Et3N - r.t.-60 48 n.c. 
3 - Br DIPEA toluene r.t.-reflux 48 n.c. 
4 - Br n-BuLi THF -78-r.t. 6 n.c. 
5 Ph Cl Et3N THF 0-r.t. 24 n.c. 
6 Ph Cl n-BuLi THF -78-r.t. 5 n.c. 
7 Ph Cl NaH THF -10-r.t. 6 n.c. 
8 H Cl AlCl3 CH2Cl2 0-r.t. 48 n.c. 
9 Ph Cl TiCl4 CH2Cl2 -78-r.t. 2.5 n.c. 
n.c.: no conversion was observed for the oxadiazole 167. 
In all these trials, no conversion was observed for the oxadiazole compound 167. 
The reason might be that pyridinyl moiety can react as a nucleophile using the 
nitrogen lone pair which means trap the TMS group and the acyl chloride during the 
reaction. While in Zarudnitskii et al.99 case only a phenyl group was attached to the 
oxadiazole ring in all the examples. Since the methods to introduce the TMS or the 
enone unit to the oxadiazole ring failed, a new pathway was used. In this case an 
ester group in position 2 of 172 was prepared using Leung et al.59 method. 
Isonicotinic hydrazide (166) was treated with ethyl oxalyl chloride, Et3N and p-TsCl in 
CH2Cl2 at 0 °C-r.t. for 30 h to produce the desired ester 172 in 93% yield (Scheme 
48). 
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Scheme 48: Synthesis of ethyl 5-(pyridin-4-yl)-1,3,4-oxadiazole-2-carboxylate (172). 
With having the oxadiazole ester 172 in hand, the next step was the substitution 
reaction to convert ester 172 to the ketone 169. A complex mixture was observed 
using Grignard reagent MeMgBr (Table 13, Entry 1) or MeLi (Table 13, Entry 2), 
because the ketone product was more reactive than the ester starting material 172 
which led to a consecutiveof reaction of the product. An excess of ester 172 led to 
traces from the product 169 (Table 13, Entry 3). Similarly, introducing vinyl moiety by 
the Grignard reaction gave complex mixture (Table 13, Entry 4).    
Table 13: Attempts to convert the oxadiazole ester 172 to the corresponding ketone.  
 
Entry RX (eq) Result 
1 MeMgBr (1) complex mixture 
2 MeLi (1) complex mixture 
3 MeMgBr (0.5) traces 
4 CH2=CHMgBr (1) complex mixture 
Since some oxadiazole ring with sulfur atom in position two show interesting 
biological activity, so the idea was to couple the oxadiazole ring with enone moiety 
using a sulfur atom at position 2 of the ring. The isonicotinic hydrazide (166) and 
carbondisulfide were refluxed in ethanol and triethylamine to produce 2-thiol-1,3,4-
oxadiazole 174 with 78% yield after 24 h. The 2-thiol-1,3,4-oxadiazole 174 was 
combined with ,-unsaturated acid chloride at 0 °C with triethylamine to generate 
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compounds 175 (Table 14, Entry 1) and 176 (Table 14, Entry 2) with 72% and 53% 
yield, respectively.  
Table 14: Combine the oxadiazole 174 with enone unit using sulfur bridge.  
 
Entry Product R1 R2 t (h) Yield (%) 
1 175 C6H4 H 3 72 
2 176 p-MeO-C6H4 H 3 53 
3 177 H H 3 n.c 
4 178 H CH3 4 n.c 
n.c: no conversion was observed for the oxadiazole 174. 
Aliphatic ,-unsaturated acid chloride (Table 14, Entry 3 and 4) did not show any 
conversion of the oxadiazole starting material 176. Which seems to be the product 
unstable, because in the case of aromatic substituent in the -position (Table 14, 
Entry 1 and 2) the product is stabilized by the conjugation (Scheme 49), while it is not 
the case with short conjugation in the aliphatic products (Table 14, Entry 3 and 4). 
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Scheme 49: A: long conjugation with -aryl group stabilize the oxadiazole derivative 176, B: short 
conjugation with unsubstituted enone system destabilize the oxadiazole derivative 177. 
 
3.4.2. Synthesis of 2,3-dihydro-1,3,4-oxadiazoles with an additional enone unit 
in position three 
To prepare 1,3,4-oxadiazole with enone unit in position three and pyridinyl moiety in 
position, isonicotinic hydrazide (166) was treated with different aldehydes and 
ketones to have a set of hydrazones (179-190) (Table 15). In these examples 
monosubstituted, disubstituted, aliphatic, aromatic and cyclic carbonyl compounds 
were used to decorate the hydrazones 179-190 in order to study the structure activity 
relationship (SAR) of the resulting final compounds. Generally, the reaction produced 
hydrazones from moderate to high yield (41-98%) with catalytic amounts of glacial 
acetic acid. The differences are obvious in the reaction times, since the aldehydes 
react faster (3 h) compared with the ketones (24 h). This is related to the 
electrophilicity of the aldehydes which is higher than the ketones (Table 15). 
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Table 15: Synthesis of hydrazones 179-190 
 
Product R1 R2 t (h) Yield (%) 
179 C6H5 H 3 76 
180 p-MeO-C6H4 H 3 96 
181 p-NO2-C6H4 H 3 98 
182 C6H5 CH3 24 95 
183 -CH2(CH2) 3CH2- 24 55 
184 p-MeO-C6H4 CH3 24 67 
185 C6H5 CH3 21 47 
186 p-NO2-C6H4 CH3 24 41 
187 p-CF3-C6H4 CH3 24 92 
188 p-OCF3-C6H4 CH3 24 96 
189 4-pyridinyl CH3 24 91 
190 2-pyridinyl CH3 24 97 
* phenyl moiety in position 5 of the oxadiazole ring instead of the pyridinyl, compounds 186 and 187 
were prepared by Maria Landa and 188 was prepared by Thomas Klein. 
The next step was the formation of the 2,3-dihydro-1,3,4-oxadiazole ring from the 
corresponding hydrazone. To achieve this, hydrazone 180 was refluxed with acetic 
anhydride to produce the desired 2,3-dihydro-1,3,4-oxadiazole 191 with acetyl group 
in position 3 with only 34% yield after 3 h (Scheme 50).  
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Scheme 50: Synthesize 1,3,4-oxadiazole with acetyl group in position three 191. 
The acetyl group in position 3 in compound 191 was then available to create the ,-
unsaturated carbonyl unit. The oxadiazole 191 was treated with benzaldehyde under 
different conditions, by using the most common bases in the Claisen-Schmidt 
condensation (Table 16, Entry 1-3) under various conditions this caused hydrolysis of 
the oxadiazole starting material 191, also with nonpolar solvent (Table 16, Entry 4). 
As a result, compound 191 was unstable in the basic medium since in all these cases 
complete conversion of the oxadiazole was observed, which means that this strategy 
is not useful to synthesize the desired derivatives. 
Table 16: Claisen-Schmidt condensation conditions to form the enone unit in position 3 of the 
oxadiazole ring.   
 
Entry Base Solvent T (°C) t (h) Result 
1 Ba(OH)2·8H2O MeOH reflux 0.5 hydrolysis of 191 
2 NaOH EtOH reflux 3 hydrolysis of 191 
3 NaOH EtOH r.t. 5 hydrolysis of 191 
4 piperidine toluene reflux 0.5 hydrolysis of 191 
An alternative pathway was necessary in order to prepare the desired products. 
Going back to the original mechanism of the 1,3,4-oxadiazole ring formation 
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(Scheme 8 in the introduction) a weak base (CH3COO-) was used to deprotonate the 
N-H and a carbonyl electrophile source (Ac2O) was used to add carbonyl moiety to 
the position 3 of the oxadiazole ring. The new strategy used Et3N as a base and ,-
unsaturated acid chloride as a carbonyl electrophile source. In this case the enone 
system was synthesized separately and then added to the ring during the formation 
of the heterocyclic. The proposed mechanism (Scheme 51) shows that Et3N 
deprotonates the N-H in compound 192 to form the enolate 193, then the enolate 
oxygen attacks the carbon in the C=N bond. The result is 1,3,4-oxadiazole ring with a 
nitrogen anion in position 3 in 194 which works as nucleophile and immediately 
attacks the excellent electrophile ,-unsaturated acid chloride and looses chloride 
as a leaving group to form compound 196. The advantages of this method are the 
following: mild conditions, formation of oxadiazole ring with the enone unit take place 
in one step and a wide range of aliphatic and aromatic , -unsaturated acid chloride 
can be used. 
 
Scheme 51: Proposed mechanism for 2,3-dihydro-1,3,4-oxadiazole ring formation with an additional 
,-unsaturated carbonyl unit in position three.100 
In this method, ,-unsaturated acid chlorides were synthesized from the 
corresponding aldehyde as described by Pau et al.101 the aliphatic ,-unsaturated 
acid chloride are commercially available. Various acid chlorides were used in order to 
study the effect of the substituent around the enone unit on the biological activity of 
the compounds, the synthesis was done in parallel with testing. Reaction times, 
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temperatures and yields are summarized in Table 17. In general the reactions are 
fast and the aliphatic acid chlorides gave higher yields in comparison with the 
aromatic one since they are better electrophiles. 
Table 17: Yields and reaction times for compounds 197-214. 
 
SMa Product R1 R2 R3 R4 t (h) Yield (%) 
179 199 C6H5 H H C6H5 4 69 
180 200 p-MeO-C6H4 H H C6H5 5 72 
181 201 p-NO2-C6H4 H H C6H5 5 83 
182 204 C6H5 CH3 H p-MeO-C6H4 5 25 
182 197 C6H5 CH3 H C6H5 5 78 
182 206 C6H5 CH3 H CH3 4 86 
182 205 C6H5 CH3 H H 4 98 
182 207 C6H5 CH3 CH3 H 4 98 
183 203 -CH2(CH2)3CH2- H C6H5 5 62 
184 202 p-MeO-C6H4 CH3 H C6H5 4 57 
185b 198b C6H5 CH3 H C6H5 24 83 
186 209 p-NO2-C6H4 CH3 H H 3 27 
187 210 p-CF3-C6H4 CH3 H H 3 17 
188 211 p-OCF3-C6H4 CH3 H H 1.5 59 
182 208 C6H5 CH3 H p-CF3-C6H4 24 65 
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189 212 4-pyridinyl CH3 H H 2 25 
190 213 2-pyridinyl CH3 H H 3 58 
182 214c C6H5 CH3 H H 1 54 
aSM, starting material; bphenyl moiety in position 5 of the oxadiazole ring; csaturated carbonyl unit, 
compounds 209 and 210 were prepared by Maria Landa and 211 was prepared by Thomas Klein. 
Twenty derivatives were synthesized in which the 1,3,4-oxadiazole ring, an ,-
unsaturated carbonyl unit and a pyridinyl moiety are combined together. All these 
moieties showed interesting biological activity as discussed before.     
3.4.3. Antibacterial and antifungal activity of the 1,3,4-oxadiazole derivatives 
This data was obtained by Galina Sergeev and Mark Brönstrup (Department of 
Chemical Biology, Helmholtz Center for Infection Research, Braunschweig, 
Germany). The synthesized compounds were tested against different gram-negative 
bacteria: Acinetobacter baumannii (DSM 30007, ATCC 19606), Enterobacter cloacae 
(DSM 26481, ATCC 23355), Escherichia coli (DSM 1116, ATCC 9637), Klebsiella 
pneumoniae (DSM 11678, ATCC 33495), Pseudomonas aeruginosa PA7 (DSM 
24068), gram-positive bacteria: Enterococcus faecium (DSM 20477, ATCC 19434), 
Staphylococcus aureus MRSA (DSM 11822, ICB 25701), Staphylococcus aureus 
MRSA Nr.5 (RKI Nr. 11-02670) and also against the fungi Candida albicans (DSM 
11225, ATCC 90028). All the derivatives were not active against the pathogens 
tested, which did not give any promising data for further investigations towards 
antimicrobial properties. 
3.4.4. Antiproliferative activity of the 1,3,4-oxadiazole derivatives 
This data was obtained by Galina Sergeev and Mark Brönstrup (Department of 
Chemical Biology, Helmholtz Center for Infection Research, Braunschweig, 
Germany). All the compounds 197-214 and 175-176 were screened for 
antiproliferative activity against L929 (mouse adipose tissue), MCF-7 (human breast 
adenocarcinoma) and KB-31 (human cervical carcinoma) cells. The derivatives were 
incubated for 5 days with the tested cell lines.  
The results (Table 18) revealed that the pyridinyl moiety in position 5 of the 1,3,4-
oxadiazole ring is necessary for the antiproliferative activity. This becomes clear by 
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comparing compound 197 with 198 (Table 18). The IC50 values are 15.7 µM against 
L929 for 197, while compound 198 the same skeleton with phenyl moiety in position 
5 of the ring instead of the pyridinyl was not active at all against the tested cells. The 
second step was focusing on position 2 of the oxadiazole ring. In this case a series of 
monosubstituted compounds including electron withdrawing and electron releasing 
groups 199, 200 and 201 was prepared. These analogues did not show any activity 
against the tested cells. Consequently, a new set of disubstituted compounds in 
position 2 of the ring was synthesized. This time, an electron donating group in 202 
reduced the activity, while the spirosystem in 203 showed week activity with IC50 
values 20.9 µM against L929. The SAR showed that methyl and phenyl groups in 
position 2 of the ring are essential for the activity with pyridinyl moiety in position 5. 
Then the effect of the substituents around the enone unit was studied, so compounds 
204, 205, 206, 207 and 208 were synthesized. The unsubstituted enone compound 
205 was the most active derivative with IC50 values 4.5 µM, 11.4 µM and 11.5 µM, 
against L929, KB-31 and MCF-7, respectively. At the same time electron donating 
groups decrease the activity, and an electron withdrawing group inhibits the activity. 
The SAR led us to compound 205 with promising activity. Further investigations were 
done in position 2 of the ring. In this case electron withdrawing groups were added to 
the phenyl moiety such as NO2, CF3 (209 and 210, respectively). These three 
compounds were very active and showed the promising results in comparison to the 
previous derivatives. In particular, compound 209 was the most potent derivative with 
IC50 values 3.2 µM, 6.0 µM and 6.3 µM against L929, KB-31 and MCF-7, 
respectively. Since the pyridinyl moiety in position 5 is important it was decided to 
introduce another pyridinyl moiety in position 2 of the ring as 4-pyridinyl 212 and 2-
pyridinyl 213. These compounds showed moderate activity with IC50 values around 
10 µM. In order to proof the importance of the enone unit in the activity, a compound 
with saturated carbonyl group was synthesized 214 and the antiproliferative test 
showed no activity at all for this compound 214. Indeed, the ,-unsaturated carbonyl 
group is essential in the antiproliferative activity. Finally, the compounds containing 
the sulfur bridge between the oxadiazole ring and the enone unit 175 and 176 were 
tested and did not show any activity against the tested cell lines, so no further 
investigation was done in this skeleton. 
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Table 18: Antiproliferative activity for compounds 197-214 and 175-176. 
 Cell line (IC50, µM) 
Compound L929 KB-31 MCF-7 
197 15.6 n.a. >25 
198 n.a. >25 >25 
199 n.a. n.a. n.a. 
200 n.a. n.a. n.a. 
201 n.a. n.a. n.a. 
202 >25 n.a. >25 
203 20.9 n.a. >25 
204 >25 n.a. >25 
205 4.5 11.4 11.5 
206 n.a. n.a. n.a. 
207 n.a. n.a. n.a. 
208 n.a. n.a. n.a. 
209 3.2 6.0 6.3 
210 5.2 5.0 4.2 
211 13.6 8.4 9.4 
212 8.6 11.0 14.6 
213 9.4 6.3 14.6 
214 n.a. n.a. n.a. 
175 n.a. n.a. n.a. 
176 n.a. n.a. n.a. 
IC50 values for antiproliferative activity with different cell lines (L929: mouse adipose tissue; KB-31: 
human cervical carcinoma; MCF-7: human breast adenocarcinoma) after incubation for 5 days.  n.a.: 
not active. This data was obtained by Galina Sergeev and Mark Brönstrup (Department of Chemical 
Biology, Helmholtz Center for Infection Research, Braunschweig, Germany).  
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3.4.5. Michael acceptor activity of the oxadiazole derivatives   
As the synthesized compounds contain Michael acceptor moieties, they are in 
principle able to react with biologically importance thiols, such as cysteine residues in 
proteins in a Michael addition reaction. This can lead to a great variety of biological 
activities. To evaluate the reactivity of this type of reaction, a thiol assay developed 
by Amslinger and Al-Rifai can be used.8, 102 An UV/VIS monitoring of the thiol addition 
reaction for compound 205 as an example (Scheme 52) is possible because of a 
time-dependent decay of the absorption band of the enone system. Figure 29 shows 
that at λmax = 330 nm the absorbance was dropped after the addition of cysteamine 
within only 1 min this shows fast reaction of the compound 205 as Michael acceptor. 
After 31 min the absorbance showed large decreasing while after 1 h there is no 
change in the absorbance, this indicates that the reaction reached the equilibrium. 
The reaction was performed in Tris-HCl buffer pH 7.4/ethylene glycol 20:80 and 
monitored at 330 nm. The second order rate constant (k2) for the reaction of 
compound 205 with cysteamine is 1.40 M-1s-1. This value displays medium reactivity 
comparing to previously measured chalcones (k2 ꞊ 0.0037-5800 M-1s-1) by Amslinger 
and Al-Rifai. This gave promising data to study the anti-inflammatory activity for the 
synthesized compounds. Further investigation of these compounds may lead to the 
development of new potent antiproliferative and anti-inflammatory analogues. 
   
Scheme 52: Reaction of compound 205 as thia-Michael addition with cysteamine as model thiol. 
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Figure 29: UV/VIS spectra for the reaction between compound 205 (40 µM) and cysteamine (50 fold) 
in Tris-HCl buffer pH 7.4/ethylene glycol 20:80 after different times. This data was obtained by Monika 
Enzinger and Sabine Amslinger. 
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4. Summary 
In this work, a new derivative of the natural product limnophilaspiroketone called 
methylene-Limno-CP was synthesized, then different substituents were introduced to 
the -position (Cl, Br, I, CN, Ph and p-NO2-Ph) to modify the electrophilicity (Scheme 
53). The key step of this synthetic sequence was the Heck reaction in order to form 
the enone system with an aryl group in the -position. The synthesized derivatives 
did not show any reactivity as Michael acceptors with cysteamine as model thiol. 
Attempts to synthesize other derivatives of limnophilaspiroketone including S-Limno-
CP and N-Limno-CP were not successful. Also the total synthesis of 
limnophilaspiroketone could not be accomplished. 
 
Scheme 53: Structures of -X-methylene-Limno-CP derivatives. 
The biological activity of the natural product zerumbone (1) is encouraging, and 
therefore the ability to produce derivatives. The followed approval starts from the 
cheap starting material isoprenol. The key step in the sequence was transformation 
applying alkene ring closing metathesis (Scheme 54) to produce the cyclic compound 
1. Different ruthenium catalysts were used, but the precursor showed some rigidity, 
therefore the cyclization failed. A new precursor was prepared with smaller number 
double bonds 154 and the ring closing metathesis was tried again, but the ring closed 
product was not formed. 
Scheme 54: Attempts to synthesize zerumbone (1) and zerumbone derivative 157 by ring closing 
metathesis. 
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The ability to produce derivatives such as -X-modified enone derivatives is an 
important measure to get potentially biologically active electrophiles. Finally, twenty 
derivatives of 2,3-dihydro-1,3,4-oxadiazole and 1,3,4-oxadiazole in combination with 
an enone unit and a pyridinyl moiety were synthesized (Scheme 55). These 
derivatives were tested as antibacterial agents against different gram-positive and 
gram-negative bacteria, but they were not active against the tested cells. Also, the 
oxadiazole derivatives were screened as antiproliferative compounds against L929 
(mouse adipose tissue), MCF-7 (human breast adenocarcinoma) and KB-31 (human 
cervical carcinoma) cells. The derivatives with an enone unit in position 2 did not 
show any activity, while some of the derivatives with enone unit in position 3 were 
active, and the most active compounds were 209 and 210. 
Scheme 55: SAR for the 2,3-dihydro-1,3,4-oxadiazole derivatives as antiproliferative agents and the 
IC50 values (µM) against 3 cell lines for active compounds 209 and 210 and non active 206.   
Further investigation is needed for the enone unit as a part of small molecules and its 
application in drug research.   
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Zusammenfassung 
In dieser Arbeit wurde ein neues Derivat des Naturstoffes Limnophilaspiroketon, 
Methylen-Limnophilaspiroketon, synthetisiert, außerdem wurden verschiedene 
Substituenten (Cl, Br, I, Ph und p-NO2-Ph) in die -Position eingeführt um die 
Elektrophilie zu modifizieren (Schema 53). Der Schlüsselschritt dieser 
Synthesesequenz war die Heck-Reaktion um das Enonsystem mit einer Arylfunktion 
in -Position aufzubauen. Die synthetisierten Derivate zeigten keine Reaktivität als 
Michael-Akzeptoren mit Cysteamin als Modell-Thiol. Auch konnte die Totalsynthese 
von Limnophilaspiroketon nicht vollendet werden. 
 
Schema 53: Strukturen der -X-Methylen-Limno-CP-Derivate. 
Die biologische Aktivität des Naturstoffes Zerumbon (1) ist vielversprechend und 
deshalb wurde auch die Möglichkeit angestrebt, 1 und dessen Derivate zu 
synthetisieren. Der verfolgte Ansatz zur Totalsynthese von Zerumbon begann mit 
dem kostengünstigen Ausgangsstoff Isoprenol. Der Schlüsselschritt in der 
Synthesesequenz war die Anwendung der Ringschlussmetathese (Schema 54) um 
die zyklische Verbindung 1 zu erhalten. Verschiedene Rutheniumkatalysatoren 
wurden verwendet, doch da die offenkettige Vorstufe 129 Starrheit im Molekül 
aufwies, misslang die Zyklisierung. Eine neue Vorstufe mit verringerter Anzahl an 
Doppelbindungen (154) wurde synthetisiert und ebenfalls mit Ringschlussmetathese 
umgesetzt, doch das zyklische Produkt 157 wurde nicht erhalten.
Schema 54: Versuche der Synthese von Zerumbon (1) und des Zerumbon-Derivates 157 mit 
Ringschlussmetathese. 
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Die Möglichkeit, Derivate wie zum Beispiel -X-modifizierte Enone herzustellen, ist 
ein wichtiges Mittel um biologisch aktive Elektrophile zu erhalten. Im Hauptteil dieser 
Doktorarbeit wurden zwanzig Derivate von 2,3-Dihydro-1,3,4-Oxadiazol und 1,3,4-
Oxadiazol in Kombination mit einer Enon-Einheit und einer Pyridinylgruppe 
synthetisiert (Schema 55). Diese Derivate wurden auf antibakterielle Aktivität gegen 
verschiedene gram-positive und gram-negative Bakterien getestet, allerdings konnte 
keine Aktivität gegen diese Zellen gefunden werden. Des Weiteren wurde die 
Oxadiazolderivate als antiproliferative Wirkstoffe gegen die Zelllinien L929 (Maus-
Fettgewebe), MCF-7 (humanes Brust-Adenokarzinom) und KB-31 (humanes 
Zervixkarzinom) gescreent. Die Derivate mit der Enoneinheit in Position 2 zeigten 
keine Aktivität wohingegen einige Derivate mit der Enoneinheit in Position 3 aktiv 
waren. Die aktivsten Substanzen waren 209 und 210. 
Schema 55: Struktur-Wirkungsbeziehung für 2,3-Dihydro-1,3,4-Oxadiazolderivate als antiproliferative 
Wirkstoffe und die entsprechenden IC50-Werte (µM) der aktiven Substanzen 209 und 210 sowie der 
inaktiven Substanz 206 gegen 3 Zellinien.  
Weitere Untersuchungen der Enoneinheit als funktionelle Gruppe in 
niedermolekularen Verbindungen und deren Einsatz in der Wirkstoffforschung sind 
notwendig. 
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5. Experimental part 
5.1. General methods and materials  
All reagents were purchased from commercial sources and were used without further 
purification. Solvents were distilled before use. All reactions were carried out under 
nitrogen gas and the glassware was heated at 110 °C before use when dry 
conditions were necessary. The reactions were monitored by TLC on silica gel plates 
60 F254 by MERCK (Darmstadt, Germany). Spots were detected under UV light (λ = 
254 and 366 nm) or visualized by staining with vanillin reagent (15 g vanillin in 250 ml 
95% ethanol and 2.5 ml conc. sulfuric acid). Column chromatography was performed 
on silica gel Geduran Si 60 (0.063-0.200 mm) by MERCK (Darmstadt, Germany), 
while preparative plates were prepared using silica gel 60 GF254 by MERCK 
(Darmstadt, Germany). Melting points were determined using BUCHI melting point B-
545 (Switzerland) and were uncorrected.   
1H-NMR spectra were recorded on a Avance 300 (300 MHz) and Avance 400 (400 
MHz) spectrometer. Chemical shifts  are referenced to CDCl3 (7.26 ppm), DMSO-d6 
(2.50 ppm) and acetone-d6 (2.05 ppm). The NMR data were reported in ppm and the 
abbreviations were mentioned as: s = singlet, d = doublet, t = triplet, q = quartet, sept 
= septet, m = multiplet, dt = doublet of triplet, dd = doublet of doublet, coupling 
constants in Hz.  
13C NMR spectra were recorded on a Bruker Avance 300 (75 MHz) and Avance 400 
(100 MHz) spectrometer and are given in ppm. Chemical shifts  are referenced to 
CDCl3 (77.0 ppm), DMSO-d6 (39.4 ppm) and acetone-d6 (29.8 ppm). 
19F-NMR spectra were recorded on a Bruker Avance 300 (282 MHz) spectrometer.  
31P-NMR spectra were recorded on a Bruker Avance 300 (121 MHz) spectrometer.  
IR spectroscopy was carried out on a Specac Golden Gate Diamond Single 
Reflection ATR System Excalibur Series FTS3000MX by BIO-RAD (Munich, 
Germany) and samples were measured as neat compounds and the wave numbers 
are reported in cm-1.  
Mass data was obtained on Agilent Technologies 6540 UHD (Agilent, Santa Clara, 
USA), Finnigan MAT 95 or Thermo Quest Finnigan TSQ 7000 instruments (Bremen, 
Germany). 
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5.2. Experimental procedures  
3-(4-Isopropoxyphenyl)cyclopent-2-enone (71) 
 
Aryl iodide 69 (30.0 g, 114 mmol, 1.0 eq), cyclopentenone (18.7 g, 228 mmol, 2.0 
eq), KF (13.3 g, 229 mmol, 2.0 eq) and Pd(OAc)2 (0.509 g, 2.27 mmol, 0.02 eq) were 
dissolved in 100 ml DMF under N2. The reaction mixture was stirred at 130 °C for 20 
h. Then the mixture was cold to room temperature and 50 ml H2O was added and 
extracted with EtOAc (3 x 50 ml). The combined organic layers were dried over 
MgSO4 and the solvent was removed in vacuo. The product was purified by silica gel 
column chromatography (20 cm x 10 cm) (petroleum ether-EtOAc, 4:1) to produce 
aryl cyclopentenone 71 (13.4 g, 62.0 mmol, 54%) as an orange solid. Rf = 0.17 (SiO2, 
petroleum ether-EtOAc, 4:1); Mp 87 °C. 
1H-NMR (300 MHz, CDCl3):  = 7.60 (d, J = 8.9 Hz, 2 H, CH, Ar), 6.92 (d, J = 8.9 Hz, 
2 H, CH, Ar), 6.46 (s, 1 H, C=CH), 4.63 (sept, J = 6.1 Hz, 1 H, CH, iPr), 3.01 (m, 2 H, 
CH2), 2.56 (m, 2 H, CH2), 1.36 (d, J = 6.1 Hz, 6 H, CH3, iPr) ppm.  
13C-NMR (75 MHz, CDCl3):  = 209.4, 173.8, 160.5, 128.6, 126.3, 125.2, 115.7, 70.0, 
35.2, 28.5, 21.9 ppm. 
IR (neat): 2978, 2932, 1668, 1592, 1565, 1506, 1260, 1183, 1139, 1120, 950 cm–1. 
MS (EI, 70 eV): m/z (%) = 217.1 (100) [M+H]+, 175.1 (5.6). 
HRMS (EI-MS): m/z calcd for C14H16O2: 216.1150 [M+]; found 216.1151. 
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3-(4-Isopropoxyphenyl)spiro[4.4]non-2-en-1-one (72) 
 
To a magnetically stirred solution of aryl cyclopentenone 71 (13.3 g, 61.4 mmol, 1.0 
eq) and 1,4-dibromobutane (19.9 g, 92.1 mmol, 1.5 eq) in 80 ml of dry benzene was 
added t-BuOK (17.2 g, 153 mmol, 2.5 eq) in one portion. The mixture was refluxed 
for 3 h. Then the mixture was poured into 100 ml H2O and extracted with EtOAc (3 x 
50 ml). The combined organic layers were dried over MgSO4 and the solvent was 
removed in vacuo. The product was purified by silica gel column chromatography (20 
cm x 5.5 cm) (petroleum ether-EtOAc, 4:1) to produce -H-cyclopentenone 72 (6.21 
g, 23.0 mmol, 37%) as a yellow solid. Rf = 0.44 (SiO2, petroleum ether-EtOAc, 4:1); 
Mp 65 °C. 
1H-NMR (300 MHz, CDCl3):  = 7.58 (d, J = 8.9 Hz, 2 H, CH, Ar), 6.91 (d, J = 8.9 Hz, 
2 H, CH, Ar), 6.44 (s, 1 H, C=CH), 4.62 (sept, J = 6.1 Hz, 1 H, CH), 2.90 (d, J = 1.6  
Hz, 2 H, CH2), 1.98-1.84 (m, 4 H, CH2), 1.79-165 (m, 2 H, CH2), 1.60-1.50 (m, 2 H, 
CH2), 1.36 (d, J = 6.1 Hz, 6 H, CH3, iPr) ppm. 
13C-NMR (100 MHz, CDCl3):  = 213.4, 170.8, 160.4, 128.6, 126.4, 123.9, 115.7, 
70.0, 55.6, 45.7, 38.3, 25.5, 21.9 ppm. 
IR (neat): 3065, 2974, 2932, 2869, 1675, 1587, 1506, 1421, 1338, 1311, 1258 cm–1. 
MS (EI, 70 eV): m/z (%) = 271.2 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C18H22O2: 270.1620 [M+]; found 270.1621. 
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2-Chloro-3-(4-isopropoxyphenyl)spiro[4.4]non-2-en-1-one (74) 
 
A stirred solution of spiro compound 72 (0.102 g, 0.377 mmol, 1.0 eq) and N-
chlorosuccinimide (64.5 mg, 0.485 mmol, 1.2 eq) in 20 ml MeOH was refluxed for 20 
h. After removing the solvent 20 ml saturated NaHCO3 solution was added and 
extracted with EtOAc (3 x 20 ml). The organic layer was washed with 10 ml brine 
solution and the combined organic layers were dried over MgSO4 and the solvent 
was removed in vacuo. The product was purified by preparative thin layer 
chromatography on SiO2 (petroleum ether-EtOAc, 4:1) to give -Cl-cyclopentenone 
74 (82.4mg, 0.270 mmol, 72%) as a white solid. Rf = 0.60 (SiO2, petroleum ether-
EtOAc, 4:1); Mp 93 °C. 
1H-NMR (300 MHz, CDCl3):  = 7.96 (d, J = 9.0 Hz, 2 H, CH, Ar), 6.96 (d, J = 9.0 Hz, 
2 H, CH, Ar), 4.65 (sept, J = 6.1 Hz, 1 H, CH), 2.94 (s, 2 H, CH2), 2.11-1.88 (m, 4 H, 
CH2), 1.84-1.71 (m, 2 H, CH2), 1.67-1.55 (m, 2 H, CH2), 1.37 (d, J = 6.1 Hz, 6 H, CH3, 
iPr) ppm. 
13C-NMR (75 MHz, CDCl3):  = 205.7, 160.3, 160.0, 130.1, 126.2, 125.3, 115.4, 70.0, 
52.9, 45.6, 38.6, 25.4, 21.9 ppm. 
IR (neat): 2968, 2937, 2877, 1702, 1601, 1562, 1506, 1259, 1190, 1128, 1108 cm–1. 
MS (EI, 70 eV): m/z (%) = 305.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C18H22ClO2: 305.1308 [M+H]+; found 305.1307. 
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2-Bromo-3-(4-isopropoxyphenyl)spiro[4.4]non-2-en-1-one (75) 
 
Method A: A stirred solution of -H-cyclopentenone 72 (0.116 g, 0.427 mmol, 1.0 eq) 
in 5 ml of CH2Cl2 was treated with a 1 M bromine solution (0.51 ml, 0.51 mmol, 1.2 
eq) in CH2Cl2 at 0 °C. After 1 h a solution of Et3N (84.3 mg, 0.835 mmol, 3.0 eq) in 5 
ml CH2Cl2 was added dropwise. The solution was stirred 1 h at 0 °C and 1 h at room 
temperature before it was diluted with 10 ml of H2O and extracted with CH2Cl2 (3 x 20 
ml). The combined organic layers were washed with 10 ml of brine solution and dried 
over MgSO4 followed by concentration in vacuo. The product was purified by 
preparative thin layer chromatography on SiO2 (petroleum ether-EtOAc, 4:1) and 
gave -Br-cyclopentenone 75 (0.120 g, 0.344 mmol, 81%) as a yellow solid. 
Method B: To a solution of -H-cyclopentenone 72 (1.53 g, 5.67 mmol, 1.0 eq) in 20 
ml of MeCN was added N-bromosuccinimide (1.11 g, 6.24 mmol, 1.1 eq) in portions 
at 0 °C. After 30 min saturated NaHCO3 (20 ml) was added and the mixture was 
extracted with EtOAc (3 x 25 ml). The combined organic layers were dried over 
MgSO4 and the solvent was removed in vacuo. The product was purified by silica gel 
thin layer chromatography (petroleum ether-EtOAc, 4:1) to afford -Br-
cyclopentenone 75 (1.17 g, 3.35 mmol, 59%) as a yellow solid. Rf = 0.58 (SiO2, 
petroleum ether-EtOAc, 4:1); Mp 107 °C. 
1H-NMR (300 MHz, CDCl3):  = 7.98 (d, J = 9.0 Hz, 2 H, CH, Ar), 6.96 (d, J = 9.0 Hz, 
2 H, CH, Ar), 4.65 (sept, J = 6.1 Hz, 1 H, CH), 2.96 (s, 2 H, CH2), 2.09-1.86 (m, 4 H, 
CH2), 1.81-1.67 (m, 2 H, CH2), 1.64-1.55 (m, 2 H, CH2), 1.38 (d, J = 6.1 Hz, 6 H, CH3, 
iPr) ppm. 
13C-NMR (75 MHz, CDCl3):  = 206.2, 163.8, 160.3, 130.0, 125.8, 117.6, 115.3, 70.1, 
53.0, 47.5, 38.7, 25.4, 21.9 ppm.  
IR (neat): 2969, 2934, 2875, 1700, 1600, 1561, 1504, 1258, 1188, 1106, 949 cm–1.  
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MS (EI, 70 eV): m/z (%) = 349.1 (100) [M+H]+, 255.3 (3.2), 254.2 (16). 
HRMS (EI-MS): m/z calcd for C18H22BrO2: 349.0803 [M+H]+; found 349.0802. 
 
2-Iodo-3-(4-isopropoxyphenyl)spiro[4.4]non-2-en-1-one (76) 
 
A stirred solution of -H-cyclopentenone 72 (0.300 g, 1.11 mmol, 1.0 eq) and N-
iodosuccinimide (0.265 g, 1.18 mmol, 1.1 eq) in 25 ml of MeCN was refluxed for 20 
h. Saturated NaHCO3 solution 10 ml was added to the mixture and the aqueous 
phase was extracted with EtOAc (3 x 20 ml). The combined organic layers were 
washed with 20 ml of brine solution followed by drying over MgSO4. The solvent was 
removed in vacuo and the product was purified by silica gel thin layer 
chromatography on SiO2 (petroleum ether-EtOAc, 4:1) afforded -I-cyclopentenone 
76 (0.370 g, 0.934 mmol, 84%) as a yellow solid. Rf = 0.61 (SiO2, petroleum ether-
EtOAc, 4:1); Mp 124 °C. 
1H-NMR (300 MHz, CDCl3):  = 7.93 (d, J = 9.0 Hz, 2 H, CH, Ar), 6.96 (d, J = 9.0 Hz, 
2 H, CH, Ar), 4.65 (sept, J = 6.1 Hz, 1 H, CH), 3.05 (s, 2 H, CH2), 2.08-1.85 (m, 4 H, 
CH2), 1.81-1.67 (m, 2 H, CH2), 1.66-1.51 (m, 2 H, CH2), 1.38 (d, J = 6.1 Hz, 6 H, CH3, 
iPr) ppm. 
13C-NMR (75 MHz, CDCl3):  = 208.1, 170.2, 160.2, 129.7, 126.9, 115.2, 96.9, 70.0, 
53.0, 49.8, 38.7, 25.3, 21.9 ppm. 
IR (neat): 2954, 2911, 2860, 1689, 1598, 1549, 1503, 1419, 1253, 1185, 1107 cm–1. 
MS (EI, 70 eV): m/z (%) = 397.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C18H22IO2: 397.0664 [M+H]+; found 397.0660. 
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3-(4-Isopropoxyphenyl)-1-oxospiro[4.4]non-2-ene-2-carbonitrile (77) 
 
A microwave glass tube with a magnetic stirring bar was placed -I-cyclopentenone 
76 (0.117 g, 0.317 mmol, 1.0 eq), sodium cyanide (31.1 mg, 0.635 mmol, 2.0 eq) and 
nickel(II) bromide (71.0 mg, 0.325 mmol, 1.0 eq), in 4 ml N-methyl-2-pyrrolidinone. 
The mixture was heated at 200 °C for 10 min, then the green mixture was cold to 
room temperature and diluted with 20 ml H2O followed by extraction with EtOAc (3 x 
20 ml). The combined organic layers were washed with 20 ml brine solution followed 
by drying over MgSO4. The solvent was removed in vacuo and the product was 
purified by silica gel thin layer chromatography on SiO2 (petroleum ether-EtOAc, 4:1) 
to afford -CN-cyclopentenone 77 (73.7 mg, 0.250 mmol, 85%) as a yellow solid Rf = 
0.42 (SiO2, petroleum ether-EtOAc, 4:1); Mp 121 °C. 
1H-NMR (300 MHz, CDCl3):  = 8.04 (d, J = 9.0 Hz, 2 H, CH, Ar), 6.98 (d, J = 9.0 Hz, 
2 H, CH, Ar), 4.69 (sept, J = 6.1 Hz, 1 H, CH), 3.10 (s, 2 H, CH2), 2.10-1.86 (m, 4 H, 
CH2), 1.83-1.67 (m, 2 H, CH2), 1.64-1.58 (m, 2 H, CH2), 1.39 (d, J = 6.1 Hz, 6 H, CH3, 
iPr) ppm. 
13C-NMR (75 MHz, CDCl3):  = 206.7, 176.6, 162.6, 130.7, 124.1, 115.9, 114.8, 
108.1, 70.5, 54.9, 46.3, 38.5, 25.5, 21.8 ppm.  
IR (neat): 2947, 2898, 2868, 2214, 1699, 1600, 1582, 1556, 1507, 1342, 1303 cm–1. 
MS (EI, 70 eV): m/z (%) = 296.2 (100) [M+H]+, 121.1 (9.7). 
HRMS (EI-MS): m/z calcd for C19H21NO2: 295.1572 [M+]; found 295.1575. 
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3-(4-Isopropoxyphenyl)-2-phenylspiro[4.4]non-2-en-1-one (78) 
 
To a solution of -I-cyclopentenone 76 (0.201 g, 0.507 mmol, 1.0 eq) in a 4 ml 
mixture of toluene-EtOH 3:1 were added Pd2(dba)3·CHCl3 (30.0 mg, 0. 0290 mmol, 
0.05 eq), triphenylphosphine (13.3 mg, 0.0500 mmol, 0.1 eq) and phenyl boronic acid 
(81.1 mg, 0.665 mmol, 1.2 eq). After stirring for 10 min 0.08 ml Et2NH and 1 ml H2O 
were added and the mixture was refluxed for 20 h. Then the mixture was extracted 
with EtOAc (3 x 10 ml). The combined organic layers were washed with 10 ml brine 
solution and dried over MgSO4. The solvent was removed in vacuo and the product 
was purified by silica gel thin layer chromatography on SiO2 (petroleum ether-EtOAc, 
4:1) to give -Ph-cyclopentenone 78 (0.125 g, 0.361 mmol, 71%) as an orange solid. 
Rf = 0.60 (SiO2, petroleum ether-EtOAc, 4:1); Mp 95 °C. 
1H-NMR (300 MHz, CDCl3):  = 7.39-7.22 (m, 7 H, CH, Ar), 6.75 (d, J = 8.9 Hz, 2H, 
CH, Ar), 4.55 (sept, J = 6.1 Hz, 1 H, CH), 2.95 (s, 2 H, CH2), 2.09-2.01 (m, 2 H, CH2), 
1.97-1.88 (m, 2 H, CH2), 1.86-1.74 (m, 2 H, CH2), 1.70-1.58 (m, 2 H, CH2), 1.33 (d, J 
= 6.1 Hz, 6 H, CH3, iPr) ppm. 
13C-NMR (75 MHz, CDCl3):  = 211.3, 164.4, 159.3, 136.7, 133.3, 129.9, 129.5, 
128.4, 127.5, 127.5, 115.1, 69.8, 54.7, 46.8, 38.5, 25.6, 21.9 ppm. 
IR (neat): 2978, 2934, 2869, 1678, 1601, 1563, 1508, 1490, 1350, 1293, 1250 cm–1. 
MS (EI, 70 eV): m/z (%) = 347.2 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C24H27O2: 347.2011 [M+H]+; found 347.2013. 
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3-(4-Isopropoxyphenyl)-2-(4-nitrophenyl)spiro[4.4]non-2-en-1-one (79) 
 
To a stirred solution of -Br-cyclopentenone 75 (0.206 g, 0.591 mmol, 1.0 eq) in a 4 
ml mixture of toluene-EtOH 3:1 were added Pd2(dba)3·CHCl3 (30.3 mg, 0.0293 mmol, 
0.05 eq), triphenylphosphine (15.5 mg, 0.0590 mmol, 0.1 eq) and p-NO2-phenyl 
boronic acid (0.118 g, 0.709 mmol, 1.2 eq). After stirring for 10 min 0.08 ml Et2NH 
and 1 ml H2O were added and the mixture was refluxed for 20 h. Then the mixture 
was extracted with EtOAc (3 x 10 ml). The combined organic layers were washed 
with 10 ml brine solution and dried over MgSO4. The solvent was removed in vacuo 
and the product was purified by silica gel thin layer chromatography on SiO2 
(petroleum ether-EtOAc, 4:1) afforded -(p-NO2-C6H4)-cyclopentenone 79 (0.175 g, 
0.447 mmol, 76%) as a yellow solid. Rf = 0.47 (SiO2, petroleum ether-EtOAc, 4:1); Mp 
99 °C. 
1H-NMR (300 MHz, CDCl3):  = 8.20 (d, J = 8.9 Hz, 2 H, CH, Ar), 7.47(d, J = 8.9 Hz, 
2 H, CH, Ar), 7.24 (d, J = 8.9 Hz, 2 H, CH, Ar), 6.78 (d, J = 8.9 Hz, 2 H, CH, Ar), 4.56 
(sept, J = 6.1 Hz, 1 H, CH), 2.99 (s, 2 H, CH2), 2.11-1.87 (m, 4 H, CH2), 1.85-1.74 (m, 
2 H, CH2), 1.70-1.57 (m, 2 H, CH2), 1.34 (d, J = 6.1 Hz, 6 H, CH3, iPr) ppm. 
13C-NMR (75 MHz, CDCl3):  = 210.5, 167.6, 159.9, 147.1, 140.4, 134.4, 130.8, 
130.0, 126.6, 123.8, 115.4, 70.0, 55.3, 47.1, 38.7, 25.6, 21.9 ppm.  
IR (neat): 3064, 2983, 2869, 1681, 1599, 1510, 1341, 1292, 1254, 1186, 1107 cm–1. 
MS (EI, 70 eV): m/z (%) = 392.2 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C24H26NO4: 392.1856 [M+H]+; found 392.1858. 
 
 
Experimental part 
91 
 
General procedure for the deprotection of isopropyl ethers 80-86: 
-(X)-Cyclopentenones 72-79 (38.1-102 mg, 0.125 mmol-0.257 mmol, 1.0 eq) were 
dissolved in 1 ml CH2Cl2 and 6.0 eq of 1 M solution of BCl3 in n-hexane were added 
slowly at -78 °C to the solution. The solution was warmed to room temperature and 
stirred until the reaction was complete (45 min to 16 h). Then THF (0.5 ml) and 1 M 
aqueous HCl (0.5 ml) were added and the solvent was removed before adding 10 ml 
of H2O. The mixture was extracted with EtOAc (3 x 20 ml) and the combined organic 
layers were dried over MgSO4. Then the solvent was removed in vacuo and the 
produced solid was washed with CH2Cl2 (2 x 2 ml) to produce the metyelen-Limno-
CP products 80-86. 
3-(4-Hydroxyphenyl)spiro[4.4]non-2-en-1-one (80) 
 
-H-cyclopentenone 72 (56.4 mg, 0.209 mmol, 1.0 eq) gave after 16 h -H-
methylene-Limno-CP (80) (44.3 mg, 0.194 mmol, 93%) as a yellow solid. Rf = 0.19 
(SiO2, petroleum ether-EtOAc, 7:3); Mp 192 °C. 
1H-NMR (300 MHz, acetone-d6):  = 9.03 (s, 1 H, OH), 7.68 (d, J = 8.8 Hz, 2 H, CH, 
Ar), 6.94 (d, J = 8.8 Hz, 2 H, CH, Ar), 6.43 (s, 1 H, CH), 2.96 (s, 2 H, CH2), 1.89-1.72 
(m, 6 H, CH2), 1.62-1.52 (m, 2 H, CH2) ppm.  
13C-NMR (75 MHz, acetone-d6):  = 212.4, 171.6, 161.1, 129.8, 126.8, 123.8, 116.5, 
56.0, 46.0, 38.8, 26.1 ppm. 
IR (neat): 3151, 3031, 2949, 2917, 2864, 2828, 1659, 1602, 1571, 1510, 1335 cm–1. 
MS (EI, 70 eV): m/z (%) = 229.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C15H16O2: 228.1150 [M+]; found 228.1138. 
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2-Chloro-3-(4-hydroxyphenyl)spiro[4.4]non-2-en-1-one (81) 
 
-Cl-cyclopentenone 74 (38.1 mg, 0.125 mmol, 1.0 eq) gave after 45 min -Cl-
methylene-Limno-CP (81) (29.5 mg, 0.112 mmol, 90%) as a yellow solid. Rf = 0.38 
(SiO2, petrolum ether-EtOAc, 7:3); Mp 208 °C. 
1H-NMR (300 MHz, acetone-d6):  = 9.12 (s, 1 H, OH), 7.98 (d, J = 8.9 Hz, 2 H, CH, 
Ar), 7.00 (d, J = 8.9 Hz, 2 H, CH, Ar), 3.06 (s, 2 H, CH2), 1.94-1.73 (m, 6 H, CH2), 
1.72-1.57 (m, 2 H, CH2) ppm. 
13C-NMR (75 MHz, acetone-d6):  = 205.2, 161.6, 161.1, 131.2, 125.8, 125.7, 116.4, 
53.5, 45.9, 38.9, 25.9 ppm.  
IR (neat): 3210, 2946, 2924, 2868, 1679, 1607, 1561, 1508, 1266, 1229, 1181 cm–1. 
MS (EI, 70 eV): m/z (%) = 263.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C15H15ClO2: 262.0761 [M+]; found 262.0754. 
 
2-Bromo-3-(4-hydroxyphenyl)spiro[4.4]non-2-en-1-one (82) 
 
-Br-cyclopentenone 75 (50.0 mg, 0.143 mmol, 1.0 eq) gave after 45 min -Br-
methylene-Limno-CP (82) (39.8 mg, 0.130 mmol, 91%) as a yellow solid. Rf = 0.38 
(SiO2, petroleum ether-EtOAc, 7:3); Mp 201 °C. 
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1H-NMR (300 MHz, acetone-d6):  = 9.11 (s, 1 H, OH), 8.00 (d, J = 8.9 Hz, 2 H, CH, 
Ar), 6.99 (d, J = 8.9 Hz, 2 H, CH, Ar), 3.09 (s, 2 H, CH2), 1.88-1.79 (m, 6 H, CH2), 
1.71-1.59 (m, 2 H, CH2) ppm. 
13C-NMR (75 MHz, acetone-d6):  = 205.7, 165.4, 161.1, 131.2, 126.3, 117.3, 116.3, 
53.6, 47.8, 39.0, 25.9 ppm. 
IR (neat): 3226, 2946, 2924, 2868, 1678, 1604, 1556, 1504, 1452, 1263, 1226 cm–1. 
MS (EI, 70 eV): m/z (%) = 307.0 (100) [M+H]+, 223.0 (3.1), 215.0 (4.8), 214.0 (4.5), 
121.1 (5.7). 
HRMS (EI-MS): m/z calcd for C15H16BrO2: 307.0334 [M+H]+; found 307.0333. 
 
3-(4-Hydroxyphenyl)-2-iodospiro[4.4]non-2-en-1-one (83) 
 
-I-cyclopentenone 76 (102 mg, 0.257 mmol, 1.0 eq) gave after 45 min -I-
methylene-Limno-CP (83) (87.2 mg, 0.246, 96%) as a yellow solid. Rf = 0.41 (SiO2, 
petroleum ether-EtOAc, 7:3); Mp 198 °C. 
1H-NMR (300 MHz, acetone-d6):  = 9.08 (s, 1 H, OH), 7.96 (d, J = 8.9 Hz, 2 H, CH, 
Ar), 6.99 (d, J = 8.9 Hz, 2 H, CH, Ar), 3.17 (s, 2 H, CH2), 1.89-1.79 (m, 6 H, CH2), 
1.68-1.58 (m, 2 H, CH2) ppm. 
13C-NMR (75 MHz, acetone-d6):  = 207.9, 171.8, 160.9, 130.9, 127.5, 116.1, 96.7, 
53.6, 50.1, 39.1, 25.9 ppm. 
IR (neat): 3232, 2948, 2922, 2867, 1673, 1603, 1548, 1499, 1451, 1261, 1224 cm–1. 
 
MS (EI, 70 eV): m/z (%) = 355.0 (100) [M+H]+, 246.0 (4.11), 238.0 (8.3), 121.1 (13.8). 
HRMS (EI-MS): m/z calcd for C15H15IO2: 354.0117 [M+]; found 354.0112. 
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3-(4-Hydroxyphenyl)-1-oxospiro[4.4]non-2-ene-2-carbonitrile (84) 
 
-CN-cyclopentenone 77 (66.6 mg, 0.225 mmol, 1.0 eq) gave after 3 h -CN-
methylene-Limno-CP (84) (54.3 mg, 0.214 mmol, 95%) as a yellow solid. Rf = 0.15 
(SiO2, petroleum ether-EtOAc, 7:3); Mp 239 °C. 
1H-NMR (300 MHz, acetone-d6):  = 9.60 (s, 1 H, OH), 8.08 (d, J = 8.9 Hz, 2 H, CH, 
Ar), 7.06 (d, J = 8.9 Hz, 2 H, CH, Ar), 3.28 (s, 2 H, CH2), 1.91-1.79 (m, 6 H, CH2), 
1.72-1.65 (m, 2 H, CH2) ppm. 
13C-NMR (75 MHz, acetone-d6):  = 207.3, 178.8, 163.4, 131.9, 124.9, 117.0, 115.7, 
107.9, 55.7, 46.6, 38.8, 26.0 ppm. 
IR (neat): 3209, 2957, 2870, 2232, 1699, 1605, 1559, 1512, 1340, 1277, 1232 cm–1. 
MS (EI, 70 eV): m/z (%) = 254.1 (100) [M+H]+, 130.2 (4.4), 121.1 (3.9). 
HRMS (EI-MS): m/z calcd for C16H15NO2: 253.1103 [M+]; found 253.1085. 
 
3-(4-Hydroxyphenyl)-2-phenylspiro[4.4]non-2-en-1-one (85) 
 
-Ph-cyclopentenone 78 (38.9 mg, 0.112 mmol, 1.0 eq) gave after 45 min -Ph-
methylene-Limno-CP (85) (32.8 mg, 0.108 mmol, 96%) as a yellow solid. Rf = 0.38 
(SiO2, petroleum ether-EtOAc, 7:3); Mp 207 °C. 
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1H-NMR (300 MHz, acetone-d6):  = 8.91(s, 1 H, OH), 7.37-7.15 (m, 7 H, CH, Ar), 
6.75 (d, J = 8.8 Hz, 2 H, CH, Ar), 3.02 (s, 2 H, CH2), 1.96-1.77 (m, 6 H, CH2), 1.69-
1.59 (m, 2 H, CH2) ppm. 
13C-NMR (75 MHz, acetone-d6):  = 210.9, 165.7, 160.0, 137.0, 135.0, 131.0, 130.5, 
129.0, 128.2, 127.8, 116.0, 55.3, 47.2, 39.0, 26.2 ppm. 
IR (neat): 3236, 2950, 2861, 1661, 1601, 1568, 1515, 1485, 1349, 1284, 1226 cm–1.  
MS (EI, 70 eV): m/z (%) = 305.2 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C21H21O2: 305.1542 [M+H]+; found 305.1544. 
 
3-(4-Hydroxyphenyl)-2-(4-nitrophenyl)spiro[4.4]non-2-en-1-one (86) 
 
-(p-NO2-C6H4)-cyclopentenone 79 (64.1 mg, 0.164 mmol, 1.0 eq) gave after 16 h -
(p-NO2-C6H4)-methylene-Limno-CP (86) (52.2 mg, 0.149 mmol, 91%) as a yellow 
solid. Rf = 0.72 (SiO2, petroleum ether-EtOAc, 1:1); Mp 254 °C. 
1H-NMR (300 MHz, acetone-d6):  = 8.23 (d, J = 8.9 Hz, 2 H, CH, Ar), 7.51 (d, J = 8.9 
Hz, 2 H, CH, Ar), 7.31 (d, J = 8.8 Hz, 2 H, CH, Ar), 6.81 (d, J = 8.8 Hz, 2 H, CH, Ar), 
3.10 (s, 2 H, CH2), 1.99-1.65 (m, 8 H, CH2) ppm. 
13C-NMR (75 MHz, acetone-d6):  = 210.2, 168.4, 160.5, 147.9, 142.0, 135.0, 132.0, 
131.3, 127.4, 124.3, 116.5, 62.9, 55.6, 47.5, 39.1, 26.2 ppm. 
IR (neat): 3212, 2936, 2868, 1658, 1599, 1572, 1507, 1340, 1283, 1224, 1173 cm–1.  
MS (EI, 70 eV): m/z (%) = 350.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C21H19NO4: 349.1309 [M+]; found 349.1312. 
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((4-Isopropoxyphenyl)ethynyl)trimethylsilane (89) 
 
Aryl iodide 69 (9.02 g, 34.4 mmol, 1.0 eq), ethynyl trimethyl silane (7.53 g, 76.6 
mmol, 2.2 eq), CuI (0.170 g, 894 mmol, 0.025 eq) and PdCl2(PPh3)2 (0.303 g, 0.431 
mmol, 0.012 eq) were added to 30 ml of dry Et3N. N2 gas was bubbled through the 
mixture at room temperature for 5 min and stirred for 12 h at the same conditions. 
After complete of the reaction the solvent was evaporated and 25 ml water was 
added followed by extraction with CH2Cl2 (3 x 20 ml). The combined organic layers 
were washed with 20 ml 1M aqueous HCl, then 20 ml brine solution. The organic 
phase was dried over MgSO4 and the solvent was removed in vacuo. The product 
was purified by silica gel column chromatography (15 cm x 5.5 cm) using petroleum 
ether to afford alkyne 89 (7.93 g, 34.2 mmol, 99%) as a pale yellow oil. Rf = 0.63 
(SiO2, petroleum ether-EtOAc, 9:1). 
1H-NMR (300 MHz, CDCl3):  = 7.38 (d, J = 8.9 Hz, 2 H, CH, Ar), 6.79 (d, J = 8.9 Hz, 
2 H, CH, Ar), 4.55 (sept, J = 6.1 Hz, 1 H, CH, iPr), 1.32 (d, J = 6.1 Hz, 6 H, CH3, iPr), 
0.23 (s, 9 H, (CH3)3Si) ppm.  
13C-NMR (75 MHz, CDCl3):  = 158.1, 133.4, 115.5, 114.8, 106.3, 92.2, 69.8, 21.9, 
0.1 ppm. 
IR (neat): 2960, 2151, 1604, 1504, 1287, 1246, 1181, 1118, 952, 830, 757 cm–1.  
MS (EI, 70 eV): m/z (%) = 175.1 (100), 190.1 (22), 232.1 (19) [M+]. 
HRMS (EI-MS): m/z calcd for C14H20OSI: 232.1283 [M+]; found 232.1285. 
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1-Ethynyl-4-isopropoxybenzene (90) 
 
Alkyne 89 (7.80 g, 33.6 mmol, 1.0 eq) was dissolved in 10 ml of MeOH, then a 
solution of KOH (3.05 g, 54.4 mmol, 1.6 eq) in 50 ml MeOH-CH2Cl2 (1:1) was added 
to the mixture which stirred for 1 h at room temperature. After that the solvent was 
evaporated in vacuo followed by adding 50 ml 1M aqueous HCl. The mixture was 
extracted with CH2Cl2 (3 x 25 ml). The combined organic layers were dried over 
MgSO4 and the solvent was removed in vacuo. The product was purified by silica gel 
column chromatography (5 cm x 5.5 cm) using petroleum ether to produce the 
terminal alkyne 90 (5.38 g, 33.6, 100%) as a yellow oil. Rf = 0.53 (SiO2, petroleum 
ether-EtOAc, 9:1). 
1H-NMR (300 MHz, CDCl3):  = 7.41 (d, J = 8.9 Hz, 2 H, CH, Ar), 6.82 (d, J = 8.9 Hz, 
2 H, CH, Ar), 4.56 (sept, J = 6.1 Hz, 1 H, CH, iPr), 2.99 (s, 1 H, alkyne), 1.34 (d, J = 
6.1 Hz, 6 H, CH3, iPr) ppm. 
13C-NMR (100 MHz, CDCl3):  = 158.3, 133.6, 115.6, 113.7, 83.7, 75.6, 96.8, 21.9 
ppm. 
The 1H NMR and 13C NMR spectral data is in accordance with the literature.103 
IR (neat): 3287, 2980, 1604, 1503, 1285, 1234, 1167, 1116, 951, 831 cm–1.  
MS (EI, 70 eV): m/z (%) = 98.1 (22), 118.0 (100), 160.1 (37) [M+]. 
HRMS (EI-MS): m/z calcd for C11H12O: 160.0888 [M+]; found 160.0887. 
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1,4-Dichloro-4-(4-isopropoxyphenyl)but-3-en-2-one (91) 
 
To a stirred suspension of AlCl3 (40.1 mg, 0.301 mmol, 1.1 eq) in dry 2 ml CH2Cl2 at  
-78 °C, was added alkyne 90 (50.1 mg, 0.313 mmol, 1.0 eq) and chloroacetyl 
chloride (38.1 mg, 0.270 mmol, 1.0 eq) dropwise over 10 min under N2. The mixture 
was warmed to room temperature and stirred for 1 h, followed by pouring it into 10 ml 
of ice cold brine solution and stirred for 2 h. After that the mixture was extracted with 
CH2Cl2 (3 x 10 ml). The product was purified by silica gel thin layer chromatography 
on SiO2 (petroleum ether-EtOAc, 4:1) to give dichloro compound 91 (22.4 mg, 0.0820 
mmol, 26%) as a yellow oil.  
1H-NMR (300 MHz, CDCl3):  = 7.69 (d, J = 9.0 Hz, 2 H, CH, Ar), 7.01 (s, 1 H, CH), 
6.90 (d, J = 9.0 Hz, 2 H, CH, Ar), 4.62 (sept, J = 6.1 Hz, 1 H, CH, iPr), 4.32 (s, 2 H, 
CH2Cl) 1.36 (d, J = 6.1 Hz, 6 H, CH3, iPr) ppm. 
13C-NMR (75 MHz, CDCl3):  = 189.3, 160.8, 147.1, 129.3, 128.5, 117.4, 115.5, 70.2, 
49.3, 21.9 ppm. 
MS (EI, 70 eV): m/z (%) = 118.1 (13.4), 181.0 (100), 183.1(29), 272.0 [M+]. 
 
2-((4-Isopropoxyphenyl)ethynyl)cyclohexanol (97) 
 
To a stirred solution of alkyne 90 (59.5 mg, 0.371 mmol, 1.0 eq) in 15 ml of dry THF 
at -78 °C was added dropwise a solution of n-BuLi (302 µl, 1.6 M, 0.483 mmol, 1.3 
eq). The reaction solution was stirred at -78 °C for 30 min, followed by treated 
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dropwise with BF3-Et2O (0.120 ml, 50%, 0.483 mmol, 1.3 eq). Then after 15 min at -
78 °C, the epoxide solution 96 (43.7 mg, 0.445 mmol, 1.2 eq) in 5 ml of dry THF was 
added with stirrer at -78 °C for 2 h. The reaction was quenched with 10 ml saturated 
NH4Cl solution and extracted with EtOAc (3 x 10 ml). The combined organic layers 
were dried over MgSO4 and the solvent was removed in vacuo. The product was 
purified by silica gel thin layer chromatography on SiO2 (petroleum ether-EtOAc, 4:1) 
to give alcohol 97 (20.3 mg, 0.0786 mmol, 21%) as a colorless oil. Rf = 0.44 (SiO2, 
petroleum ether-EtOAc, 4:1). 
1H-NMR (300 MHz, CDCl3):  = 7.32 (d, J = 8.8 Hz, 2 H, CH, Ar), 6.79 (d, J = 8.8 Hz, 
2 H, CH, Ar), 4.53 (sept, J = 6.1 Hz, 1 H, CH, iPr), 3.52 (m, 1 H, CH), 2.51-2.36 (m, 2 
H, CH2), 2.11-2.01 (m, 2 H, CH2), 1.86-1.63 (m, 2 H, CH2), 1.55-1.40 (m, 1 H, CH2), 
1.37-1.16 (m, 9 H, CH3, iPr and CH2) ppm. 
13C-NMR (75 MHz, CDCl3):  = 157.6, 133.0, 115.6, 115.0, 89.0, 82.5, 73.6, 69.8, 
39.6, 33.0, 31.1, 24.9, 24.2, 21.9 ppm.  
IR (neat): 3211, 2932, 2856, 1605, 1506, 1446, 1278, 1244, 1181, 1117, 1074 cm–1.  
MS (EI, 70 eV): m/z (%) = 259.2 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C17H23O2: 259.1693 [M+H]+; found 259.1696. 
 
2-(4-Isopropoxyphenyl)-1-oxaspiro[4.4]non-2-ene-4-thione (99) 
 
Method A from alcohol 29: A solution of alcohol 29 (59.7 mg, 0.219 mmol, 1.0 eq) 
and Lawesson's reagent (177 mg, 0.438 mmol, 2.0 eq) in toluene (10 ml) was stirred 
at room temperature for 4 h. The solvent was removed and the product was purified 
by silica gel thin layer chromatography on SiO2 (petroleum ether-EtOAc, 4:1) gave 99 
(41.6 mg, 0.144 mmol, 66%) as an orange solid.  
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Method B from furanone 30: A solution of furanone 30 (55.1 mg, 0.202 mmol, 1.0 
eq) and Lawesson's reagent (81.7 mg, 0.202 mmol, 1.0 eq) in toluene (10 ml) was 
refluxed for 48 h. The solvent was removed and the product was purified by silica gel 
thin layer chromatography on SiO2 (petroleum ether-EtOAc, 4:1) to afford 
thiocarbonyl compound 99 (26.3 mg, 0.0912 mmol, 45%) as an orange solid. Rf = 
0.56 (SiO2, petroleum ether-EtOAc, 4:1). Mp 108 °C. 
1H-NMR (300 MHz, CDCl3):  = 7.82 (d, J = 9.0 Hz, 2 H, CH, Ar), 6.96 (d, J = 9.0 Hz, 
2 H, CH, Ar), 6.77 (s, 1 H, C=CH), 4.67 (sept, J = 6.1 Hz, 1 H, CH, iPr), 2.39-2.17 (m, 
2 H, CH2), 2.13-1.92 (m, 6 H, CH2), 1.38 (d, J = 6.1 Hz, 6 H, CH3, iPr) ppm. 
13C-NMR (75 MHz, CDCl3):  = 230.6, 182.4, 162.4, 130.0, 120.2, 116.7, 115.9, 
112.7, 70.3, 41.6, 25.8, 21.8 ppm. 
IR (neat): 3093, 2974, 2933, 2871, 1600, 1542, 1483, 1429, 1385, 1301, 1253 cm–1.  
MS (EI, 70 eV): m/z (%) = 121.0 (26), 205.0 (100), 247.1 (91), 288.1 (59) [M+]. 
HRMS (EI-MS): m/z calcd for C17H20O2S: 288.1184 [M+]; found 288.1185. 
*Compounds 29 and 30 were prepared by Sabine Amslinger and Simon Lindner.32 
 
1-(4-Isopropoxyphenyl)prop-2-yn-1-ol (109) 
 
To aldehyde 111 (214 mg, 1.30 mmol, 1.0 eq) in 15 ml of dry THF at -78 °C was 
added dropwise ethynylmagnesium bromide (3.40 ml, 0.5 M in THF , 1.70 mmol, 1.3 
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eq). The reaction mixture was stirred at -78 °C for 30 min, then at room temperature 
for 1.5 h. After that the mixture was quenched with 20 ml saturated NH4Cl solution 
and extracted with EtOAc (3 x 20 ml). The combined organic layers were dried over 
MgSO4 and the solvent was removed in vacuo. The product was purified by silica gel 
thin layer chromatography SiO2 (petroleum ether-EtOAc, 4:1) to produce alcohol 109 
(242 mg, 1.27 mmol, 98%) as a yellow oil. Rf = 0.43 (SiO2, petroleum ether-EtOAc, 
4:1). 
1H-NMR (300 MHz, CDCl3):  = 7.45 (d, J = 8.6 Hz, 2 H, CH, Ar), 6.98 (d, J = 8.6 Hz, 
2 H, CH, Ar), 5.41 (s, 1 H, CH), 4.65 (sept, J = 6.1 Hz, 1 H, CH, iPr), 2.67 (s, 1 H, 
alkyne), 2.52 (d, 1 H, J = 5.6 Hz, OH), 1.33 (d, J = 6.1 Hz, 6 H, CH3, iPr) ppm.  
13C-NMR (75 MHz, CDCl3):  = 158.1, 132.0, 128.1, 115.8, 83.7, 74.6, 69.9, 64.0, 
22.0 ppm. 
IR (neat): 3446, 3270, 2984, 1605, 1505, 1383, 1300, 1250, 1177, 1121, 1015 cm–1.  
MS (EI, 70 eV): m/z (%) = 95.1 (82), 102.1(35), 131.1 (71), 147.0 (100) [M+]. 
HRMS (EI-MS): m/z calcd for C12H14O2: 190.0994 [M+]; found 190.0996. 
 
2,3,5,6-Tetramethoxycyclohexa-2,5-diene-1,4-dione (114) 
 
Sodium methoxide solution was prepared by adding sodium metal (1.31 g, 57.1 
mmol, 4.0 eq) of under N2 to dry methanol (50 ml) at 0 °C. After 2 h chloranil (115) 
(3.51 g, 14.3 mmol, 1.0 eq) was added. The mixture immediately turned red, which 
was heated at 85 °C for 6 h. The mixture was cold to 0 °C and the formed orange 
needles were filtrated and washed with water (3 x 10 ml) followed by washing with 
petroleum ether (3 x 10 ml) to produce p-quinone 114 (2.58 g, 11.3 mmol, 79%) as a 
pure orange needles. Rf = 0.50 (SiO2, petroleum ether-EtOAc, 1:1). 
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1H-NMR (300 MHz, CDCl3):  = 3.98 (s, 12 H, OCH3) ppm. 
13C-NMR (100 MHz, CDCl3):  = 180.4, 142.7, 61.3 ppm. 
IR (neat): 2946, 1662, 1600, 1463, 1437, 1265, 1201, 1073, 1058, 965, 867 cm–1.  
MS (EI, 70 eV): m/z (%) = 229.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C10H13O6: 229.0707 [M+H]+; found 229.0709. 
The 1H NMR and 13C NMR spectral data is in accordance with the literature. 
 
Methyl 1-hydroxy-2,3,5,5-tetramethoxy-4-oxocyclopent-2-enecarboxylate (113) 
 
To a solution of p-quinone 114 (91.6 mg, 0.401 mmol, 1.0 eq) in 30 ml MeOH was 
added sodium metaperiodate (343 mg, 1.61 mmol, 4.0 eq) and 3 ml water. The 
reaction mixture was refluxed for 50 h. Then the formed solid was filtrated off and the 
filtrate was evaporated and the product was purified using silica gel thin layer 
chromatography on SiO2 (petroleum ether-EtOAc, 1:1) afforded cyclopentenone 113 
(23.7 mg, 0.0858 mmol, 21%) as a colorless oil. Rf = 0.33 (SiO2, petroleum ether-
EtOAc, 1:1). 
1H-NMR (300 MHz, CDCl3):  = 4.12 (s, 3 H, OCH3, β-position), 3.88 (s, 3 H, OCH3, 
α-position), 3.80 (s, 3 H, OCH3, COOCH3), 3.74 (s, 1 H, OH), 3.47 (s, 3 H, OCH3, 
acetal), 3.39 (s, 3 H, OCH3, acetal) ppm. 
13C-NMR (75 MHz, CDCl3):  = 189.4, 169.9, 164.0, 136.3, 97.3, 80.6, 59.9, 59.5, 
53.7, 52.3, 51.9 ppm. 
The 1H NMR and 13C NMR spectral data is in accordance with the literature.77 
IR (neat): 3503, 2955, 1747, 1636, 1454, 1339, 1210, 1047, 994, 872, 732 cm–1.  
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MS (EI, 70 eV): m/z (%) = 185.0 (15), 213.0 (13), 245.1 (100). 
HRMS (EI-MS): m/z calcd for C11H17O8: 277.0918 [M+H]+; found 277.0921. 
 
2-Hydroxy-3,5,6-trimethoxycyclohexa-2,5-diene-1,4-dione (116) 
 
p-Quinone 114 (1.00 g, 4.39 mmol, 1.0 eq) was dissolved in 30 ml of dry CH2Cl2 
followed by additive of BCl3 (4.83 ml, 1M solution in n-hexane), 4.83 mmol, 1.1 eq) 
dropwise at -78 °C. The solution was kept at this temperature for 2 h, then warmed to 
room temperature. 2 ml, 1 M aqueous HCl solution was added to the mixture 
followed by adding 20 ml brine solution. The mixture was extracted with CH2Cl2 (3 x 
20 ml) and the combined organic layers were dried over MgSO4 and evaporated to 
produce alcohol 116 (0.924 g, 4.31 mmol, 98%) as pure purple solid. Rf = 0.17 (SiO2, 
petroleum ether-EtOAc, 1:1). 
1H-NMR (300 MHz, CDCl3):  = 7.56 (s, 1 H, OH), 4.04 (s, 3 H, OCH3), 4.04 (s, 3 H, 
OCH3), 2.96 (s, 3 H, OCH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 180.9, 179.7, 143.8, 140.7, 138.1, 135.3, 61.4, 60.4 
ppm.  
IR (neat): 3383, 3357, 1609, 1461, 1440, 1372, 1264, 1233, 1197, 1067 cm–1.  
MS (EI, 70 eV): m/z (%) = 215.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C9H10O6: 214.0472 [M+]; found 214.0443. 
 
 
 
2,2-Dimethylpent-4-enenitrile (142) 
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To a solution of diethyl amine (6.01 g, 82.1 mmol, 1.1 eq), in 100 ml of dry Et2O at 0 
°C under N2 was added dropwise a solution of n-BuLi (51.3 ml, 1.6 M in hexanes, 
82.1 mmol, 1.1 eq). The solution was stirred at 0 °C for 40 min followed by adding 
isobutyronitrile 141 (5.16 g, 74.7 mmol, 1.0 eq) dropwise at 0 °C. After 1 h a solution 
of allyl bromide (9.94 g, 82.1 mmol, 1.1 eq) in 20 ml of Et2O was added dropwise at 0 
°C, the reaction was warmed to room temperature and stirred overnight. Then the 
solution was cold to 0 °C, quenched with 20 ml of ice and then extracted with Et2O (3 
x 25 ml). The combined organic layers were dried over MgSO4 and the solvent was 
removed in vacuo to give nitrile 142 (8.02 g, 73.5 mmol, 98%) as a colorless oil. Rf = 
0.40 (SiO2, petroleum ether-EtOAc, 9:1). 
1H-NMR (300 MHz, CDCl3):  = 5.99-5.69 (m, 1 H, CH), 5.26-5.06 (m, 2 H, vinyl), 
2.23 (dt, J = 7.3, 1.2 Hz, 2 H, CH2), 1.29 (s, 6 H, CH3) ppm.  
13C-NMR (75 MHz, CDCl3):  = 132.0, 124.5, 119.7, 44.8, 31.9, 26.0 ppm. 
The 1H NMR and 13C NMR spectral data is in accordance with the literature.90 
IR (neat): 2981, 2340, 2239, 1977, 1470, 997, 922, 406 cm–1.  
MS (EI, 70 eV): m/z (%) = 41.2 (100), 68.2 (24), 109.2 (31) [M]+. 
HRMS (EI-MS): m/z calcd for C7H11N: 109.0891 [M+]; found 109.0889. 
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2,2-Dimethylpent-4-enal (136) 
 
To a solution of nitrile 136 (3.00 g, 27.5 mmol, 1.0 eq) in dry n-pentane (50 ml) at -78 
°C under N2 was added dropwise a solution of DIBAL-H (31.6 ml, 1.0 M in THF, 31.6 
mmol, 1.1 eq). The reaction was kept 2 h at the same temperature followed by 
stirring at room temperature for 6.5 h then ethyl formate (0.611 g, 8.25 mmol, 0.3 eq) 
was added dropwise. After stirring for 1 h the reaction was quenched with 20 ml 
saturated NH4Cl solution. The suspension was diluted with HCl (20 ml 10% in H2O) 
and the organic layer was separated and diluted with H2SO4 (10 ml, 2.5 M in H2O). 
The aqueous layer was extracted with n-pentane (3 x 20 ml). The combined organic 
layers were dried over MgSO4 and the solvent was removed in vacuo to give 
aldehyde 136 (3.03 g, 27.0 mmol, 98%) as a colorless oil. Rf = 0.40 (SiO2, petroleum 
ether-EtOAc, 9:1). 
1H-NMR (300 MHz, CDCl3):  = 9.44 (s, 1 H, CHO), 5.82-5.50 (m, 1 H, CH), 5.14-
4.89 (m, 2 H, CH2), 2.17 (d, J = 7.5 Hz, 2 H, CH2), 1.01 (s, 6 H, CH3) ppm.  
13C-NMR (75 MHz, CDCl3):  = 205.8, 133.0, 118.3, 45.6, 41.3, 21.0 ppm. 
The 1H NMR and 13C NMR spectral data is in accordance with the literature.88 
IR (neat): 2972, 2149, 1997, 1721, 1665, 1471, 1092, 996, 913 cm–1.  
MS (EI, 70 eV): m/z (%) = 55.2 (100), 56.2 (25), 70.2 (22). 
 
 
 
 
 
 
Experimental part 
106 
 
3-Methylbut-3-en-1-yl 4-methylbenzenesulfonate (153) 
 
 
 
 
 
To a solution of isoprenol (152) (10.0 g, 116 mmol, 1.0 eq) and p-TsCl (24.4 g, 127 
mmol, 1.1 eq) in dry CH2Cl2 (100 ml) was added Et3N (14.1 g, 11.8 mmol, 1.2 eq) at 
0 °C. The reaction was stirred 2 h at 0 °C and at room temperature overnight. Then 
H2O (100 ml) was added and the mixture was extracted with CH2Cl2 (3 x 25 ml). The 
combined organic layers were dried over MgSO4 and the solvent was removed in 
vacuo to afford tosylate 153 (27.1 g, 112 mmol, 97%) as a colorless oil. Rf = 0.23 
(SiO2, petroleum ether-EtOAc, 9:1). 
1H-NMR (300 MHz, CDCl3):  = 7.74 (d, J = 7.4 Hz, 2 H, CH, Ar), 7.31 (d, J = 7.4 Hz, 
2 H, CH, Ar), 4.74 (s, 1 H, CH), 4.63 (s, 1 H, CH), 4.07 (t, J = 6.7 Hz, 2 H, CH2), 2.39 
(s, 3 H, CH3), 2.30 (t, J = 6.7 Hz, 2 H, CH2), 1.60 (s, 3 H, CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 144.6, 139.9, 132.8, 129.6, 127.6, 112.9, 68.3, 36.5, 
22.0, 21.4 ppm. 
IR (neat): 1356, 1173, 1097, 961, 901, 814, 777, 660, 551, cm–1.  
MS (EI, 70 eV): m/z (%) = 258.1 (100) [M+NH4]+. 
HRMS (EI-MS): m/z calcd for C12H17O3S: 241.0893 [M+H]+; found 241.0894. 
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4-Methylpent-4-enenitrile (145) 
 
A solution of tosylate 153 (10.0 g, 41.6 mmol, 1.0 eq) and sodium cyanide (2.86 g, 
58.3 mmol, 1.4 eq) in DMSO (50 ml) was heated at 90 °C for 2 h. The solution was 
cold to room temperature and poured into 100 ml H2O followed by extraction with 
Et2O (3 x 25 ml). The combined organic layers were dried over MgSO4 and the 
solvent was removed in vacuo to produce nitrile 145 (3.87 g, 40.7 mmol, 98%) as a 
colorless oil. Rf = 0.23 (SiO2, petroleum ether-EtOAc, 9:1). 
1H-NMR (300 MHz, CDCl3):  = 4.82 (s, 1 H, CH, vinyl), 4.74 (s, 1 H, CH, vinyl), 2.43 
(t, J = 7.3 Hz, 2 H, CH2), 2.28 (t, J = 7.3 Hz, 2 H, CH2), 1.70 (s, 3 H, CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 141.4, 119.1, 112.0, 32.7, 21.7, 15.5 ppm. 
IR (neat): 2906, 2245, 1652, 1437, 1379, 896 cm–1.  
MS (EI, 70 eV): m/z (%) = 39.1 (31), 53.1 (20) 55.1 (100), 95.2 (32) [M+]. 
 
4-methylpent-4-enal (143) 
 
To a solution of nitrile 145 (3.01 g, 31.7 mmol, 1.0 eq) in dry n-pentane (50 ml) at -78 
°C under N2 was added dropwise a solution of DIBAL-H (36.4 ml, 1.0 M in THF, 36.4 
mmol, 1.1 eq). The reaction was kept 2 h at the same temperature followed by 
stirring at room temperature for 7 h. Then ethyl formate (0.705 g, 9.52 mmol, 0.3 eq) 
was added dropwise. After stirring for 1 h the reaction was quenched with 20 ml 
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saturated NH4Cl solution and the suspension was diluted with HCl (20 ml, 10%). The 
organic layer was separated and diluted with H2SO4 (10 ml, 2.5 M). The aqueous 
layer was extracted with n-pentane (3 x 20 ml). The combined organic layers were 
dried over MgSO4 and the solvent was removed in vacuo to give aldehyde 143 (3.03 
g, 27.0 mmol, 98%) as a colorless oil. Rf = 0.16 (SiO2, petroleum ether-EtOAc, 9:1). 
1H-NMR (300 MHz, CDCl3):  = 9.69 (m, 1 H, CHO), 4.69 (s, 1 H, CH), 4.61 (s, 1 H, 
CH), 2.50 (m, 2 H, CH2), 2.27 (m, 2 H, CH2), 1.67 (s, 3 H, CH3) ppm.  
13C-NMR (75 MHz, CDCl3):  = 201.9, 143.5, 110.4, 41.5, 29.6, 22.3 ppm. 
IR (neat): 2963, 2927, 1679, 1648, 1447, 1375, 884 cm–1.  
MS (EI, 70 eV): m/z (%) = 39.1 (47), 41.1 (100), 55.1 (53), 56.1 (52), 69.2 (46), 70.2 
(51), 98.1 (5) [M+]. 
 
Diethyl (3-oxobutan-2-yl)phosphonate (144) 
 
Ketone 147 (5.00 g, 46.9 mmol, 1.0 eq) and methyl hydrazinecarboxylate (4.44 g, 
49.3 mmol, 1.1 eq) was dissolved in 50 ml toluene under reflux condition with a 
Dean-Stark apparatus. After removing the H2O (4 h) triethyl phosphite (8.58 g, 51.6 
mmol, 1.1 eq) was added dropwise under reflux. The mixture was kept 2 h at the 
same conditions, then the solvent was removed and 10 ml acetone were added 
followed by HCl (10 ml, 3 N in H2O). After 3 h at room temperature the acetone was 
removed and 25 ml H2O were added and the mixture was extracted with CH2Cl2 (3 x 
20 ml). The combined organic layers were dried over MgSO4 and the solvent was 
removed in vacuo. The product was purified by silica gel column chromatography (15 
cm × 5.5 cm) using EtOAc to afford phosphonate 114 (6.26 g, 30.1 mmol, 64%) as a 
yellow oil.  
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1H-NMR (300 MHz, CDCl3):  = 4.11-3.89 (m, 4 H, CH2), 3.22-2.95 (m, 1 H, CH), 
2.28-2.11 (m, 3 H, CH3), 1.28-1.11 (m, 9 H, CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 203.5, 62.3 (t, J = 7.6 Hz), 47.1 (d, J = 126.8 Hz), 
30.1, 16.1 (d, J = 5.9 Hz), 10.6 (d, J = 6.4 Hz) ppm.  
31P-NMR (121 MHz, CDCl3): = 24.0 ppm. 
MS (EI, 70 eV): m/z (%) = 209.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C8H17O4P: 208.0859 [M+]; found 208.0873. 
 
3,7-Dimethylocta-3,7-dien-2-one (137) 
 
To a suspension of NaH (49.0 mg (from 60% NaH suspension in paraffine oil), 1.26 
mmol, 1.2 eq) in 5 ml of dry THF at 0 °C under N2 was added ethyl phosphonate 144 
(0.255 g, 1.23 mmol, 1.2 eq) and the mixture was stirred for 30 min at room 
temperature. Then the solution was cold to 0 °C followed by adding aldehyde 143 
(0.100 g, 1.02 mmol, 1.0 eq). The reaction mixture was warmed to room temperature 
and stirred for 4 h followed by quenching with 20 ml brine solution and extracted with 
Et2O (3 x 10 ml). The combined organic layers were dried over MgSO4 and the 
solvent was removed in vacuo. The product was purified by silica gel thin layer 
chromatography (petroleum ether-EtOAc, 95:5) to give ketone 137 (0.119 g, 0.782 
mmol, 77%) as a yellow oil. Rf = 0.26 (SiO2, petroleum ether-EtOAc, 9:1). 
1H-NMR (300 MHz, CDCl3):  = 6.57 (m, 1 H, CH, vinyl), 4.72 (s, 1 H, CH, vinyl), 4.66 
(s, 1 H, CH, vinyl), 2.41-2.28 (m, 2 H, CH2), 2.24 (s, 3 H, CH3), 2.13 (t, J = 7.5, 2 H, 
CH2), 1.72 (s, 3 H, CH3), 1.70 (s, 3 H, CH3) ppm. 
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13C-NMR (75 MHz, CDCl3):  = 199.7, 144.4, 143.0, 137.6, 110.6, 36.3, 27.0, 25.3, 
22.2, 11.0 ppm. 
MS (EI, 70 eV): m/z (%) = 153.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C10H16O: 152.1196 [M+]; found 152.1186. 
 
2,6,10,10-Tetramethyltrideca-1,5,8,12-tetraen-7-one (129) 
  
To a suspension of NaH (6.4 mg (from 60% NaH suspension in paraffine oil), 0.16 
mmol, 1.2 eq) in dry THF (2 ml) at 0 °C under N2 was added a solution of ketone 137 
(20.2 mg, 0.133 mmol, 1.0 eq) in 1 ml of dry THF. The mixture was stirred for 30 min 
at 0 °C, followed by adding a solution of aldehyde 136 (14.9 mg, 0.133 mmol, 1.0 eq) 
in 1 ml of dry THF. The reaction mixture was stirred at 0 °C for 1 h followed by 
quenching with 20 ml brine solution and extracted with CH2Cl2 (3 x 5 ml). The 
combined organic layers were dried over MgSO4 and the solvent was removed in 
vacuo. The product was purified by silica gel thin layer chromatography on SiO2 
(petroleum ether-EtOAc, 95:5) gave ketone 129 (3.1 mg, 0.13 mmol, 9%) as a 
colorless oil. Rf = 0.67 (SiO2, petroleum ether-EtOAc, 95:5). 
1H-NMR (300 MHz, CDCl3):  = 6.77 (d, J = 15.7 Hz, 1 H, CH), 6.54 (m, 1 H, CH), 
7.24 (d, J = 15.7 Hz, 1 H, CH), 5.79-5.61 (m, 1 H, CH, vinyl), 5.07-4.97 (m, 2 H, CH, 
vinyl), 4.76 (s, 1 H, CH, vinyl), 4.71 (s, 1 H, CH, vinyl), 2.45-2.34 (m, 2 H, CH2), 2.21-
2.14 (m, 2 H, CH2), 2.14-2.09 (m, 2 H, CH2), 1.84 (s, 3 H, CH3), 1.75 (s, 3 H, CH3), 
1.06 (s, 6 H, CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 193.0, 155.6, 144.6, 141.9, 137.9, 134.6, 121.6, 
117.6, 110.7, 46.5, 36.8, 36.4, 27.1, 26.3, 22.3, 11.9 ppm.  
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MS (EI, 70 eV): m/z (%) = 247.2 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C17H27NO: 247.2056 [M+H]+; found 247.2060. 
 
6,6-Dimethylnona-4,8-dien-3-one (155) 
  
Ethyl methyl ketone (156) (9.1 mg, 0.13 mmol, 1.0 eq) was dissolved in 10 ml dry 
Et2O. Then LiI (64.4 mg, 0.481 mmol, 3.8 eq) was added to the solution followed by 
adding aldehyde 136 (21.6 mg, 0.193 mmol, 1.5 eq) in 2 ml of dry Et2O. The mixture 
was refluxed for 30 h, and then cold to room temperature and 10 ml H2O was added. 
The aqueous phase was extracted with Et2O (3 x 10 ml). The combined organic 
layers were dried over MgSO4 and the solvent was removed in vacuo. The product 
was purified by silica gel thin layer chromatography on SiO2 (petroleum ether-EtOAc, 
95:5) gave ketone 155 (17 mg, 0.10 mmol, 81%) as a colorless oil. Rf = 0.49 (SiO2, 
petroleum ether-EtOAc, 9:1). 
1H-NMR (300 MHz, CDCl3):  = 6.78 (d, J = 16.2 Hz, 1 H, CH), 5.99 (d, J = 16.2 Hz, 1 
H, CH), 5.82-5.58 (m, 1 H, CH, vinyl), 5.14-4.90 (m, 2 H, CH2, vinyl), 2.57 (q, J = 7.3 
Hz, 2 H, CH2), 2.11 (dt, J = 7.5, 0.9 Hz, 2 H, CH2), 1.09 (t, J = 7.3 Hz, 3 H, CH3), 1.05 
(s, 6 H, CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 201.5, 155.3, 134.3, 126.3, 117.8, 46.5, 36.7, 33.4, 
26.1, 8.2 ppm. 
The 1H NMR and 13C NMR spectral data is in accordance with the literature.89 
MS (EI, 70 eV): m/z (%) = 167.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C11H18O: 166.1352 [M+]; found 166.1350. 
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6,6-Dimethylnona-2,4,8-trien-3-yl)oxy)trimethylsilane  
 
A solution of LHMDS (0.150 ml, 1M, 0.15 mmol, 2.0 eq) was added dropwise to a 
solution of ketone 155 (12.4 mg, 0.0746 mmol, 1.0 eq) in 10 ml of dry THF at -78 °C. 
The mixture was stirred at -78 °C for 20 min followed by addition of Et3N (22.6 mg, 
0.223 mmol, 3.0 eq) and TMSCl (28.4 µl, 0.224 mmol, 3.0 eq). The mixture was 
stirred at -78 °C for 30 min, followed by warming to room temperature for another 30 
min. The mixture was concentrated in vacuo and the residue was washed with n-
pentane (3 x 5 ml). The n-pentane was evaporated to give a yellow oil (17.9 mg) 
which was used in the next step without further purification. 
 
9-Hydroxy-4,4,8,10,10-pentamethyltrideca-1,5,12-trien-7-one (154) 
 
To aldehyde 136 (8.3 mg, 0.074 mmol, 1.0 eq) in 5 ml dry CH2Cl2 at -78 °C was 
added TiCl4 (8.3 µl, 0.074 mmol, 1.0 eq). After 10 min silyl ether (17.7 mg, 0.0742 
mmol, 1.0 eq) in 1 ml of dry CH2Cl2 was added to the solution at -78 °C and stirred 
for 30 min. Then the solution was quenched with 10 ml saturated aqueous NaHCO3 
solution. After warmed up to room temperature the mixture was extracted with Et2O 
(3 x 10 ml) and the combined organic layers were dried over MgSO4 and the solvent 
was removed in vacuo. The product was purified by silica gel thin layer 
chromatography on SiO2 (petroleum ether-EtOAc, 90:10) afforded ketone 154 (2.6 
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mg, 0.0093 mmol, 13%) over two steps as a colorless oil. Rf = 0.12 (SiO2, petroleum 
ether-EtOAc, 9:1). 
1H-NMR (300 MHz, CDCl3):  = 6.84 (d, J = 16.1 Hz, 1 H, CH), 6.00 (m, 1 H, CH), 
5.93-5.57 (m, 2 H, CH, vinyl), 5.11-4.94 (m, 4 H, CH, vinyl), 3.68 (d, J = 3.1 Hz, 1 H, 
CH), 3.21-2.94 (m, 1 H, CH), 2.64-2.32 (br, 1 H, OH), 2.27-1.93 (m, 4 H, CH2), 1.17 
(d, J = 7.1 Hz, 3 H, CH3), 1.07 (s, 6 H, CH3), 0.91 (s, 3 H, CH3), 0.88 (s, 3 H, CH3) 
ppm. 
13C-NMR (75 MHz, CDCl3):  = 205.1, 156.9, 135.3, 134.1, 125.1, 117.9, 117.3, 75.6, 
46.5, 44.6, 43.9, 38.4, 36.9, 26.1, 23.9, 23.5, 12.4 ppm.  
MS (EI, 70 eV): m/z (%) = 167.1 (30), 179.6 (20), 279.2 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C18H31O2: 279.2319 [M+], found 279.2327. 
 
Isonicotinohydrazide (166) 
 
A solution of ethyl isonicotinate (165) (22.2 g, 147 mmol, 1.0 eq) and hydrazine 
monohydrate (14.7 g, 249 mmol, 2.0 eq) in ethanol (100 ml) were refluxed for 3 h, the 
solvent was evaporated approximately by half and the mixture was cold to -10 °C. 
The formed white precipitate was filtered and washed with cold EtOH (2 x 20 ml) and 
petroleum ether (2 x 20 ml) respectively, to give hydrazide 166 (18.0 g, 131 mmol, 
89%) as a white crystals. Rf = 0.44 (SiO2, CH2Cl2-MeOH, 5:1); Mp 172 °C, literature 
value 171-172 °C.104  
1H-NMR (300 MHz, DMSO-d6):  = 10.11 (s, 1 H, NH), 8.70 (d, J = 6.1 Hz, 2 H, CH, 
Ar), 7.72 (d, J = 6.1 Hz, 2 H, CH, Ar), 4.62 (s, 2 H, NH2) ppm. 
13C-NMR (75 MHz, DMSO-d6):  = 163.9, 150.2, 140.2, 121.0 ppm. 
IR (neat): 3099, 3008, 1661, 1632, 1548, 1411, 1331, 1220, 1141, 994, 887 cm–1. 
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MS (EI, 70 eV): m/z (%) = 138.1 (100) [M+H]+, 121.0 (7.7). 
HRMS (EI-MS): m/z calcd for C6H7N3O: 137.0584 [M+]; found 137.0574. 
 
2-(Pyridin-4-yl)-1,3,4-oxadiazole (167) 
 
A solution of hydrazide 166 (2.00 g, 14.6 mmol, 1.0 eq) in 10 ml triethyl orthoformate 
was stirred at 120 °C for 20 h. Then the solvent was evaporated and the mixture was 
poured on 50 ml ice. The yellow precipitate was filtered off and washed with cold H2O 
(2 x 10 ml) and petroleum ether (2 x 10 ml) respectively. Recrystallization from EtOH 
afforded oxadiazole 167 (2.03 g, 13.8 mmol, 95%) as a white solid. Rf = 0.34 (SiO2, 
EtOAc); Mp 111 °C.  
1H-NMR (300 MHz, CDCl3):  = 8.84 (d, J = 6.1 Hz, 2 H, CH, Ar), 8.57 (s, 1 H, CH) 
7.95 (d, J = 6.1 Hz, 2 H,CH, Ar), ppm. 
13C-NMR (75 MHz, CDCl3):  = 163.0, 153.4, 150.9, 130.6, 120.5 ppm. 
The 1H NMR and 13C NMR spectral data is in accordance with the literature.105 
IR (neat): 3088, 2983, 1612, 1544, 1417, 1241, 1116, 1080, 1063, 993, 954 cm–1. 
MS (EI, 70 eV): m/z (%) = 148.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C7H6N3O: 148.0505 [M+]; found 148.0504. 
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Ethyl 5-(pyridin-4-yl)-1,3,4-oxadiazole-2-carboxylate (172) 
 
Hydrazide 166 (0.434 g, 3.16 mmol, 1.0 eq) and Et3N (0.960 g, 9.48 mmol, 3.0 eq) 
were dissolved in 100 ml CH2Cl2 at 0 °C and treated dropwise with ethyl 
oxalylchloride (0.432 g, 3.16 mmol, 1.0 eq). The solution was warmed to room 
temperature and stirred 6 h, and then tosyl chloride (0.603 g, 3.16 mmol, 1.0 eq) was 
added to the solution and stirred for 20 h. The reaction was diluted with 20 ml CH2Cl2 
followed by washing with 20 ml of H2O, 20 ml of saturated aqueous NaHCO3 and 20 
ml brine solution. The organic layer was dried over MgSO4. The solvent was removed 
in vacuo and the product was purified by silica gel thin layer chromatography on SiO2 
(petroleum ether-EtOAc, 1:1) to afford ester oxadiazole 172 (0.642 g, 2.93 mmol, 
93%) as a white solid. Rf = 0.58 (SiO2, EtOAc); Mp 96 °C.  
1H-NMR (300 MHz, CDCl3):  = 8.84 (d, J = 6.1 Hz, 2 H, CH, Ar), 7.98 (d, J = 6.1 Hz, 
2 H, CH, Ar), 4.54 (q, J = 7.1 Hz, 2 H, CH2), 1.46 (t, J = 7.1 Hz, 3 H, CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 164.5, 157.0, 154.0, 151.1, 129.8, 120.7, 63.8, 14 
ppm. 
IR (neat): 2990, 1736, 1572, 1536, 1413, 1325, 1284, 1220, 1194, 1163, 1019 cm–1. 
MS (EI, 70 eV): m/z (%) = 220.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C10H10N3O3: 220.0717 [M+H]+; found 220.0715. 
 
General procedure for the synthesis of hydrazones 179-190106 
Isonicotinohydrazide 166 (0.510 g-5.00 g, 3.72 mmol-36.5 mmol, 1.0 eq) and 
aldehyde or ketone (0.434 g-0.662 g, 4.09 mmol-4.01 mmol, 1.1eq) were dissolved in 
50 ml EtOH then 0.1 ml glacial acetic acid was added and the mixture was refluxed 
until the reaction was completed. After cooling to room temperature the mixture was 
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poured into 20 ml H2O and the solid was filtered. The precipitate was washed with 
H2O (2 x 10 ml) and petroleum ether (2 x 10 ml) to afford the corresponding 
hydrazone 179-190. 
 
N'-Benzylideneisonicotinohydrazide (179) 
 
Isonicotinohydrazide (166) (0.510 g, 3.72 mmol, 1.0 eq) gave after 8 h N'-
benzylideneisonicotinohydrazide (179) (0.824 g, 3.66 mmol, 98%) as a white solid. Rf 
= 0.21 (SiO2, EtOAc); Mp 199 °C, lit 205-207 °C.107 
1H-NMR (300 MHz, DMSO-d6):  = 12.11 (s, 1 H, NH), 8.79 (d, J = 6.0 Hz, 2 H, CH, 
Ar), 8.48 (s, 1 H, CH. N=CH), 7.83 (d, J = 6.1 Hz, 2 H, CH, Ar), 7.75 (m, 2 H, CH, Ar), 
7.46 (m, 3 H, CH, Ar) ppm. 
13C-NMR (75 MHz, DMSO-d6):  = 161.6, 150.3, 149.0, 140.4, 134.0, 130.4, 128.9, 
127.2, 121.5 ppm. 
IR (neat): 3200, 3020, 1682, 1562, 1412, 1282, 1228, 1148, 1057, 998, 994 cm–1. 
MS (EI, 70 eV): m/z (%) = 226.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C13H11N3O: 225.0902 [M+]; found 225.0905. 
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N'-(4-Methoxybenzylidene)isonicotinohydrazide (180) 
 
Isonicotinohydrazide (166) (5.01 g, 36.5 mmol, 1.0 eq) gave after 20 h N'-(4-
methoxybenzylidene)isonicotinohydrazide (180) (8.93 g, 35.0 mmol, 96%) as a white 
solid. Rf = 0.14 (SiO2, EtOAc); Mp 163 °C. 
1H-NMR (300 MHz, DMSO-d6):  = 11.69 (s, 1 H, NH), 8.78 (d, J = 6.0 Hz, 2 H, CH, 
Ar), 8.41 (s, 1 H, CH, N=CH), 7.82 (d, J = 6.1 Hz, 2 H, CH, Ar), 7.70 (d, J = 8.8 Hz, 2 
H, CH, Ar), 7.04 (d, J = 8.8 Hz, 2 H, CH, Ar), 3.81 (s, 3 H, OCH3) ppm. 
13C-NMR (75 MHz, DMSO-d6):  = 161.3, 161.0, 150.2, 148.8, 140.5, 128.8, 126.4, 
121.4, 114.3, 55.2 ppm. 
IR (neat): 3426, 3023, 1652, 1597, 1550, 1514, 1412, 1316, 1253, 1169, 1024 cm–1. 
MS (EI, 70 eV): m/z (%) = 255.1 (11.7) [M+], 134.1 (27.5), 133.1 (100.0), 106.1 
(25.2), 79.1(10.1), 78.1(20.0), 51.1(12.6). 
HRMS (EI-MS): m/z  calcd for C14H14N3O2: 256.1081 [M+H]+; found 256.1084. 
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N'-(4-Nitrobenzylidene)isonicotinohydrazide (181) 
 
Isonicotinohydrazide (166) (3.84 g, 28.0 mmol, 1.0 eq) gave after 1 h N'-(4-
nitrobenzylidene)isonicotinohydrazide (181) (7.44 g, 27.5 mmol, 98%) as a yellow 
solid. Rf = 0.14 (SiO2, EtOAc); Mp 277 °C. 
1H-NMR (300 MHz, DMSO-d6):  = 12.40 (s, 1 H, NH), 8.81 (d, J = 6.0 Hz, 2 H, CH, 
Ar), 8.59 (s, 1 H, CH, N=CH), 8.31 (d, J = 8.8 Hz, 2 H, CH, Ar), 8.02 (d, J = 8.8 Hz, 2 
H, CH, Ar), 7.85 (d, J = 6.0 Hz, 2 H, CH, Ar) ppm. 
13C-NMR (75 MHz, DMSO-d6):  = 161.9, 150.3, 147.9, 146.4, 140.2, 140.0, 128.1, 
124.0, 121.5 ppm. 
IR (neat): 3189, 2992, 2828, 1681, 1553, 1507, 1416, 1334, 1274, 1217, 1141 cm–1. 
The IR and 13C NMR spectral data is in accordance with the literature.106 
MS (EI, 70 eV): m/z (%) = 271.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C13H11N4O3: 271.0826 [M+H]+; found 271.0829. 
 
N'-(1-Phenylethylidene)isonicotinohydrazide (182) 
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Isonicotinohydrazide (166) (0.508 g, 3.71 mmol, 1.0 eq) gave after 24 h N'-(4-
nitrobenzylidene)isonicotinohydrazide (182) (0.843 g, 3.53 mmol, 95%) as a yellow 
solid. Rf = 0.26 (SiO2, EtOAc); Mp 173 °C, lit 169-171 °C.107  
1H-NMR (300 MHz, DMSO-d6):  = 11.06 (s, 1 H, NH), 8.77 (d, J = 5.2 Hz, 2 H, CH, 
Ar), 7.84 (m, 3 H, CH, Ar), 7.54 (m, 4 H, CH, Ar) 2.39 (s, 3 H, CH3) ppm. 
13C-NMR (75 MHz, DMSO-d6):  = 162.4, 156.8, 150.0, 149.3, 141.0, 137.7, 129.6, 
128.3, 126.5, 125.9, 122.9, 121.8, 14.7 ppm. 
IR (neat): 3176, 3061, 1651, 1596, 1549, 1384, 1298, 1153, 1118, 989, 843 cm–1. 
MS (EI, 70 eV): m/z (%) = 240.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C14H14N3O: 240.1131 [M+H]+  ; found 240.1136. 
 
N'-Cyclohexylideneisonicotinohydrazide (183) 
 
Isonicotinohydrazide (166) (0.462 g, 3.37 mmol, 1.0 eq) gave after 24 h N'-(4-
nitrobenzylidene)isonicotinohydrazide (183) (0.401 g, 1.85 mmol, 55%) as a yellow 
solid. Rf = 0.53 (SiO2, CH2Cl2-MeOH, 5:1); Mp 165 °C.  
1H-NMR (300 MHz, CDCl3):  = 8.74 (d, J = 4.2 Hz, 2 H, CH, Ar), 7.67 (d, J = 3.4 Hz, 
2 H, CH, Ar), 2.67-2.11 (m, 4 H, CH2), 2.00-1.38 (m, 6 H, CH2) ppm. 
13C-NMR (75 MHz, DMSO-d6):  = 167.7, 161.6, 150.0, 141.0, 121.5, 35.0, 28.1, 
26.8, 25.7, 24.9 ppm. 
IR (neat): 3217, 3035, 2932, 2852, 1658, 1638, 1525, 1407, 1302, 1284, 1140 cm–1. 
MS (EI, 70 eV): m/z (%) = 218.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C12H16N3O: 218.1288 [M+H]+  ; found 218.1289. 
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N'-(1-(4-Methoxyphenyl)ethylidene)isonicotinohydrazide (184) 
 
Isonicotinohydrazide (166) (0.482 g, 3.21 mmol, 1.0 eq) gave after 24 h N'-(1-(4-
methoxyphenyl)ethylidene)isonicotinohydrazide (184) (0.528 g, 1.96 mmol, 67%) as 
white solid. Rf = 0.41 (SiO2, EtOAc); Mp 196 °C.  
1H-NMR (300 MHz, DMSO-d6):  = 10.98 (s, 1 H, NH), 8.76 (d, J = 5.7 Hz, 2 H, CH, 
Ar), 7.82 (m, 4 H, CH, Ar), 7.00 (d, J = 8.8 Hz, 2 H, CH, Ar), 3.80 (s, 3 H, OCH3), 2.35 
(s, 3 H, CH3) ppm. 
13C-NMR (75 MHz, DMSO-d6):  = 162.1, 160.5, 157.1, 150.0, 141.1, 130.0, 128.0, 
121.7, 131.6, 55.1, 14.6 ppm. 
IR (neat): 3170, 3057, 2900, 1656, 1599, 1384, 1302, 1247, 1179, 1113, 1031 cm–1. 
MS (EI, 70 eV): m/z (%) = 270.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C15H16N3O2: 270.1237 [M+H]+  ; found 270.1238. 
 
N'-(1-Phenylethylidene)benzohydrazide (185) 
 
Benzohydrazide (0.150 g, 1.09 mmol, 1.0 eq) gave after 21 h N'-(1-
phenylethylidene)benzohydrazide (185) (0.122 g, 0.512 mmol, 47%) as a white solid. 
Rf = 0.55 (SiO2, petroleum ether-EtOAc, 1:1); Mp 155 °C. 
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1H-NMR (300 MHz, (DMSO-d6):  = 10.80 (s, 1 H, NH), 8.17-7.69 (m, 4 H, CH, Ar), 
7.67-7.23 (m, 6 H, CH, Ar), 2.38 (s, 3 H, CH3) ppm. 
13C-NMR (300 MHz, (DMSO-d6):  = 163.9, 155.4, 138.0, 134.0, 131.4, 129.3, 128.3, 
127.8, 126.3, 14.5 ppm. 
IR (neat): 3171, 3006, 1636, 1602, 1578, 1537, 1486, 1443, 1317, 1280, 1134 cm–1. 
MS (EI, 70 eV): m/z (%) = 239.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C15H15N2O: 239.1179 [M+]; found 239.1181. 
 
N'-(1-(4-Nitrophenyl)ethylidene)isonicotinohydrazide (186) 
 
Isonicotinohydrazide (166) (0.500 g, 3.65 mmol, 1.0 eq) gave after 24 h N'-(1-(4-
nitrophenyl)ethylidene)isonicotinohydrazide (186) (0.471 g, 1.65 mmol, 41%) as a 
yellow solid. Rf = 023 (SiO2, EtOAc); Mp 286 °C.  
1H-NMR (300 MHz, DMSO-d6):  = 11.08 (s, 1 H, NH), 8.77 (d, J = 4.3 Hz, 2 H, CH, 
Ar), 8.25 (d, J = 8.5 Hz, 2 H, CH, Ar), 8.04 (br, 2 H, CH, Ar), 7.76 (s, 2 H, CH, Ar), 
2.38 (s, 3 H, CH3) ppm. 
13C-NMR (75 MHz, DMSO-d6):  = 162.4, 149.5, 147.5, 143.6, 140.9, 139.1, 127.0, 
123.0, 121.7, 13.9 ppm. 
IR (neat): 3196, 3108, 1668, 1579, 1551, 1513, 1494, 1385, 1349, 1299, 1154 cm–1. 
MS (EI, 70 eV): m/z (%) = 285.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C14H13N4O3: 285.0982 [M+]; found 285.0985. 
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N'-(1-(4-(Trifluoromethyl)phenyl)ethylidene)isonicotinohydrazide (187) 
 
Isonicotinohydrazide (166) (0.500 g, 3.65 mmol, 1.0 eq) gave after 24 h N'-(1-(4-
(trifluoromethyl)phenyl)ethylidene)isonicotinohydrazide (187) (1.03 g, 3.35 mmol, 
92%) as white solid. Rf = 0.36 (SiO2, EtOAc); Mp 224 °C.  
1H-NMR (300 MHz, DMSO-d6):  = 11.16 (s, 1H, NH), 8.78 (d, J = 4.7 Hz, 2H, CH, 
Ar), 8.07 (d, J = 7.9 Hz, 2H, CH, Ar), 7.81 (m, 4H, CH, Ar), 2.43 (s, 3H, CH3) ppm. 
13C-NMR (75 MHz, DMSO-d6):  = 162.7, 154.5, 150.0, 141.6, 140.9, 127.2, 126.6, 
125.2 (q, J = 3.8 Hz, CHCCF3), 124.0 (q, J = 280.0 Hz, CF3), 121.9, 14.6 ppm. 
19F-NMR (282 MHz, DMSO-d6):  = (-60.8, CF3) ppm. 
IR (neat): 3185, 3064, 1660, 1598, 1550, 1387, 1331, 1159, 1106, 1079, 1013 cm–1. 
MS (EI, 70 eV): m/z (%) = 308.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C15H13F3N3O: 308.1005 [M+]; found 308.1004. 
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N'-(1-(4-(Trifluoromethoxy)phenyl)ethylidene)isonicotinohydrazide (188) 
 
(0.501 g, 3.65 mmol, 1.0 eq) of isonicotinohydrazide (166) gave after 24 h N'-(1-(4-
(trifluoromethoxy)phenyl)ethylidene)isonicotino hydrazide (188) (1.14 g, 3.51 mmol, 
96%) as a white solid. Rf = 0.33 (SiO2, EtOAc); Mp 203 °C.  
1H-NMR (300 MHz, DMSO-d6):  = 11.17 (br, 1H, NH), 8.77 (s, 2H, CH, Ar), 8.14-
7.20 (m, 6H, CH, Ar), 2.40 (s, 3H, CH3) ppm. 
13C-NMR (75 MHz, DMSO-d6):  = 162.5, 155.1, 150.0, 149.2, 140.9, 136.9, 128.5, 
121.8, 120.7, 119.9 (q, J = 255.0, OCF3).1, 14.7 ppm. 
19F-NMR (282 MHz, DMSO-d6)  = (-56.2, OCF3) ppm. 
IR (neat): 3188, 3080, 1668, 1387, 1280, 1201, 1151, 1113, 1070, 1017, 836 cm–1. 
MS (EI, 70 eV): m/z (%) = 324.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C15H13F3N3O2: 324.0954 [M+]; found 324.0958. 
 
N'-(1-(Pyridin-4-yl)ethylidene)isonicotinohydrazide (189) 
 
Isonicotinohydrazide (166) (0.502 g, 3.66 mmol, 1.0 eq) afforded after 24 h N'-(1-
(pyridin-4-yl)ethylidene)isonicotinohydrazide (189) (0.799 g, 3.33 mmol, 91%) as a 
white solid. Rf = 0.82 (SiO2, CH2Cl2-MeOH, 4:1); Mp 186 °C.  
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1H-NMR (300 MHz, DMSO-d6):  = 11.19 (s, 1 H, NH), 8.77 (s, 2 H, CH, Ar), 8.66 (s, 
2 H, CH, Ar), 7.80 (s, 4 H, CH, Ar), 2.40 (s, 3 H, CH3) ppm. 
13C-NMR (75 MHz, DMSO-d6):  = 162.8, 153.6, 150.0, 150.0, 149.9, 144.8, 121.9, 
120.5, 14.2 ppm. 
IR (neat): 3519, 3185, 3038, 1672, 1591, 1539, 1410, 1387, 1275, 1141, 995 cm–1. 
MS (EI, 70 eV): m/z (%) = 241.1(100) [M+H]+, 121.1 (32.4). 
HRMS (EI-MS): m/z   calcd for C13H13N4O: 241.1084 [M+H]+; found 241.1082. 
 
N'-(1-(Pyridin-2-yl)ethylidene)isonicotinohydrazide (190) 
 
(0.502 g, 3.65 mmol, 1.0 eq) of isonicotinohydrazide (166) gave after 24 h N'-(1-
(pyridin-2-yl)ethylidene)isonicotinohydrazide (190) (0.854 g, 3.55 mmol, 97%) as a 
white solid. Rf = 0.74 (SiO2, CH2Cl2-MeOH, 4:1); Mp 168 °C.  
1H-NMR (300 MHz, DMSO-d6):  = 11.12 (s, 1 H, NH), 8.78 (d, J = 4.1 Hz, 2 H, CH, 
Ar), 8.62 (m, 1 H, CH, Ar), 8.13 (d, J = 7.9 Hz, 1 H, CH, Ar), 7.91-7.28 (m, 4 H, CH, 
Ar), 2.48 (s, 3 H, CH3) ppm. 
13C-NMR (75 MHz, DMSO-d6):  = 162.7, 156.1, 154.7, 150.0, 148.6, 140.9, 136.6, 
124.3, 121.9, 120.5, 12.8 ppm. 
IR (neat): 3181, 3100, 2367, 1666, 1624, 1581, 1409, 1375, 1302, 1218, 1151 cm–1. 
MS (EI, 70 eV): m/z (%) = 241.1(100) [M+H]+, 150.01 (7.4). 
HRMS (EI-MS): m/z   calcd for C13H13N4O: 241.1084 [M+H]+; found 241.1085. 
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5-(Pyridin-4-yl)-1,3,4-oxadiazole-2-thiol (174) 
 
To a solution of isonicotinohydrazide (166) (0.302 g, 2.20 mmol, 1.0 eq) in 5 ml EtOH 
was added carbon disulfide (0.502 g, 6.60 mmol, 3.0 eq) and Et3N (0.267 g, 2.64 
mmol, 1.2 eq). The solution was refluxed for 24 h then cold to room temperature and 
acidified with HCl (0.1 M in H2O) and let stand for 4 h. The formed precipitate was 
filtered and washed with H2O (2 x 10 ml) and petroleum ether (2 x 10 ml) to give 
oxadiazole-2-thiol 174 (0.296 g, 1.66 mmol, 76%) as a yellow solid. Rf = 0.27 (SiO2, 
EtOAc); Mp 260 °C.  
1H-NMR (300 MHz, DMSO-d6):  = 8.78 (s, 2 H, CH, Ar), 7.79 (s, 2 H, CH, Ar) ppm. 
13C-NMR (75 MHz, DMSO-d6):  = 177.7, 158.7, 150.7, 129.7, 119.5 ppm. 
IR (neat): 3090, 3034, 2281, 1860, 1596, 1550, 1533, 1494, 1358, 1329, 1234 cm–1. 
MS (EI, 70 eV): m/z (%) = 180.0 (100) [M+]. 
HRMS (EI-MS): m/z calcd for C7H5N3OS: 179.0153 [M+]; found 179.0157. 
 
(5-(Pyridin-4-yl)-1,3,4-oxadiazol-2-yl) 3-phenylprop-2-enethioate (175) 
 
To oxadiazole-2-thiol 174 (0.142 g, 0.793 mmol, 1.0 eq) in 10 ml of dry THF at 0 °C 
was added 0.5 ml Et3N then cinnamoyl chloride (0.145 g, 0.872 mmol, 1.1 eq) was 
added dropwise to the solution at 0 °C. The reaction was warmed to room 
temperature and stirred for 3 h, then the solvent was evaporated and 10 ml saturated 
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NaHCO3 solution was added. The precipitate was filtered and washed with H2O (2 x 
10 ml) and petroleum ether (2 x 10 ml). The product was recrystallized from EtOH to 
give oxadiazole 175 (0.176 g, 0.570 mmol, 72%) as a yellow solid. Rf = 0.45 (SiO2, 
petroleum ether-EtOAc, 1:1); Mp 181 °C.  
1H-NMR (300 MHz, CDCl3):  = 8.88 (d, J = 4.5 Hz, 2 H, CH, Ar), 8.08 (d, J = 15.7 
Hz, 1 H, =CH), 7.89 (d, J = 5.6 Hz, 2 H, CH, Ar), 7.74 (d, J = 15.7 Hz, 1 H, =CH), 
7.70-7.59 (m, 2 H, CH, Ar and CH), 7.65-7.37 (m, 3 H, CH, Ar) ppm. 
13C-NMR (75 MHz, CDCl3):  = 173.1, 161.6, 156.3, 151.0, 150.3, 133.9.0, 131.8, 
129.1, 129.1, 129.0, 120.2, 115.2 ppm. 
IR (neat): 3108, 3051, 1727, 1616, 1549, 1310, 1277, 1242, 1137, 1052, 984 cm–1. 
MS (EI, 70 eV): m/z (%) = 310.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C16H12N3O2S: 310.0645 [M+]; found 310.0650. 
 
(5-(Pyridin-4-yl)-1,3,4-oxadiazol-2-yl) 3-(4-methoxyphenyl)prop-2-enethioate 
(176) 
 
To oxadiazole-2-thiol 174 (0.168 g, 0.947 mmol, 1.0 eq) in 10 ml of dry THF at 0 °C 
was added Et3N (0.5 ml) then a dropwise addition of 4-methoxycinnamoyl chloride 
(0.105 g, 0.534 mmol, 1.1 eq) dropwise at 0 °C. The reaction was warmed to room 
temperature and stirred for 3 h, then the solvent was evaporated and 10 ml saturated 
aqueous NaHCO3 solution was added. The precipitate was filtered and washed with 
H2O (2 x 10 ml) and petroleum ether (2 x 10 ml). The product was recrystallized from 
EtOH to afford oxadiazole 176 (0.171 g, 0.503 mmol, 53%) as a yellow solid. Rf = 
0.35 (SiO2, petroleum ether-EtOAc, 1:1); Mp 214 °C.  
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1H-NMR (300 MHz, CDCl3):  = 8.88 (d, J = 4.9 Hz, 2 H, CH, Ar), 8.05 (d, J = 15.6 
Hz, 1 H, CH), 7.90 (d, J = 5.9 Hz, 2 H, CH, Ar), 7.71-7.54 (m, 3 H, CH, Ar and CH), 
6.97 (d, J = 8.8 Hz, 2 H, CH, Ar), 3.88 (s, 3 H, OCH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 162.8, 161.8, 158.8, 156.2, 153.2, 151.1, 150.3, 
131.2, 126.8, 120.2, 114.7, 112.5, 55.6 ppm. 
IR (neat): 3036, 2999, 2937, 1117, 1592, 1571, 1514, 1314, 1285, 1238, 1176 cm–1. 
MS (EI, 70 eV): m/z (%) = 340.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C17H14N3O3S: 340.0750 [M+]; found 340.0753. 
 
1-(2-(4-Methoxyphenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)ethanone (191) 
 
Hydrazone 180 (3.50 g, 13.7 mmol, 1.0 eq), was dissolved in 30 ml acetic anhydride, 
the mixture was refluxed for 3 h. Then the solvent was evaporated and 20 ml H2O 
was added, the mixture was extracted with EtOAc (3 x 20 ml), the organic layer dried 
over MgSO4 and evaporated. The product was purified on column chromatography 
(SiO2, petrolum ether-EtOAc, 1:1) to afford oxadiazole 191 (1.39 g, 4.68 mmol, 34%) 
as pale yellow solid. Rf = 0.45 (SiO2, EtOAc); Mp 112 °C.  
1H-NMR (300 MHz, CDCl3):  = 8.74 (d, J = 6.1 Hz, 2 H, CH, Ar), 7.73 (d, J = 6.1 Hz, 
2 H, CH, Ar), 7.39 (d, J = 8.8 Hz, 2 H, CH, Ar), 7.07 (s, 1 H, CH), 6.92 (d, J = 8.8 Hz, 
2 H, CH, Ar), 3.81 (s, 3 H, OCH3), 2.36 (s, 3 H, CH3) ppm. 
The 1H NMR and spectral data is in accordance with the literature.108 
13C-NMR (75 MHz, CDCl3):  = 167.9, 160.9, 153.6, 150.3, 132.2, 128.0, 120.4, 
114.2, 93.1, 55.3, 21.4 ppm. 
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IR (neat): 3030, 2930, 2835, 1668, 1612, 1553, 1514, 1405, 1331, 1315, 1252 cm–1. 
MS (EI, 70 eV): m/z (%) = 298.1 (100) [M+H]+, (7.8). 
HRMS (EI-MS): m/z calcd for C16H15N3O3: 297.1108 [M+]; found 297.1098. 
 
Synthesis of 2,3-dihydro-1,3,4-oxadiazole derivatives with an additional enone 
unit in position three 197-214: 
To hydrazones 179-190 (0.0416 g-0.500 g, 0.163 mmol-2.22 mmol, 1.0 eq) in 10 ml 
of dry THF at 0 °C was added triethylamine (0.0198 g-0.270 g, 0.196 mmol-2.67 
mmol, 1.2 eq). Then a solution of ,-unsaturated acid chlorides (0.0299 g-0.407 g, 
0.179 mmol-2.44 mmol, 1.1eq) in 5 ml THF was added dropwise to the mixture, the 
reaction was warmed to room temperature and stirred until it was finished (1-24 h). 
The solvent was evaporated and the residue was purified by TLC (SiO2, petroleum 
ether-EtOAc, 1:1) to afford the desired 2,3-dihydro-1,3,4-oxadiazoles 197-214. 
1-(2-Methyl-2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)-3-phenylprop-2-
en-1-one (197) 
 
Hydrazone 182 (0.100 g, 0.420 mmol, 1.0 eq) gave after 5 h oxadiazole 197 (0.120 
g, 0.325 mmol, 78%) as a yellow solid. Rf = 0.63 (SiO2, petroleum ether-EtOAc, 1:1); 
Mp 139 °C.  
1H-NMR (300 MHz, CDCl3):  = 8.76 (d, J = 5.6 Hz, 2 H, CH, Ar), 7.78 (d, J = 6.0 Hz, 
2 H, CH, Ar), 7.71 (d, J = 15.9 Hz, 1 H, =CH), 7.64-7.56 (m, 4 H, Ar), 7.46 (d, J = 
15.9 Hz, 1 H, =CH), 7.43-7.33 (m, 6 H, Ar), 2.40 (s, 3 H, CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 162.1, 152.1, 150.3, 143.3, 138.5, 134.9, 132.4, 
130.0, 129.5, 128.8, 128.6, 128.2, 125.7, 120.4, 117.5, 102.0, 23 ppm. 
IR (neat): 3061, 2940, 2860, 1653, 1612, 1596, 1407, 1343, 1263, 1229, 1140 cm–1. 
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MS (EI, 70 eV): m/z (%) = 370.1 (100) [M+H]+, 240.1 (8.2). 
HRMS (EI-MS): m/z calcd for C23H19N3O2: 369.1472 [M+]; found 369.1473. 
 
1-(2-Methyl-2,5-diphenyl-1,3,4-oxadiazol-3(2H)-yl)-3-phenylprop-2-en-1-one 
(198) 
 
Hydrazone 185 (0.0985 g, 0.413 mmol, 1.0 eq) gave after 24 h oxadiazole 198 
(0.126 g, 0.343 mmol, 83%) as a white solid. Rf = 0.84 (SiO2, petroleum ether-EtOAc, 
1:1); Mp 105 °C.  
1H-NMR (300 MHz, CDCl3):  = 8.01-7.90 (m, 2 H, CH, Ar), 7.70 (d, J = 15.9 Hz, 1 H, 
CH), 7.64-7.57 (m, 4 H, CH, Ar), 7.56-7.45 (m, 4 H, CH, Ar), 7.45-7.33 (m, 6 H, CH, 
Ar), 2.39 (s, 3 H, CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 161.8, 161.8, 154.1, 154.1, 128.7, 128.7, 128.5, 
128.5, 128.2, 128.2, 125.8, 125.8, 118.1, 118.1, 101.0, 101.0, 23.0 ppm. 
IR (neat): 3061, 1653, 1619, 1449, 1411, 1378, 1333, 1287, 1258, 1197, 1058 cm–1. 
MS (EI, 70 eV): m/z (%) = 369.2 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C24H21N2O2: 369.1598 [M+H]+; found 369.1605. 
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3-Phenyl-1-(2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-1-one 
(199) 
 
Hydrazone 179 (0.500 g, 2.22 mmol, 1.0 eq) gave after 4 h oxadiazole 199 (0.597 g, 
1.68 mmol, 69%) as a white solid. Rf = 0.53 (SiO2, petroleum ether-EtOAc, 1:1); Mp 
194 °C.  
1H-NMR (300 MHz, DMSO-d6):  = 8.78 (d, J = 4.4 Hz, 2 H, CH, Ar), 7.97-7.28 (m, 15 
H, CH and CH, Ar) ppm. 
13C-NMR (75 MHz, DMSO-d6):  = 161.5, 155.9, 153.3, 150.3, 142.5, 134.2, 130.3, 
130.0, 128.9, 128.8, 128.2, 126.7, 120.3, 117.0, 93.0 ppm. 
IR (neat): 3056, 3033, 1660, 1620, 1598, 1411, 1340, 1239, 1212, 1077, 1010, 913, 
825, 759, 698, 662 cm–1. 
MS (EI, 70 eV): m/z (%) = 356.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C22H18N3O2: 356.1394 [M+H]+; found 356.1395. 
 
1-(2-(4-Methoxyphenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)-3-phenylprop-
2-en-1-one (200)
 
Hydrazone 180 (41.6 mg, 0.163 mmol, 1.0 eq) gave after 5 h oxadiazole 200 (43.5 
mg, 0.113 mmol, 72%) as a yellow solid. Rf = 0.44 (SiO2, petroleum ether-EtOAc, 
1:1); Mp 156 °C.  
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1H-NMR (300 MHz, DMSO-d6):  = 8.77 (d, J = 5.9 Hz, 2 H, CH, Ar), 7.84 (d, J = 5.9 
Hz, 2 H, CH, Ar), 7.75 (d, J = 3.8 Hz, 2 H, CH, Ar), 7.61 (d, J = 16.0 Hz, 1 H, =CH), 
7.50 (m, 6 H, CH, Ar), 7.34 (s, 1 H, CH), 7.00 7.61 (d, J = 8.7 Hz, 2 H, CH, Ar), 3.77 
(s, 3 H, OCH3) ppm. 
13C-NMR (75 MHz, DMSO-d6):  = 161.4, 160.4, 153.2, 150.5, 142.4, 134.3, 131.4, 
130.3, 128.9, 128.2, 128.2, 128.1, 120.2, 117.1, 114.1, 92.9, 55.2 ppm. 
IR (neat): 3061, 3023, 1651, 1609, 1517, 1434, 1338, 1297, 1253, 1239, 1181 cm–1. 
MS (EI, 70 eV): m/z (%) = 386.2 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C23H20N3O3: 386.1499 [M+H]+; found 386.1501. 
 
1-(2-(4-Nitrophenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)-3-phenylprop-2-en-
1-one (201) 
 
Hydrazone 181 (0.300 g, 0.111 mmol, 1.0 eq) gave after 5 h oxadiazole 201 (0.371 
g, 0.927 mmol, 83%) as a white solid. Rf = 0.41 (SiO2, petroleum ether-EtOAc, 1:1); 
Mp 212 °C.  
1H-NMR (300 MHz, DMSO-d6):  = 8.79 (d, J = 5.8 Hz, 2 H, CH, Ar), 8.30 (d, J = 8.6 
Hz, 2 H, CH, Ar), 7.86 (d, J = 6.4 Hz, 4 H, CH, Ar), 7.79-7.71 (m, 2 H, CH, Ar), 7.65 
(d, J = 16.0 Hz, 1 H, CH), 7.51 (d, J = 16.8 Hz, 1 H, CH),7.48-7.34 (m, 4 H, CH, Ar 
and CH) ppm. 
13C-NMR (75 MHz, DMSO-d6):  = 161.8, 153.4, 150.5, 148.4, 142.9, 142.2, 134.1, 
131.0, 130.4, 128.9, 128.4, 128.3, 124.0, 122.0, 120.3, 116.6 ppm. 
IR (neat): 3078, 2186, 1654, 1597, 1522, 1428, 1409, 1347, 1300, 1310, 1234 cm–1. 
MS (EI, 70 eV): m/z (%) = 401.1 (100) [M+H]+. 
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HRMS (EI-MS): m/z calcd for C22H17N4O4: 401.1244 [M+H]+; found 401.1245. 
 
1-(2-(4-Methoxyphenyl)-2-methyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)-3-
phenylprop-2-en-1-one (202) 
 
Hydrazone 184 (0.0850 g, 0.316 mmol, 1.0 eq) gave after 4 h oxadiazole 202 
(0.0725 g, 0.181 mmol, 57%) as a white solid. Rf = 0.48 (SiO2, petroleum ether: 
EtOAc, 1:1); Mp 203 °C.  
1H-NMR (300 MHz, CDCl3):  = 8.75 (d, J = 6.1 Hz, 2 H, CH, Ar), 7.77 (d, J = 6.1 Hz, 
2 H, CH, Ar), 7.70 (d, J = 15.9 Hz, 1 H, CH), 7.59 (m, 2 H, CH, Ar), 7.51 (d, J = 8.9 
Hz, 2 H, CH, Ar), 5.45 (d, J = 15.9 Hz, 1 H, CH), 7.42-7.38 (m, 3 H, CH, Ar), 6.92 (d, 
J = 8.9 Hz, 2 H, CH, Ar), 3.8 (s, 3 H, OCH3), 2.36 (s, 3 H, CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 162.0, 160.3, 152.1, 150.4, 143.2, 135.0, 132.4, 
130.7, 130.0, 128.8, 128.2, 127.3, 120.4, 117.6, 113.9, 102.0, 55.3, 23.0 ppm. 
IR (neat): 3056, 3033, 1660, 1620, 1598, 1411, 1340, 1290, 1239, 1212, 1077 cm–1. 
MS (EI, 70 eV): m/z (%) = 400.2 (100) [M+H]+, 270.1 (6.4). 
HRMS (EI-MS): m/z calcd for C24H21N3O3: 399.1577 [M+]; found 399.1598. 
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3-Phenyl-1-(3-(pyridin-4-yl)-4-oxa-1,2-diazaspiro[4.5]dec-2-en-1-yl)prop-2-en-1-
one (203) 
 
Hydrazone 183 (0.114 g, 0.522 mmol, 1.0 eq) gave after 5 h oxadiazole 203 (0.112 
g, 0.323 mmol, 62%) as a white solid. Rf = 0.50 (SiO2, petroleum ether-EtOAc, 1:1); 
Mp 143 °C.  
1H-NMR (300 MHz, CDCl3):  = 8.74 (d, J = 4.1 Hz, 2 H, CH, Ar), 7.79-7.66 (m, 3 H, 
CH, Ar and CH), 7.64-7.54 (m, 2 H, CH, Ar), 7.47-7.31 (m, 4 H, Ar and CH), 2.89-
2.59 (m, 2 H, CH2), 2.07-1.92 (m, 2 H, CH2), 1.86-1.56 (m, 5 H, CH2), 1.53-1.29 (m, 1 
H, CH2) ppm. 
13C-NMR (75 MHz, CDCl3):  = 162.2, 152.0, 150.3, 142.5, 135.0, 132.7, 129.8, 
128.7, 128.1, 120.3, 118.1, 103.7, 32.5, 24.2, 22.7 ppm. 
IR (neat): 3067, 3036, 2996, 1655, 1599, 1422, 1406, 1336, 1315, 1241, 1193 cm–1. 
MS (EI, 70 eV): m/z (%) = 348.2 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C21H21N3O2: 347.1628 [M+]; found 347.1631. 
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3-(4-Methoxyphenyl)-1-(2-methyl-2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-
yl)prop-2-en-1-one (204) 
 
Hydrazone 182 (0.200 g, 0.838 mmol, 1.0 eq) gave after 5 h oxadiazole 204 (0.0826 
g, 0.207 mmol, 25%) as a yellow solid. Rf = 0.44 (SiO2, petroleum ether-EtOAc, 1:1); 
Mp 156 °C.  
1H-NMR (300 MHz, CDCl3):  = 8.75 (d, J = 5.9 Hz, 2 H, CH, Ar), 7.77 (d, J = 6.1 Hz, 
2 H, CH, Ar), 7.60 (d, J = 11.9 Hz, 1H, =CH), 7.60 (m, 2 H, CH, Ar), 7.51 (d, J = 6.7 
Hz, 1H, CH, Ar), 7.45 (d, J = 11.9 Hz, 2 H, =CH), 7.42-7.36 (m, 3 H, Ar), 6.92 (d, J = 
8.8 Hz, 2H, CH, Ar), 3.84 (s, 3 H, CH3), 2.38 (s, 3 H, CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 162.5, 161.2, 152.0, 150.4, 143.0, 138.6, 132.4, 
129.9, 129.4, 128.6, 127.7, 125.7, 120.4, 115.0, 114.2, 102.0, 55.3, 23.0 ppm. 
IR (neat): 3050, 2837, 1655, 1597, 1511, 1405, 1336, 1244, 1172, 1028, 987 cm–1. 
MS (EI, 70 eV): m/z (%) = 400.2 (100) [M+H]+, 240.1 (7.7). 
HRMS (EI-MS): m/z calcd for C24H22N3O3: 400.1656 [M+H]+; found 400.1655. 
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1-(2-Methyl-2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-1-one 
(205) 
 
Hydrazone 182 (0.151 g, 0.632 mmol, 1.0 eq) gave after 4 h oxadiazole 205 (0.181 
g, 0.618 mmol, 98%) as a yellow solid. Rf = 0.48 (SiO2, petroleum ether-EtOAc, 1:1); 
Mp 106 °C.  
1H-NMR (300 MHz, CDCl3):  = 8.71 (d, J = 6.1 Hz, 2 H, CH, Ar), 7.70 (d, J = 6.1 Hz, 
2 H, CH, Ar), 7.63-7.47 (m, 2 H, CH, Ar), 7.45-7.32 (m, 3 H, CH, Ar), 7.14 (dd, J = 
17.2, 10.4 Hz, 1 H, CH), 6.41 (dd, J = 17.2, 1.8 Hz, 1 H, CH), 5.77 (dd, J = 10.4, 1.8 
Hz, 1 H, CH), 2.34 (s, 3 H, CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 161.3, 152.1, 150.3, 138.2, 132.0, 129.3, 128.9, 
128.4, 127.4, 125.6, 120.2, 101.7, 22.7 ppm. 
IR (neat): 3080, 3033, 2991, 2934, 1660, 1626, 1597, 1427, 1412, 1377, 1332 cm–1. 
MS (EI, 70 eV): m/z (%) = 294.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C17H16N3O2: 294.1237 [M+H]+; found 294.1239. 
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1-(2-Methyl-2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)but-2-en-1-one 
(206) 
 
Hydrazone 182 (0.100 g, 0.295 mmol, 1.0 eq) gave after 4 h oxadiazole 206 (0.0781 
g, 0.254 mmol, 86%) as a yellow solid. Rf = 0.52 (SiO2, petroleum ether-EtOAc, 1:1); 
Mp 116 °C. 
1H-NMR (300 MHz, CDCl3):  = 8.73 (d, J = 6.1 Hz, 2 H, CH, Ar), 7.73 (d, J = 6.1 Hz, 
2 H, CH, Ar), 7.55 (m, 2 H, CH, Ar), 7.39 (m, 3 H, CH, Ar), 6.97 (m, 1 H, CH), 6.85 (d, 
J = 15.5 Hz, 1 H, CH), 2.34 (s, 3 H, CH3), 1.94 (d, J = 6.5 Hz, 3 H, CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 162.0, 151.9, 150.4, 143.1, 138.6, 132.4, 129.4, 
128.5, 125.7, 121.9, 120.3, 101.8, 23.0, 18.2 ppm. 
IR (neat): 3060, 3016, 2987, 2942, 1663, 1631, 1597, 1408, 1382, 1335, 1316 cm–1. 
MS (EI, 70 eV): m/z (%) = 308.1 (100) [M+H]+. 
HRMS (EI-MS): m/z  calcd for C18H18N3O2: 308.1394 [M+H]+; found 308.1395. 
 
2-Methyl-1-(2-methyl-2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)prop-2-
en-1-one (207) 
 
Hydrazone 182 (0.200 g, 0.590 mmol, 1.0 eq) gave after 4 h oxadiazole 207 (0.179 
g, 0.581 mmol, 98%) as a colorless oil. Rf = 0.35 (SiO2, petroleum ether-EtOAc, 1:1). 
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1H-NMR (300 MHz, CDCl3):  = 8.69 (d, J = 6.1 Hz, 2 H, CH, Ar), 7.67 (d, J = 6.1 Hz, 
2 H, CH, Ar), 7.59-7.48 (m, 2 H, CH, Ar), 7.45-7.29 (m, 3 H, CH, Ar), 5.74 (t, 1 H, J = 
0.9 Hz, CH), 5.49 (t, J = 1.5 Hz, 1 H, CH), 2.32 (s, 3 H, CH3), 2.04 (t, J = 1.2 Hz, 3 H, 
CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 165.8, 151.9, 150.2, 139.1, 138.4, 132.2, 129.3, 
128.4, 125.5, 121.7, 120.2, 102.0, 22.6, 19.9 ppm. 
IR (neat): 2990, 1652, 1623, 1598, 1426, 1407, 1333, 1313, 1250, 1184, 1049 cm–1. 
MS (EI, 70 eV): m/z (%) = 308.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C18H17N3O2: 307.1315 [M+]; found 307.1324. 
 
1-(2-Methyl-2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)-3-(4-
(trifluoromethyl) phenyl)prop-2-en-1-one (208)
 
Hydrazone 182 (22.0 mg, 0.089 mmol, 1.0 eq) gave after 24 h oxadiazole 208 (25.4 
mg, 0.058 mmol, 65%) as a yellow solid. Rf = 0.58 (SiO2, petroleum ether-EtOAc, 
1:1); Mp 189 °C.  
1H-NMR (300 MHz, CDCl3):  = 8.77 (d, J = 4.8 Hz, 2 H, CH, Ar), 7.79 (d, J = 4.5 Hz, 
2 H, CH, Ar), 7.72 (d, J = 6.9 Hz, 1 H, CH), 7.67 (m, 3 H, CH, Ar), 7.63 (d, J = 5.7 Hz, 
1 H, CH), 7.60 (m, 1 H, CH, Ar), 7.58 (d, J = 1.5 Hz, 1 H, CH, Ar), 7.52 (d, J = 12.0 
Hz, 1 H, CH), 7.42 (m, 3 H, CH, Ar), 2.40 (s, 3 H, CH3) ppm. 
13C-NMR (101 MHz, CDCl3):  = 161.4, 152.4, 150.3, 141.4, 138.4, 132.4, 131.5 (q, J 
= 32.8 Hz, CCF3), 129.6, 128.6, 128.3, 127.8, 125.8, 125.8, 123.9 (q, J = 269.0 Hz, 
CF3), 120.5, 120.1, 102.2, 23.0 ppm. 
IR (neat): 3061, 1656, 1619, 1408, 1317, 1253, 1171, 1119, 1064, 984, 831 cm–1. 
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19F-NMR (282 MHz, CDCl3):  = (s, -62.7, CF3) ppm. 
MS (ESI, 120 V): m/z (%) = 438.1(100) [M+H]+. 
HRMS (EI-MS): m/z  calcd for C24H19F3N3O2: 438.1424 [M+H]+; found: 438.1428. 
 
1-(2-Methyl-2-(4-nitrophenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-
1-one (209) 
 
Hydrazone 186 (0.101 g, 0.352 mmol, 1.0 eq) gave after 3 h oxadiazole 209 (32.3 
mg, 0.095 mmol, 27%) as a yellow oil. Rf = 0.36 (SiO2, petroleum ether-EtOAc, 1:1). 
 1H-NMR (300 MHz, CDCl3):  = 8.77 (d, J = 5.6 Hz, 2 H, CH, Ar), 8.25 (d, J = 9.0 Hz, 
2 H, CH, Ar), 7.77 (d, J = 9.0 Hz, 2 H, CH, Ar), 7.73 (d, J = 6.1 Hz, 2 H, CH, Ar), 7.10 
(dd, J = 17.2, 10.4 Hz, 1 H, =CH), 6.43 (dd, J = 17.2, 1.7 Hz, 1 H, =CH), 5.84 (dd, J = 
10.4, 1.7 Hz, 1 H, =CH), 2.37 (s, 3 H, CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 161.8, 152.2, 150.5, 148.4, 144.8, 131.8, 129.8, 
127.2, 127.1, 123.8, 120.3, 100.7, 23.0 ppm. 
IR (neat): 3051, 1660, 1622, 1598, 1521, 1427, 1410, 1348, 1330, 1310, 1256 cm–1. 
MS (ESI, 120 V): m/z (%) = 339.1 (100) [M+H]+. 
HRMS (EI-MS): m/z  calcd for C17H15N4O4: 339.1088 [M+H]+; found 339.1095. 
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1-(2-Methyl-5-(pyridin-4-yl)-2-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-3(2H)-
yl)prop-2-en-1-one (210)  
 
Hydrazone 187 (0.500 g, 1.63 mmol, 1.0 eq) gave after 3 h oxadiazole 210 (0.0986 
g, 0.0273 mmol, 17%) as a yellow oil. Rf = 0.58 (SiO2, petroleum ether-EtOAc, 1:1).  
1H-NMR (300 MHz, CDCl3):  = 8.75 (d, J = 5.1 Hz, 2 H, CH, Ar), 7.82-7.54 (m, 6 H, 
CH, Ar), 7.12 (dd, J =17.2, 10.4 Hz, 1 H, =CH), 6.43 (dd, J =17.2, 1.7 Hz, 1 H, =CH), 
5.82 (dd, J =10.4, 1.7 Hz, 1 H, CH), 2.36 (s, 3 H, CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 161.7, 152.2, 150.4, 142.0, 131.9, 131.5 (q, J = 32.3 
Hz, CCF3), 129.5, 127.3, 126.3, 125.6 (q, J = 3.7 Hz, CHCCF3), 123.7 (q, J = 270.8 
Hz, CF3), 120.3, 101.1, 22.9 ppm. 
19F-NMR (282 MHz, CDCl3):  = (-63.3, CF3) ppm. 
IR (neat): 1662, 1621, 1599, 1428, 1410, 1325, 1271, 1167, 1118, 1089, 1061 cm–1. 
MS (EI, 70 eV): m/z (%) = 362.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C18H15F3N3O2: 362.1111 [M+H]+; found 362.1113. 
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1-(2-Methyl-5-(pyridin-4-yl)-2-(4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol-3(2H)-
yl)prop-2-en-1-one (211) 
 
Hydrazone 188 (0.100 g, 0.309 mmol, 1.0 eq) gave after 1.5 h oxadiazole 211 
(0.0687 g, 0.182 mmol, 59%) as a yellow solid. Rf = 0.61 (SiO2, petroleum ether-
EtOAc, 1:1); Mp 78 °C.  
1H NMR (300 MHz, CDCl3):  = 8.74 (dd, J = 4.6, 1.5 Hz, 2H, CH, Ar), 7.72 (dd, J = 
4.5, 1.6 Hz, 2H, CH, Ar), 7.64 – 7.54 (m, 2H, CH, Ar), 7.23 (d, J = 8.1 Hz, 2H, CH, 
Ar), 7.12 (dd, J = 17.2, 10.4 Hz, 1H, =CH), 6.42 (dd, J = 17.2, 1.7 Hz, 1H, =CH), 5.80 
(dd, J = 10.4, 1.7 Hz, 1H, =CH), 2.34 (s, 3H, CH3) ppm. 
13C-NMR (101 MHz, CDCl3):  = 161.6, 152.1, 150.4, 149.8, 137.0, 132.0, 129.3, 
127.6, 127.4, 124.2 (q, J = 263.1 Hz, CF3), 120.7, 120.3, 119.0, 101.2, 23.0 ppm. 
19F-NMR (282 MHz, CDCl3):  = (s, -57.7, CF3) ppm. 
IR (neat): 1655, 1618, 1601, 1504, 1427, 1412, 1381, 1333, 1253, 1216, 1158 cm–1. 
MS (EI, 70 eV): m/z (%) = 378.1 (100) [M+H]+. 
HRMS (EI-MS): m/z calcd for C18H15F3N3O3: 378.1060 [M+H]+; found 378.1066. 
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1-(2-Methyl-2,5-di(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-1-one (212) 
 
Hydrazone 189 (0.200 g, 0.834 mmol, 1.0 eq) gave after 2 h oxadiazole 212 (0.0623 
g, 0.212 mmol, 25%) as a white solid. Rf = 0.40 (SiO2, EtOAc); Mp 128 °C.  
1H-NMR (300 MHz, CDCl3):  = 8.73 (d, J = 6.1 Hz, 2H, CH, Ar), 8.65 (d, J = 6.2 Hz, 
2H, CH, Ar), 7.69 (d, J = 6.2 Hz, 2H, CH, Ar), 7.44 (d, J = 6.2 Hz, 2H, CH, Ar), 7.08 
(dd, J = 17.2, 10.4 Hz, 1H, =CH), 6.41 (dd, J = 17.2, 1.7 Hz, 1H, =CH), 5.80 (dd, J = 
10.4, 1.8 Hz, 1H, =CH), 2.30 (s, 3H, CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 161.7, 152.2, 150.4, 150.3, 146.5, 131.6, 129.6, 
127.1, 120.3, 120.2, 100.4, 22.5 ppm. 
IR (neat): 3069, 2992, 1659, 1622, 1598, 1553, 1408, 1380, 1328, 1309, 1261 cm–1. 
MS (EI, 70 eV): m/z (%) = 295.1 (100) [M+H]+, 241.1 (10.7). 
HRMS (EI-MS): m/z calcd for C16H15N4O2: 295.1190 [M+H]+; found 295.1191. 
 
1-(2-Methyl-2-(pyridin-2-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-1-
one (213) 
 
Hydrazone 190 (0.201 g, 0.835 mmol, 1.0 eq) gave after 3 h oxadiazole 213 (0.142 
g, 0.481 mmol, 58%) as a colorless oil. Rf = 0.41 (SiO2, EtOAc).  
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1H-NMR (300 MHz, CDCl3):  = 8.70 (d, J = 6.2 Hz, 2H, CH, Ar), 8.63 (dd, J = 4.8, 
0.8 Hz, 1H, CH, Ar), 7.76 (dd, J = 7.8, 1.8 Hz, 1H, CH, Ar), 7.71 (d, J = 6.1 Hz, 2H, 
CH, Ar), 7.54 (d, J = 8.0 Hz, 1H, CH, Ar), 7.29 (d, J = 7.6, 1H, CH, Ar), 7.17 (dd, J = 
17.2, 10.4 Hz, 1H, =CH), 6.39 (dd, J = 17.2, 1.8 Hz, 1H, =CH), 5.80 (dd, J = 10.4, 1.8 
Hz, 1H, =CH), 2.38 (s, 3H, CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 161.6, 155.7, 152.5, 150.3, 149.6, 136.9, 132.4, 
129.2, 127.4, 124.3, 120.6, 120.5, 101.5, 21.5 ppm. 
IR (neat): 3055, 1658, 1621, 1598, 1430, 1410, 1373, 1331, 1312, 1270, 1204 cm–1. 
MS (EI, 70 eV): m/z (%) = 295.1 (100) [M+H]+, 241.1 (8.4). 
HRMS (EI-MS): m/z  calcd for C16H15N4O2: 295.1190 [M+H]+; found 295.1193. 
 
1-(2-Methyl-2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)propan-1-one (214) 
 
Hydrazone 182 (0.200 g, 0.837 mmol, 1.0 eq) gave after 1 h oxadiazole 214 (0.133 
g, 0.451 mmol, 54%) as a brown solid. Rf = 0.57 (SiO2, petroleum ether-EtOAc, 1:1); 
Mp 71 °C. 
1H-NMR (300 MHz, CDCl3):  = 8.71 (d, J = 5.9 Hz, 2H, CH, Ar), 7.70 (d, J = 6.1 Hz, 
2H, CH, Ar), 7.53 (dd, J = 7.8, 2.0 Hz, 2H, CH, Ar), 7.36 (m, 3H, CH, Ar), 2.71 (dq, J 
= 7.5, 3.3 Hz, 2H, CH2), 2.29 (s, 3H, CH3), 1.15 (t, J = 7.5 Hz, 3H, CH3) ppm. 
13C-NMR (75 MHz, CDCl3):  = 170.5, 151.6, 150.2, 138.8, 132.4, 129.3, 128.4, 
125.6, 120.2, 101.5, 27.7, 23.0, 8.4 ppm. 
IR (neat): 3078, 2984, 2936, 1668, 1628, 1596, 1410, 1378, 1349, 1378, 1349 cm–1. 
MS (EI, 70 eV): m/z (%) = 296.1 (100) [M+H]+, 240.1 (10.0). 
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HRMS (EI-MS): m/z calcd for C17H18N3O2: 296.1394 [M+H]+; found 296.1394. 
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6. Appendix (NMR spectra) 
3-(4-Isopropoxyphenyl)cyclopent-2-enone (71) (in CDCl3) 
1H NMR 
 
 
13C NMR
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3-(4-Isopropoxyphenyl)spiro[4.4]non-2-en-1-one (72) (in CDCl3) 
1H NMR 
 
 
13C NMR 
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2-Chloro-3-(4-isopropoxyphenyl)spiro[4.4]non-2-en-1-one (74) (in CDCl3) 
1H NMR 
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13C NMR 
 
 
2-Bromo-3-(4-isopropoxyphenyl)spiro[4.4]non-2-en-1-one (75) (in CDCl3) 
1H NMR 
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13C NMR 
 
 
2-Iodo-3-(4-isopropoxyphenyl)spiro[4.4]non-2-en-1-one (76) (in CDCl3) 
1H NMR  
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13C NMR 
 
 
3-(4-Isopropoxyphenyl)-1-oxospiro[4.4]non-2-ene-2-carbonitrile (77) (in CDCl3) 
1H NMR 
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13C NMR 
 
 
3-(4-Isopropoxyphenyl)-2-phenylspiro[4.4]non-2-en-1-one (78) (in CDCl3) 
1H NMR 
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13C NMR 
 
 
3-(4-isopropoxyphenyl)-2-(4-nitrophenyl)spiro[4.4]non-2-en-1-one (79) (in CDCl3) 
1H NMR 
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13C NMR 
 
 
3-(4-Hydroxyphenyl)spiro[4.4]non-2-en-1-one (80) (in acetone-d6) 
1H NMR 
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13C NMR 
 
 
2-Chloro-3-(4-hydroxyphenyl)spiro[4.4]non-2-en-1-one (81) (in acetone-d6) 
1H NMR 
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13C NMR 
 
 
2-Bromo-3-(4-hydroxyphenyl)spiro[4.4]non-2-en-1-one (82) (in acetone-d6) 
1H NMR 
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13C NMR 
 
 
3-(4-Hydroxyphenyl)-2-iodospiro[4.4]non-2-en-1-one (83) (in acetone-d6) 
1H NMR 
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13C NMR 
 
 
3-(4-Hydroxyphenyl)-1-oxospiro[4.4]non-2-ene-2-carbonitrile (84) (in acetone-d6) 
1H NMR 
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13C NMR 
 
 
3-(4-Hydroxyphenyl)-2-phenylspiro[4.4]non-2-en-1-one (85) (in acetone-d6) 
1H NMR 
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13C NMR 
 
 
3-(4-Hydroxyphenyl)-2-(4-nitrophenyl)spiro[4.4]non-2-en-1-one (86) (in acetone-
d6) 
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1H-NMR 
 
 
13C-NMR 
 
((4-Isopropoxyphenyl)ethynyl)trimethylsilane (89) (in CDCl3) 
1H NMR 
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13C NMR 
 
1-Ethynyl-4-isopropoxybenzene (90) (in CDCl3) 
1H NMR 
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13C NMR 
 
1,4-Dichloro-4-(4-isopropoxyphenyl)but-3-en-2-one (91) (in CDCl3) 
1H NMR 
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13C NMR 
 
2-((4-Isopropoxyphenyl)ethynyl)cyclohexanol (97) (in CDCl3) 
1H NMR 
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13C NMR 
 
2-(4-Isopropoxyphenyl)-1-oxaspiro[4.4]non-2-ene-4-thione (99) (in CDCl3) 
1H NMR  
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13C NMR 
 
1-(4-Isopropoxyphenyl)prop-2-yn-1-ol (109) (in CDCl3) 
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1H NMR   
 
 
13C NMR 
 
2,3,5,6-Tetramethoxycyclohexa-2,5-diene-1,4-dione (114) (in CDCl3) 
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1H NMR 
 
 
13C NMR 
 
Methyl 1-hydroxy-2,3,5,5-tetramethoxy-4-oxocyclopent-2-enecarboxylate (113) 
(in CDCl3) 
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1H NMR 
 
 
13C NMR 
 
2-Hydroxy-3,5,6-trimethoxycyclohexa-2,5-diene-1,4-dione (116) (in CDCl3) 
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1H NMR 
 
 
13C NMR  
 
2,2-Dimethylpent-4-enenitrile (142) (in CDCl3) 
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1H NMR 
 
 
13C NMR 
 
2,2-Dimethylpent-4-enal (136) (in CDCl3) 
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1H NMR 
 
 
13C NMR 
 
3-Methylbut-3-en-1-yl 4-methylbenzenesulfonate (153) (in CDCl3) 
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1H NMR 
 
 
13C NMR 
 
4-Methylpent-4-enenitrile (145) (in CDCl3) 
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1H NMR 
 
 
13C NMR 
 
4-Methylpent-4-enal (143) (in CDCl3) 
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1H NMR  
 
 
13C NMR 
 
Diethyl (3-oxobutan-2-yl)phosphonate (144) (in CDCl3) 
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1H NMR 
 
 
13C NMR 
 
31P NMR 
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3,7-Dimethylocta-3,7-dien-2-one (137) (in CDCl3) 
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1H NMR 
 
 
13C NMR 
 
2,6,10,10-Tetramethyltrideca-1,5,8,12-tetraen-7-one (129) (in CDCl3) 
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1H NMR 
 
 
13C NMR 
 
6,6-Dimethylnona-4,8-dien-3-one (155) (in CDCl3) 
Acetone 
Acetone 
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1H NMR 
 
 
13C NMR 
 
9-Hydroxy-4,4,8,10,10-pentamethyltrideca-1,5,12-trien-7-one (154) (in CDCl3) 
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1H NMR 
 
 
13C NMR 
 
Isonicotinohydrazide (166) (in DMSO-d6) 
Appendix 
180 
 
1H NMR 
 
 
13C NMR 
 
 
H2O 
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2-(Pyridin-4-yl)-1,3,4-oxadiazole (167) (in CDCl3) 
1H NMR 
 
 
13C NMR 
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Ethyl 5-(pyridin-4-yl)-1,3,4-oxadiazole-2-carboxylate (172) (in CDCl3) 
1H NMR 
 
 
13C NMR 
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N'-Benzylideneisonicotinohydrazide (179) (in DMSO-d6) 
1H NMR 
 
 
13C NMR 
 
H2O 
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N'-(4-Methoxybenzylidene)isonicotinohydrazide (180) (in DMSO-d6) 
1H NMR 
 
 
13C NMR 
 
H2O 
Appendix 
185 
 
 
N'-(4-Nitrobenzylidene)isonicotinohydrazide (181) (in DMSO-d6) 
1H NMR 
 
 
13C NMR 
H2O 
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N'-(1-Phenylethylidene)isonicotinohydrazide (182) (in DMSO-d6) 
1H NMR 
  
 
H2O 
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13C NMR 
 
 
N'-Cyclohexylideneisonicotinohydrazide (183) 
1H NMR (in CDCl3) 
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13C NMR (in DMSO-d6) 
 
N'-(1-(4-Methoxyphenyl)ethylidene)isonicotinohydrazide (184) (in DMSO-d6) 
1H NMR 
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13C NMR 
 
N'-(1-Phenylethylidene)benzohydrazide (185) (in DMSO-d6) 
 
H2O 
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1H NMR 
 
 
13C NMR 
 
 
H2O 
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N'-(1-(4-Nitrophenyl)ethylidene)isonicotinohydrazide (186) (in DMSO-d6) 
1H NMR 
 
 
13C NMR 
 
H2O 
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N'-(1-(4-(Trifluoromethyl)phenyl)ethylidene)isonicotinohydrazide (187) (DMSO-
d6) 
1H NMR 
 
 
13C NMR 
 
H2O 
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19F NMR 
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N'-(1-(4-(Trifluoromethoxy)phenyl)ethylidene)isonicotinohydrazide (188) (in 
DMSO-d6) 
1H NMR 
 
13C NMR 
 
 
H2O 
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19F NMR 
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N'-(1-(Pyridin-4-yl)ethylidene)isonicotinohydrazide (189) (in DMSO-d6) 
1H NMR 
 
 
13C NMR 
 
H2O 
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N'-(1-(Pyridin-2-yl)ethylidene)isonicotinohydrazide (190) (in DMSO-d6) 
1H NMR 
 
 
13C NMR 
 
H2O 
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5-(Pyridin-4-yl)-1,3,4-oxadiazole-2-thiol (174) (in DMSO-d6) 
1H NMR 
 
 
13C NMR 
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(5-(Pyridin-4-yl)-1,3,4-oxadiazol-2-yl) 3-phenylprop-2-enethioate (175) (in CDCl3) 
1H NMR 
 
 
H2O 
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13C NMR 
 
(5-(Pyridin-4-yl)-1,3,4-oxadiazol-2-yl) 3-(4-methoxyphenyl)prop-2-enethioate 
(176) (in CDCl3) 
1H NMR 
 
 
Appendix 
201 
 
13C NMR 
 
 
1-(2-(4-Methoxyphenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)ethanone (191) 
(in CDCl3) 
1H NMR 
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13C NMR 
 
1-(2-Methyl-2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)-3-phenylprop-2-
en-1-one (197) (in CDCl3) 
1H NMR 
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13C NMR 
 
1-(2-Methyl-2,5-diphenyl-1,3,4-oxadiazol-3(2H)-yl)-3-phenylprop-2-en-1-one 
(198) (CDCl3) 
1H NMR 
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13C NMR 
 
3-Phenyl-1-(2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-1-one 
(199) (in DMSO-d6) 
1H NMR 
 
H2O 
Appendix 
205 
 
 
13C NMR 
 
1-(2-(4-Methoxyphenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)-3-phenylprop-
2-en-1-one (200) ( in DMSO-d6) 
1H NMR 
 
H2O 
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13C NMR 
 
1-(2-(4-Nitrophenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)-3-phenylprop-2-en-
1-one (201) (in DMSO-d6) 
1H NMR 
 
H2O 
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13C NMR 
 
1-(2-(4-Methoxyphenyl)-2-methyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)-3-
phenylprop-2-en-1-one (202) (in CDCl3) 
1H NMR 
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13C NMR 
 
3-Phenyl-1-(3-(pyridin-4-yl)-4-oxa-1,2-diazaspiro[4.5]dec-2-en-1-yl)prop-2-en-1-
one (203) (in CDCl3) 
1H NMR 
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13C NMR 
 
3-(4-Methoxyphenyl)-1-(2-methyl-2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-
yl)prop-2-en-1-one (204) (CDCl3) 
1H NMR 
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13C NMR 
 
1-(2-Methyl-2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-1-one 
(205) (CDCl3) 
1H NMR 
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13C NMR 
 
1-(2-Methyl-2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)but-2-en-1-one 
(206) (CDCl3) 
1H NMR 
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13C NMR 
 
2-Methyl-1-(2-methyl-2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)prop-2-
en-1-one (207) (in CDCl3) 
1H NMR 
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13C NMR 
 
1-(2-Methyl-2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)-3-(4-(trifluoro 
methyl)phenyl)prop-2-en-1-one (208) (in CDCl3) 
1H NMR 
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13C NMR 
 
19F NMR 
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1-(2-Methyl-2-(4-nitrophenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-
1-one (209) (in CDCl3) 
1H NMR 
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13C NMR 
 
1-(2-Methyl-5-(pyridin-4-yl)-2-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-3(2H)-
yl)prop-2-en-1-one (210) (in CDCl3) 
1H NMR 
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13C NMR 
 
19F NMR 
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1-(2-Methyl-5-(pyridin-4-yl)-2-(4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol-3(2H)-
yl)prop-2-en-1-one (211) (in CDCl3) 
1H NMR 
 
 
13C NMR 
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19F NMR 
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1-(2-Methyl-2,5-di(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-1-one (212) (in 
CDCl3) 
1H NMR 
 
 
13C NMR 
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1-(2-Methyl-2-(pyridin-2-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)prop-2-en-1-
one (213) (in CDCl3) 
1H NMR 
 
 
13C NMR 
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1-(2-Methyl-2-phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)propan-1-one (214) 
(in CDCl3) 
1H NMR 
 
13C NMR 
Appendix 
223 
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